<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Claude Code transcript - page 3</title>
    <style>
:root { --bg-color: #f5f5f5; --card-bg: #ffffff; --user-bg: #e3f2fd; --user-border: #1976d2; --assistant-bg: #f5f5f5; --assistant-border: #9e9e9e; --thinking-bg: #fff8e1; --thinking-border: #ffc107; --thinking-text: #666; --tool-bg: #f3e5f5; --tool-border: #9c27b0; --tool-result-bg: #e8f5e9; --tool-error-bg: #ffebee; --text-color: #212121; --text-muted: #757575; --code-bg: #263238; --code-text: #aed581; }
* { box-sizing: border-box; }
body { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif; background: var(--bg-color); color: var(--text-color); margin: 0; padding: 16px; line-height: 1.6; }
.container { max-width: 800px; margin: 0 auto; }
h1 { font-size: 1.5rem; margin-bottom: 24px; padding-bottom: 8px; border-bottom: 2px solid var(--user-border); }
.header-row { display: flex; justify-content: space-between; align-items: center; flex-wrap: wrap; gap: 12px; border-bottom: 2px solid var(--user-border); padding-bottom: 8px; margin-bottom: 24px; }
.header-row h1 { border-bottom: none; padding-bottom: 0; margin-bottom: 0; flex: 1; min-width: 200px; }
.message { margin-bottom: 16px; border-radius: 12px; overflow: hidden; box-shadow: 0 1px 3px rgba(0,0,0,0.1); }
.message.user { background: var(--user-bg); border-left: 4px solid var(--user-border); }
.message.assistant { background: var(--card-bg); border-left: 4px solid var(--assistant-border); }
.message.tool-reply { background: #fff8e1; border-left: 4px solid #ff9800; }
.tool-reply .role-label { color: #e65100; }
.tool-reply .tool-result { background: transparent; padding: 0; margin: 0; }
.tool-reply .tool-result .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, #fff8e1); }
.message-header { display: flex; justify-content: space-between; align-items: center; padding: 8px 16px; background: rgba(0,0,0,0.03); font-size: 0.85rem; }
.role-label { font-weight: 600; text-transform: uppercase; letter-spacing: 0.5px; }
.user .role-label { color: var(--user-border); }
time { color: var(--text-muted); font-size: 0.8rem; }
.timestamp-link { color: inherit; text-decoration: none; }
.timestamp-link:hover { text-decoration: underline; }
.message:target { animation: highlight 2s ease-out; }
@keyframes highlight { 0% { background-color: rgba(25, 118, 210, 0.2); } 100% { background-color: transparent; } }
.message-content { padding: 16px; }
.message-content p { margin: 0 0 12px 0; }
.message-content p:last-child { margin-bottom: 0; }
.thinking { background: var(--thinking-bg); border: 1px solid var(--thinking-border); border-radius: 8px; padding: 12px; margin: 12px 0; font-size: 0.9rem; color: var(--thinking-text); }
.thinking-label { font-size: 0.75rem; font-weight: 600; text-transform: uppercase; color: #f57c00; margin-bottom: 8px; }
.thinking p { margin: 8px 0; }
.assistant-text { margin: 8px 0; }
.tool-use { background: var(--tool-bg); border: 1px solid var(--tool-border); border-radius: 8px; padding: 12px; margin: 12px 0; }
.tool-header { font-weight: 600; color: var(--tool-border); margin-bottom: 8px; display: flex; align-items: center; gap: 8px; }
.tool-icon { font-size: 1.1rem; }
.tool-description { font-size: 0.9rem; color: var(--text-muted); margin-bottom: 8px; font-style: italic; }
.tool-result { background: var(--tool-result-bg); border-radius: 8px; padding: 12px; margin: 12px 0; }
.tool-result.tool-error { background: var(--tool-error-bg); }
.file-tool { border-radius: 8px; padding: 12px; margin: 12px 0; }
.write-tool { background: linear-gradient(135deg, #e3f2fd 0%, #e8f5e9 100%); border: 1px solid #4caf50; }
.edit-tool { background: linear-gradient(135deg, #fff3e0 0%, #fce4ec 100%); border: 1px solid #ff9800; }
.file-tool-header { font-weight: 600; margin-bottom: 4px; display: flex; align-items: center; gap: 8px; font-size: 0.95rem; }
.write-header { color: #2e7d32; }
.edit-header { color: #e65100; }
.file-tool-icon { font-size: 1rem; }
.file-tool-path { font-family: monospace; background: rgba(0,0,0,0.08); padding: 2px 8px; border-radius: 4px; }
.file-tool-fullpath { font-family: monospace; font-size: 0.8rem; color: var(--text-muted); margin-bottom: 8px; word-break: break-all; }
.file-content { margin: 0; }
.edit-section { display: flex; margin: 4px 0; border-radius: 4px; overflow: hidden; }
.edit-label { padding: 8px 12px; font-weight: bold; font-family: monospace; display: flex; align-items: flex-start; }
.edit-old { background: #fce4ec; }
.edit-old .edit-label { color: #b71c1c; background: #f8bbd9; }
.edit-old .edit-content { color: #880e4f; }
.edit-new { background: #e8f5e9; }
.edit-new .edit-label { color: #1b5e20; background: #a5d6a7; }
.edit-new .edit-content { color: #1b5e20; }
.edit-content { margin: 0; flex: 1; background: transparent; font-size: 0.85rem; }
.edit-replace-all { font-size: 0.75rem; font-weight: normal; color: var(--text-muted); }
.write-tool .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, #e6f4ea); }
.edit-tool .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, #fff0e5); }
.todo-list { background: linear-gradient(135deg, #e8f5e9 0%, #f1f8e9 100%); border: 1px solid #81c784; border-radius: 8px; padding: 12px; margin: 12px 0; }
.todo-header { font-weight: 600; color: #2e7d32; margin-bottom: 10px; display: flex; align-items: center; gap: 8px; font-size: 0.95rem; }
.todo-items { list-style: none; margin: 0; padding: 0; }
.todo-item { display: flex; align-items: flex-start; gap: 10px; padding: 6px 0; border-bottom: 1px solid rgba(0,0,0,0.06); font-size: 0.9rem; }
.todo-item:last-child { border-bottom: none; }
.todo-icon { flex-shrink: 0; width: 20px; height: 20px; display: flex; align-items: center; justify-content: center; font-weight: bold; border-radius: 50%; }
.todo-completed .todo-icon { color: #2e7d32; background: rgba(46, 125, 50, 0.15); }
.todo-completed .todo-content { color: #558b2f; text-decoration: line-through; }
.todo-in-progress .todo-icon { color: #f57c00; background: rgba(245, 124, 0, 0.15); }
.todo-in-progress .todo-content { color: #e65100; font-weight: 500; }
.todo-pending .todo-icon { color: #757575; background: rgba(0,0,0,0.05); }
.todo-pending .todo-content { color: #616161; }
pre { background: var(--code-bg); color: var(--code-text); padding: 12px; border-radius: 6px; overflow-x: auto; font-size: 0.85rem; line-height: 1.5; margin: 8px 0; white-space: pre-wrap; word-wrap: break-word; }
pre.json { color: #e0e0e0; }
code { background: rgba(0,0,0,0.08); padding: 2px 6px; border-radius: 4px; font-size: 0.9em; }
pre code { background: none; padding: 0; }
.user-content { margin: 0; }
.truncatable { position: relative; }
.truncatable.truncated .truncatable-content { max-height: 200px; overflow: hidden; }
.truncatable.truncated::after { content: ''; position: absolute; bottom: 32px; left: 0; right: 0; height: 60px; background: linear-gradient(to bottom, transparent, var(--card-bg)); pointer-events: none; }
.message.user .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, var(--user-bg)); }
.message.tool-reply .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, #fff8e1); }
.tool-use .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, var(--tool-bg)); }
.tool-result .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, var(--tool-result-bg)); }
.expand-btn { display: none; width: 100%; padding: 8px 16px; margin-top: 4px; background: rgba(0,0,0,0.05); border: 1px solid rgba(0,0,0,0.1); border-radius: 6px; cursor: pointer; font-size: 0.85rem; color: var(--text-muted); }
.expand-btn:hover { background: rgba(0,0,0,0.1); }
.truncatable.truncated .expand-btn, .truncatable.expanded .expand-btn { display: block; }
.pagination { display: flex; justify-content: center; gap: 8px; margin: 24px 0; flex-wrap: wrap; }
.pagination a, .pagination span { padding: 5px 10px; border-radius: 6px; text-decoration: none; font-size: 0.85rem; }
.pagination a { background: var(--card-bg); color: var(--user-border); border: 1px solid var(--user-border); }
.pagination a:hover { background: var(--user-bg); }
.pagination .current { background: var(--user-border); color: white; }
.pagination .disabled { color: var(--text-muted); border: 1px solid #ddd; }
.pagination .index-link { background: var(--user-border); color: white; }
details.continuation { margin-bottom: 16px; }
details.continuation summary { cursor: pointer; padding: 12px 16px; background: var(--user-bg); border-left: 4px solid var(--user-border); border-radius: 12px; font-weight: 500; color: var(--text-muted); }
details.continuation summary:hover { background: rgba(25, 118, 210, 0.15); }
details.continuation[open] summary { border-radius: 12px 12px 0 0; margin-bottom: 0; }
.index-item { margin-bottom: 16px; border-radius: 12px; overflow: hidden; box-shadow: 0 1px 3px rgba(0,0,0,0.1); background: var(--user-bg); border-left: 4px solid var(--user-border); }
.index-item a { display: block; text-decoration: none; color: inherit; }
.index-item a:hover { background: rgba(25, 118, 210, 0.1); }
.index-item-header { display: flex; justify-content: space-between; align-items: center; padding: 8px 16px; background: rgba(0,0,0,0.03); font-size: 0.85rem; }
.index-item-number { font-weight: 600; color: var(--user-border); }
.index-item-content { padding: 16px; }
.index-item-stats { padding: 8px 16px 12px 32px; font-size: 0.85rem; color: var(--text-muted); border-top: 1px solid rgba(0,0,0,0.06); }
.index-item-commit { margin-top: 6px; padding: 4px 8px; background: #fff3e0; border-radius: 4px; font-size: 0.85rem; color: #e65100; }
.index-item-commit code { background: rgba(0,0,0,0.08); padding: 1px 4px; border-radius: 3px; font-size: 0.8rem; margin-right: 6px; }
.commit-card { margin: 8px 0; padding: 10px 14px; background: #fff3e0; border-left: 4px solid #ff9800; border-radius: 6px; }
.commit-card a { text-decoration: none; color: #5d4037; display: block; }
.commit-card a:hover { color: #e65100; }
.commit-card-hash { font-family: monospace; color: #e65100; font-weight: 600; margin-right: 8px; }
.index-commit { margin-bottom: 12px; padding: 10px 16px; background: #fff3e0; border-left: 4px solid #ff9800; border-radius: 8px; box-shadow: 0 1px 2px rgba(0,0,0,0.05); }
.index-commit a { display: block; text-decoration: none; color: inherit; }
.index-commit a:hover { background: rgba(255, 152, 0, 0.1); margin: -10px -16px; padding: 10px 16px; border-radius: 8px; }
.index-commit-header { display: flex; justify-content: space-between; align-items: center; font-size: 0.85rem; margin-bottom: 4px; }
.index-commit-hash { font-family: monospace; color: #e65100; font-weight: 600; }
.index-commit-msg { color: #5d4037; }
.index-item-long-text { margin-top: 8px; padding: 12px; background: var(--card-bg); border-radius: 8px; border-left: 3px solid var(--assistant-border); }
.index-item-long-text .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, var(--card-bg)); }
.index-item-long-text-content { color: var(--text-color); }
#search-box { display: none; align-items: center; gap: 8px; }
#search-box input { padding: 6px 12px; border: 1px solid var(--assistant-border); border-radius: 6px; font-size: 16px; width: 180px; }
#search-box button, #modal-search-btn, #modal-close-btn { background: var(--user-border); color: white; border: none; border-radius: 6px; padding: 6px 10px; cursor: pointer; display: flex; align-items: center; justify-content: center; }
#search-box button:hover, #modal-search-btn:hover { background: #1565c0; }
#modal-close-btn { background: var(--text-muted); margin-left: 8px; }
#modal-close-btn:hover { background: #616161; }
#search-modal[open] { border: none; border-radius: 12px; box-shadow: 0 4px 24px rgba(0,0,0,0.2); padding: 0; width: 90vw; max-width: 900px; height: 80vh; max-height: 80vh; display: flex; flex-direction: column; }
#search-modal::backdrop { background: rgba(0,0,0,0.5); }
.search-modal-header { display: flex; align-items: center; gap: 8px; padding: 16px; border-bottom: 1px solid var(--assistant-border); background: var(--bg-color); border-radius: 12px 12px 0 0; }
.search-modal-header input { flex: 1; padding: 8px 12px; border: 1px solid var(--assistant-border); border-radius: 6px; font-size: 16px; }
#search-status { padding: 8px 16px; font-size: 0.85rem; color: var(--text-muted); border-bottom: 1px solid rgba(0,0,0,0.06); }
#search-results { flex: 1; overflow-y: auto; padding: 16px; }
.search-result { margin-bottom: 16px; border-radius: 8px; overflow: hidden; box-shadow: 0 1px 3px rgba(0,0,0,0.1); }
.search-result a { display: block; text-decoration: none; color: inherit; }
.search-result a:hover { background: rgba(25, 118, 210, 0.05); }
.search-result-page { padding: 6px 12px; background: rgba(0,0,0,0.03); font-size: 0.8rem; color: var(--text-muted); border-bottom: 1px solid rgba(0,0,0,0.06); }
.search-result-content { padding: 12px; }
.search-result mark { background: #fff59d; padding: 1px 2px; border-radius: 2px; }
@media (max-width: 600px) { body { padding: 8px; } .message, .index-item { border-radius: 8px; } .message-content, .index-item-content { padding: 12px; } pre { font-size: 0.8rem; padding: 8px; } #search-box input { width: 120px; } #search-modal[open] { width: 95vw; height: 90vh; } }
</style>
</head>
<body>
    <div class="container">
        <h1><a href="index.html" style="color: inherit; text-decoration: none;">Claude Code transcript</a> - page 3/4</h1>
        

<div class="pagination">
<a href="index.html" class="index-link">Index</a>
<a href="page-002.html">&larr; Prev</a>
<a href="page-001.html">1</a>
<a href="page-002.html">2</a>
<span class="current">3</span>
<a href="page-004.html">4</a>
<a href="page-004.html">Next &rarr;</a>
</div>

        
<div class="message user" id="msg-2025-12-14T18-59-23-149Z"><div class="message-header"><span class="role-label">User</span><a href="#msg-2025-12-14T18-59-23-149Z" class="timestamp-link"><time datetime="2025-12-14T18:59:23.149Z" data-timestamp="2025-12-14T18:59:23.149Z">2025-12-14T18:59:23.149Z</time></a></div><div class="message-content">
<div class="user-content"><p>can you explain how the Hybrid Capture Metagenomics works in more detail and how it would work with high host (human) contamination</p></div></div></div>
<div class="message assistant" id="msg-2025-12-14T19-00-23-673Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T19-00-23-673Z" class="timestamp-link"><time datetime="2025-12-14T19:00:23.673Z" data-timestamp="2025-12-14T19:00:23.673Z">2025-12-14T19:00:23.673Z</time></a></div><div class="message-content">
<div class="assistant-text"><h2>Hybrid Capture Metagenomics: How It Works</h2>
<h3>The Core Problem</h3>
<p>FGT samples are brutal for metagenomics:
- <strong>90-99% human DNA</strong> in many samples
- Shotgun sequencing wastes most reads on host
- To get 10M bacterial reads, you might need 100M+ total reads
- Cost scales linearly with this inefficiency</p>
<h3>The Solution: Capture Enrichment</h3>
<p>Hybrid capture uses synthetic oligonucleotide probes (typically 80-120bp) that are complementary to your targets of interest. These probes are biotinylated, allowing you to physically pull down the sequences you want.</p>
<pre><code>                    WORKFLOW OVERVIEW

     Total DNA from FGT sample
     (95% human, 5% bacterial)
                │
                ▼
     Fragment to ~300-500bp
     Add sequencing adapters
                │
                ▼
     Denature (make single-stranded)
                │
                ▼
     Hybridize with biotinylated probes
     (probes complementary to bacterial targets)
                │
      ┌─────────┴─────────┐
      │                   │
   Bacterial           Human DNA
   fragments           (no probes
   with probes         bound)
   hybridized             │
      │                   │
      ▼                   ▼
   Streptavidin        WASHED
   magnetic beads      AWAY
   pull down              
   biotinylated           
   complexes              
      │
      ▼
   Wash stringently
   (remove non-specific binding)
      │
      ▼
   Elute captured fragments
      │
      ▼
   PCR amplify (optional, low cycles)
      │
      ▼
   Sequence
   (now 70-95% bacterial)
</code></pre>
<h3>Enrichment Efficiency</h3>
<table>
<thead>
<tr>
<th>Sample type</th>
<th>Pre-capture bacterial</th>
<th>Post-capture bacterial</th>
<th>Fold enrichment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low host</td>
<td>30%</td>
<td>90%</td>
<td>3x</td>
</tr>
<tr>
<td>Medium host</td>
<td>10%</td>
<td>85%</td>
<td>8.5x</td>
</tr>
<tr>
<td>High host</td>
<td>1%</td>
<td>70-80%</td>
<td>70-80x</td>
</tr>
<tr>
<td>Very high host</td>
<td>0.1%</td>
<td>50-60%</td>
<td>500-600x</td>
</tr>
</tbody>
</table>
<p>The worse your starting material, the more capture helps.</p>
<h3>Probe Design Strategy for FGT</h3>
<p><strong>Option 1: Whole genome probes</strong></p>
<p>Design probes tiling across complete genomes of target organisms:</p>
<pre><code>Target species list (example):
├── Lactobacillus crispatus (complete genome, ~2.0 Mb)
├── Lactobacillus iners (~1.3 Mb)
├── Lactobacillus jensenii (~1.5 Mb)
├── Lactobacillus gasseri (~1.9 Mb)
├── Gardnerella vaginalis (~1.6 Mb)
├── Gardnerella leopoldii (~1.5 Mb)
├── Gardnerella swidsinskii (~1.5 Mb)
├── Gardnerella piotii (~1.5 Mb)
├── Prevotella bivia (~2.5 Mb)
├── Prevotella amnii (~2.3 Mb)
├── Atopobium vaginae (~1.4 Mb)
├── Sneathia amnii (~1.3 Mb)
├── Sneathia sanguinegens (~1.4 Mb)
├── Megasphaera type 1 (~2.0 Mb)
├── Megasphaera type 2 (~1.9 Mb)
├── Mycoplasma hominis (~0.7 Mb)
├── Mycoplasma genitalium (~0.6 Mb)
├── BVAB1 (Candidatus Lachnocurva vaginae)
├── BVAB2
├── BVAB3
└── ... (20-40 species total)

Total target space: ~40-60 Mb
Probe count: ~300,000-500,000 probes (80bp, 2x tiling)
</code></pre>
<p><strong>Option 2: Conserved gene probes (more economical)</strong></p>
<p>Target universal + discriminatory genes only:</p>
<pre><code>Per organism:
├── cpn60 (full gene, ~1.6 kb)
├── rpoB (full gene, ~4 kb)
├── 16S rRNA (full gene, ~1.5 kb)
├── 23S rRNA (partial, ~1 kb)
├── recA (~1 kb)
├── gyrB (~2 kb)
└── Species-specific markers (~2-5 kb)

Plus functional genes of interest:
├── Sialidases (nanH family)
├── Cytolysins (vly, ily)
├── Lactate dehydrogenases
├── Biogenic amine genes
└── AMR genes

Total target space: ~2-5 Mb
Probe count: ~20,000-50,000 probes
</code></pre>
<p><strong>Option 3: Hybrid approach (recommended)</strong></p>
<pre><code>Full genome coverage:
├── Top 10 most abundant/important species (full genomes)
└── ~20 Mb target space

Conserved gene coverage:
├── Next 30-50 species (marker genes only)
└── ~5 Mb target space

Functional gene panel:
├── All known variants of key genes
└── ~1-2 Mb target space

Total: ~25-30 Mb, ~200,000-250,000 probes
</code></pre>
<h3>How Strain Resolution Works with Capture</h3>
<p>This is where it gets powerful. Unlike amplicons that give you one short region, capture gives you <strong>multiple genomic regions per organism</strong>:</p>
<pre><code>Example: Two L. crispatus strains in same sample

                    Strain A genome                 Strain B genome
                    ────────────────                ────────────────
Region 1 (cpn60):   ATGCGATCGATCG...               ATGCGATCGATCG...  (identical)
Region 2 (CRISPR):  CRISPR-A-specific              CRISPR-B-specific (different)
Region 3 (prophage):Present                        Absent
Region 4 (surface): Variant A                      Variant B
Region 5 (metabolic):Gene X present               Gene X absent

Capture recovers ALL of these regions
→ Computational deconvolution identifies both strains
→ Can track which strain dominates over time
→ Can associate specific strains with outcomes
</code></pre>
<p>Tools like <strong>StrainGE</strong>, <strong>StrainPhlAn</strong>, <strong>inStrain</strong>, or <strong>MIDAS2</strong> can resolve strains from this data.</p>
<h3>Practical Protocol</h3>
<p><strong>Day 1: Library Prep</strong></p>
<pre><code>1. Extract DNA (your existing protocol)
2. Quantify (Qubit)
3. Fragment to 350-500bp (Covaris or enzymatic)
4. End repair + A-tailing
5. Adapter ligation (unique dual indexes)
6. Size selection (beads or gel)
7. Pre-capture PCR (6-8 cycles)
8. QC: Bioanalyzer + qPCR
</code></pre>
<p><strong>Day 2: Capture</strong></p>
<pre><code>1. Pool 8-16 libraries (equal mass, ~500ng total)
2. Add blocking oligos (block adapters + human Cot-1)
3. Denature (95°C, 5 min)
4. Add probe pool
5. Hybridize (65-68°C, 16-24 hours)
</code></pre>
<p><strong>Day 3: Wash + Sequence</strong></p>
<pre><code>1. Bind to streptavidin beads
2. Stringent washes (increasing temperature)
3. Elute captured DNA
4. Post-capture PCR (8-12 cycles)
5. QC: Bioanalyzer + qPCR
6. Pool for sequencing
7. Sequence: NovaSeq S4, 2x150bp
</code></pre>
<h3>Expected Performance for FGT Samples</h3>
<table>
<thead>
<tr>
<th>Metric</th>
<th>Shotgun (no capture)</th>
<th>With capture</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reads per sample</td>
<td>50-100M needed</td>
<td>10-20M sufficient</td>
</tr>
<tr>
<td>Bacterial reads</td>
<td>1-10M</td>
<td>8-18M</td>
</tr>
<tr>
<td>Species detected</td>
<td>15-30</td>
<td>20-40 (better sensitivity)</td>
</tr>
<tr>
<td>Strain resolution</td>
<td>Marginal</td>
<td>Good</td>
</tr>
<tr>
<td>Cost per sample</td>
<td>$400-800</td>
<td>$200-400</td>
</tr>
<tr>
<td>Novel taxa detection</td>
<td>Yes</td>
<td>Limited to related sequences</td>
</tr>
</tbody>
</table>
<h3>The Trade-off: Discovery vs. Enrichment</h3>
<p><strong>Capture limitations:</strong>
- Only enriches sequences similar to probes
- Truly novel organisms (no close relative in design) will be missed
- ~15-20% sequence divergence is typical capture limit</p>
<p><strong>Mitigation strategies:</strong>
1. Include diverse representatives of each genus
2. Use degenerate probe designs for variable regions
3. Run a subset of samples with shotgun (no capture) for discovery
4. Iteratively update probe design as you find new taxa</p>
<h3>Recommended Workflow for FRESH</h3>
<pre><code>┌────────────────────────────────────────────────────────────────────┐
│                                                                    │
│   Phase 1: Discovery + Probe Design                                │
│   ├── Deep shotgun metagenomics on 50 diverse samples             │
│   │   (accept the host contamination cost for discovery)          │
│   ├── Assemble MAGs, identify population-specific taxa            │
│   ├── Design probe set based on YOUR population                   │
│   └── Include reference genomes + your novel MAGs                 │
│                                                                    │
│   Phase 2: Validation                                              │
│   ├── Capture on same 50 samples                                  │
│   ├── Compare: What did shotgun find that capture missed?         │
│   ├── Iterate probe design if needed                              │
│   └── Establish sensitivity/specificity                           │
│                                                                    │
│   Phase 3: Scale                                                   │
│   ├── Capture on 300-500 samples                                  │
│   ├── Strain-level analysis                                       │
│   ├── Correlate with HIV outcomes                                 │
│   └── Identify candidate strains/genes for mechanism              │
│                                                                    │
│   Phase 4: Validation of findings                                  │
│   ├── qPCR for specific strain markers                            │
│   ├── Test on full cohort                                         │
│   └── Functional studies on isolates                              │
│                                                                    │
└────────────────────────────────────────────────────────────────────┘
</code></pre>
<h3>Vendors and Costs</h3>
<table>
<thead>
<tr>
<th>Vendor</th>
<th>Product</th>
<th>Probes</th>
<th>Cost (probes)</th>
<th>Cost/rxn</th>
</tr>
</thead>
<tbody>
<tr>
<td>Twist Bioscience</td>
<td>Custom panels</td>
<td>Up to 1M</td>
<td>$15-25K</td>
<td>~$50-80</td>
</tr>
<tr>
<td>Agilent</td>
<td>SureSelect XT</td>
<td>Up to 6M</td>
<td>$20-40K</td>
<td>~$80-120</td>
</tr>
<tr>
<td>IDT</td>
<td>xGen Lockdown</td>
<td>Up to 500K</td>
<td>$10-20K</td>
<td>~$40-70</td>
</tr>
<tr>
<td>Roche</td>
<td>SeqCap EZ</td>
<td>Custom</td>
<td>$25-50K</td>
<td>~$100-150</td>
</tr>
<tr>
<td>Arbor Biosciences</td>
<td>myBaits</td>
<td>Custom</td>
<td>$8-15K</td>
<td>~$30-60</td>
</tr>
</tbody>
</table>
<p>At your scale (hundreds of samples), per-reaction cost dominates. Twist or Arbor are probably most cost-effective.</p>
<h3>Questions</h3>
<ol>
<li>
<p><strong>Do you have deep shotgun data on any FRESH samples already?</strong> This would jumpstart probe design.</p>
</li>
<li>
<p><strong>What's your target depth for strain resolution?</strong> 10x coverage of a genome gives species; 30-50x gives confident strain calls.</p>
</li>
<li>
<p><strong>Interest in capturing AMR genes systematically?</strong> Easy to add, potentially high-impact finding if BV-associated bacteria carry resistance.</p>
</li>
<li>
<p><strong>Would you want to include phage/mobile elements in the capture?</strong> These drive strain evolution and could explain longitudinal dynamics.</p>
</li>
</ol></div></div></div>
<div class="message user" id="msg-2025-12-14T22-31-24-844Z"><div class="message-header"><span class="role-label">User</span><a href="#msg-2025-12-14T22-31-24-844Z" class="timestamp-link"><time datetime="2025-12-14T22:31:24.844Z" data-timestamp="2025-12-14T22:31:24.844Z">2025-12-14T22:31:24.844Z</time></a></div><div class="message-content">
<div class="user-content"><p>i think i want to skip the hybrid capture for now and just focus on our PCR and amplicon survey approaches</p></div></div></div>
<div class="message assistant" id="msg-2025-12-14T22-31-41-893Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T22-31-41-893Z" class="timestamp-link"><time datetime="2025-12-14T22:31:41.893Z" data-timestamp="2025-12-14T22:31:41.893Z">2025-12-14T22:31:41.893Z</time></a></div><div class="message-content">
<div class="assistant-text"><p>Smart call. Hybrid capture adds complexity and you can always layer it in later once the amplicon foundation is solid. Let's focus.</p>
<h2>Refined Platform: Multi-Amplicon FGT Profiling</h2>
<h3>Core Amplicon Panel</h3>
<table>
<thead>
<tr>
<th>Amplicon</th>
<th>Target</th>
<th>Length</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>16S V4</td>
<td>Bacteria (broad)</td>
<td>~250bp</td>
<td>Cross-study compatibility, rare taxa</td>
</tr>
<tr>
<td>16S V1-V3</td>
<td>Bacteria (Lactobacillus-optimized)</td>
<td>~500bp</td>
<td>Better Lactobacillus species resolution</td>
</tr>
<tr>
<td>cpn60 UT</td>
<td>Bacteria (species-level)</td>
<td>~550bp</td>
<td>Gardnerella species, strain hints</td>
</tr>
<tr>
<td>rpoB</td>
<td>Bacteria (orthogonal)</td>
<td>~350bp</td>
<td>Independent species validation, Lactobacillus</td>
</tr>
</tbody>
</table>
<h3>Functional Gene Amplicons</h3>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Target organisms</th>
<th>Biological readout</th>
</tr>
</thead>
<tbody>
<tr>
<td>nanH (sialidase)</td>
<td>Gardnerella, Prevotella</td>
<td>Mucin degradation, virulence</td>
</tr>
<tr>
<td>vly (vaginolysin)</td>
<td>Gardnerella</td>
<td>Cytolysis, inflammation</td>
</tr>
<tr>
<td>ily (inerolysin)</td>
<td>L. iners</td>
<td>Epithelial damage potential</td>
</tr>
<tr>
<td>ldhD</td>
<td>L. crispatus, others</td>
<td>D-lactate production (protective)</td>
</tr>
</tbody>
</table>
<h3>Key Development Questions</h3>
<ol>
<li>
<p><strong>Primer design</strong> - Use existing published primers or design de novo from comparative genomics?</p>
</li>
<li>
<p><strong>Multiplexing strategy</strong> - How many pools? Single reaction vs. separate PCRs?</p>
</li>
<li>
<p><strong>Sequencing platform</strong> - Illumina short-read vs. PacBio/ONT for full-length amplicons?</p>
</li>
<li>
<p><strong>Reference database</strong> - Build South African-specific or augment existing?</p>
</li>
</ol>
<p>Where do you want to dig in first? I'd suggest starting with comparative genomics for primer design - that's foundational and plays to your strengths.</p></div></div></div>
<div class="message user" id="msg-2025-12-14T22-33-15-940Z"><div class="message-header"><span class="role-label">User</span><a href="#msg-2025-12-14T22-33-15-940Z" class="timestamp-link"><time datetime="2025-12-14T22:33:15.940Z" data-timestamp="2025-12-14T22:33:15.940Z">2025-12-14T22:33:15.940Z</time></a></div><div class="message-content">
<div class="user-content"><p>lets discuss primer design first. can you search the web and also consider novel designs or optimizations. perhaps there are new tech developments or approaches we could build in that would improve our technique, increase sequence quality or minimize contamination issues. I am fine sticking with published primer sets but would also be interested in enhancements</p></div></div></div>
<div class="message assistant" id="msg-2025-12-14T22-34-15-677Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T22-34-15-677Z" class="timestamp-link"><time datetime="2025-12-14T22:34:15.677Z" data-timestamp="2025-12-14T22:34:15.677Z">2025-12-14T22:34:15.677Z</time></a></div><div class="message-content">
<div class="assistant-text"><p>Let me search for recent developments in amplicon primer design and optimization strategies.</p></div>
<div class="tool-use" data-tool-id="toolu_01LDEimVr2URvibrjneSLuru"><div class="tool-header"><span class="tool-icon">⚙</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;amplicon primer design optimization 2024 microbiome sequencing contamination reduction&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div>
<div class="tool-use" data-tool-id="toolu_01JNDDT8BdUZw3d4rWAL1EfL"><div class="tool-header"><span class="tool-icon">⚙</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;cpn60 universal primer design vaginal microbiome 2023 2024&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div>
<div class="tool-use" data-tool-id="toolu_01GAaAv92HD2JhA9JWgsZrBo"><div class="tool-header"><span class="tool-icon">⚙</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;blocking primers host DNA amplicon microbiome low biomass&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T22-34-42-853Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T22-34-42-853Z" class="timestamp-link"><time datetime="2025-12-14T22:34:42.853Z" data-timestamp="2025-12-14T22:34:42.853Z">2025-12-14T22:34:42.853Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;amplicon primer design optimization 2024 microbiome sequencing contamination reduction&quot;

Links: [{&quot;title&quot;:&quot;Accelerating primer design for amplicon sequencing using large language model-powered agents | Nature Biomedical Engineering&quot;,&quot;url&quot;:&quot;https://www.nature.com/articles/s41551-025-01455-z&quot;},{&quot;title&quot;:&quot;How Amplicon Sequencing Works: From Primer Design to Data Analysis - CD Genomics&quot;,&quot;url&quot;:&quot;https://www.cd-genomics.com/resource-how-amplicon-sequencing-works.html&quot;},{&quot;title&quot;:&quot;Accelerating primer design for amplicon sequencing using large language model-powered agents - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/40738975/&quot;},{&quot;title&quot;:&quot;The Impact of Primer Design on Amplicon-Based Metagenomic Profiling Accuracy: Detailed Insights into Bifidobacterial Community Structure - PMC&quot;,&quot;url&quot;:&quot;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023036/&quot;},{&quot;title&quot;:&quot;Characterizing Microbiomes via Sequencing of Marker Loci: Techniques To Improve Throughput, Account for Cross-Contamination, and Reduce Cost | mSystems&quot;,&quot;url&quot;:&quot;https://journals.asm.org/doi/10.1128/msystems.00294-21&quot;},{&quot;title&quot;:&quot;An optimized protocol for high-throughput amplicon-based microbiome profiling | Protocol Exchange&quot;,&quot;url&quot;:&quot;https://protocolexchange.researchsquare.com/article/nprot-4831/v1&quot;},{&quot;title&quot;:&quot;EnsembleSeq: a workflow towards real-time, rapid, and simultaneous multi-kingdom-amplicon sequencing for holistic and resource-effective microbiome research at scale | Microbiology Spectrum&quot;,&quot;url&quot;:&quot;https://journals.asm.org/doi/10.1128/spectrum.04150-23&quot;},{&quot;title&quot;:&quot;Design and application of a novel two-amplicon approach for defining eukaryotic microbiota | Microbiome | Full Text&quot;,&quot;url&quot;:&quot;https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0612-3&quot;},{&quot;title&quot;:&quot;The Impact of Primer Design on Amplicon-Based Metagenomic Profiling Accuracy: Detailed Insights into Bifidobacterial Community Structure&quot;,&quot;url&quot;:&quot;https://www.mdpi.com/2076-2607/8/1/131&quot;},{&quot;title&quot;:&quot;A practical guide to amplicon and metagenomic analysis of microbiome data - PMC&quot;,&quot;url&quot;:&quot;https://pmc.ncbi.nlm.nih.gov/articles/PMC8106563/&quot;}]

Here are the search results for amplicon primer design optimization in microbiome sequencing with a focus on contamination reduction:

## Key Findings

### AI-Powered Primer Design
PrimeGen is an orchestrated multi-agent system powered by large language models, designed to streamline labour-intensive primer design tasks for targeted next-generation sequencing. PrimeGen uses GPT-4o as a central controller to engage with experimentalists for task planning and decomposition, coordinating various specialized agents to execute distinct subtasks.(no content)Experimental demonstrations showed that PrimeGen can accommodate up to 955 amplicons, ensuring high amplification uniformity and minimizing dimer formation.

### Primer Design Importance for Microbiome Accuracy
The most widespread microbiota profiling method is based on amplification and sequencing of a variable portion of the 16S rRNA gene as a universal taxonomic marker. Despite its popularity and obvious advantages, this 16S rRNA gene-based approach comes with some important limitations. In particular, the choice of the primer pair for amplification plays a major role in defining the accuracy of the reconstructed bacterial profiles.

### Contamination Reduction Strategies
The amplification and sequencing of nontarget DNA is a particular challenge for microbial ecologists studying host-associated symbionts. For instance, botanists interested in the bacteria within plants must contend with chloroplast DNA (cpDNA), which is amplified by many commonly used rRNA primers. Indeed, in some cases, 90% or more of reads recovered from plant tissues are cpDNA.(no content)While 1391f is predicted to bind more Excavata, Amoebozoa, and Alveolata genes, V9-9_F performed better for Stramenopiles, Rhizaria, Nematoda, and Platyhelminthes, with an additional advantage of low predicted binding to bacterial rRNA genes, reducing contamination.(no content)The recovery of human amplicons in analyses suggests that host contamination may restrict a more comprehensive sampling of eukaryotic microbiota. Strategies such as human DNA blocking primers are needed to reduce host DNA signal.

### Best Practices for Primer Selection
A good method for selecting primer is to evaluate their specificity and overall coverage using real samples or electronic PCR based on the SILVA database and on host factors including the presence of chloroplasts, mitochondria, ribosomes, and other potential sources of non-specific amplification.(no content)An optimized protocol for amplicon-based microbiome profiling uses a modular, two-step PCR process that provides versatility as a common set of indexing primers can be paired with many sets of marker gene specific primers. This protocol is designed for high-throughput and incorporates best practices that substantially increase accuracy compared to existing methods and also minimize the dropout of taxa that have mismatches to the amplification primers.

### Quality Control Measures
Optimization of primer sequences and reaction conditions helps balance amplification across the entire genome, resulting in more accurate sequencing data. Strict quality control (QC) is essential to ensure amplicon purity and integrity before library preparation.(no content)Attempts at optimizing the template amount, primer concentrations, and annealing conditions may yield success, thereby further reducing the time and cost associated with multi-amplicon sequencing-based microbiome studies.


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T22-37-06-647Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T22-37-06-647Z" class="timestamp-link"><time datetime="2025-12-14T22:37:06.647Z" data-timestamp="2025-12-14T22:37:06.647Z">2025-12-14T22:37:06.647Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;cpn60 universal primer design vaginal microbiome 2023 2024&quot;

API Error: 500 {&quot;type&quot;:&quot;error&quot;,&quot;error&quot;:{&quot;type&quot;:&quot;api_error&quot;,&quot;message&quot;:&quot;Internal server error&quot;},&quot;request_id&quot;:null}


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T22-37-18-653Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T22-37-18-653Z" class="timestamp-link"><time datetime="2025-12-14T22:37:18.653Z" data-timestamp="2025-12-14T22:37:18.653Z">2025-12-14T22:37:18.653Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;blocking primers host DNA amplicon microbiome low biomass&quot;

API Error: 500 {&quot;type&quot;:&quot;error&quot;,&quot;error&quot;:{&quot;type&quot;:&quot;api_error&quot;,&quot;message&quot;:&quot;Internal server error&quot;},&quot;request_id&quot;:null}


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T22-40-49-818Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T22-40-49-818Z" class="timestamp-link"><time datetime="2025-12-14T22:40:49.818Z" data-timestamp="2025-12-14T22:40:49.818Z">2025-12-14T22:40:49.818Z</time></a></div><div class="message-content">
<div class="assistant-text"><p>API Error: 529 {"type":"error","error":{"type":"overloaded_error","message":"Overloaded"},"request_id":null}</p></div></div></div>
<div class="message assistant" id="msg-2025-12-14T22-41-32-552Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T22-41-32-552Z" class="timestamp-link"><time datetime="2025-12-14T22:41:32.552Z" data-timestamp="2025-12-14T22:41:32.552Z">2025-12-14T22:41:32.552Z</time></a></div><div class="message-content">
<div class="assistant-text"><p>You're right, let me search for more recent developments.</p></div>
<div class="tool-use" data-tool-id="toolu_01HUgdm25Vm4ShMxTTCt7sHc"><div class="tool-header"><span class="tool-icon">⚙</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;amplicon primer design microbiome 2025 novel approaches&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div>
<div class="tool-use" data-tool-id="toolu_01Cxy6b5XdVLnHG6ofJC2Voz"><div class="tool-header"><span class="tool-icon">⚙</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;blocking primers host contamination low biomass microbiome 2025&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div>
<div class="tool-use" data-tool-id="toolu_01Mk4UDA25ebXfFW1JUbvrce"><div class="tool-header"><span class="tool-icon">⚙</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;cpn60 chaperonin primer vaginal microbiome 2025&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div>
<div class="tool-use" data-tool-id="toolu_018mjo4D8w8LJ8eWw5x3jme5"><div class="tool-header"><span class="tool-icon">⚙</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;PNA LNA blocking oligonucleotides microbiome host DNA depletion 2025&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T22-41-38-927Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T22-41-38-927Z" class="timestamp-link"><time datetime="2025-12-14T22:41:38.927Z" data-timestamp="2025-12-14T22:41:38.927Z">2025-12-14T22:41:38.927Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;amplicon primer design microbiome 2025 novel approaches&quot;

Links: [{&quot;title&quot;:&quot;MicrobiomePrime: A primer pair selection tool for microbial source tracking validated on a comprehensive collection of animal gut and fecal waste microbiomes | bioRxiv&quot;,&quot;url&quot;:&quot;https://www.biorxiv.org/content/10.1101/2025.07.08.663663v1&quot;},{&quot;title&quot;:&quot;Design and application of a novel two-amplicon approach for defining eukaryotic microbiota | Microbiome | Full Text&quot;,&quot;url&quot;:&quot;https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0612-3&quot;},{&quot;title&quot;:&quot;MicrobiomePrime: A primer pair selection tool for microbial source tracking validated on a comprehensive collection of animal gut and fecal waste microbiomes - ScienceDirect&quot;,&quot;url&quot;:&quot;https://www.sciencedirect.com/science/article/pii/S0043135425018937&quot;},{&quot;title&quot;:&quot;Design and application of a novel two-amplicon approach for defining eukaryotic microbiota | Microbiome&quot;,&quot;url&quot;:&quot;https://link.springer.com/article/10.1186/s40168-018-0612-3&quot;},{&quot;title&quot;:&quot;ARDEP, a Rapid Degenerate Primer Design Pipeline Based on k-mers for Amplicon Microbiome Studies - PMC&quot;,&quot;url&quot;:&quot;https://pmc.ncbi.nlm.nih.gov/articles/PMC7459862/&quot;},{&quot;title&quot;:&quot;Amplicon-Based Microbiome Profiling: From Second- to Third-Generation Sequencing for Higher Taxonomic Resolution - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/37628619/&quot;},{&quot;title&quot;:&quot;Amplicon-Based Microbiome Profiling: From Second- to Third-Generation Sequencing for Higher Taxonomic Resolution - PMC&quot;,&quot;url&quot;:&quot;https://pmc.ncbi.nlm.nih.gov/articles/PMC10454624/&quot;},{&quot;title&quot;:&quot;The Impact of Primer Design on Amplicon-Based Metagenomic Profiling Accuracy: Detailed Insights into Bifidobacterial Community Structure - PMC&quot;,&quot;url&quot;:&quot;https://pmc.ncbi.nlm.nih.gov/articles/PMC7023036/&quot;},{&quot;title&quot;:&quot;(PDF) ARDEP, a Rapid Degenerate Primer Design Pipeline Based on k-mers for Amplicon Microbiome Studies&quot;,&quot;url&quot;:&quot;https://www.researchgate.net/publication/343714996_ARDEP_a_Rapid_Degenerate_Primer_Design_Pipeline_Based_on_k-mers_for_Amplicon_Microbiome_Studies&quot;},{&quot;title&quot;:&quot;ARDEP, a Rapid Degenerate Primer Design Pipeline Based on k-mers for Amplicon Microbiome Studies&quot;,&quot;url&quot;:&quot;https://www.mdpi.com/1660-4601/17/16/5958&quot;}]


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T22-41-39-610Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T22-41-39-610Z" class="timestamp-link"><time datetime="2025-12-14T22:41:39.610Z" data-timestamp="2025-12-14T22:41:39.610Z">2025-12-14T22:41:39.610Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;blocking primers host contamination low biomass microbiome 2025&quot;

Links: [{&quot;title&quot;:&quot;Guidelines for preventing and reporting contamination in low-biomass microbiome studies - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/40542287/&quot;},{&quot;title&quot;:&quot;Guidelines for preventing and reporting contamination in low-biomass microbiome studies | Nature Microbiology&quot;,&quot;url&quot;:&quot;https://www.nature.com/articles/s41564-025-02035-2&quot;},{&quot;title&quot;:&quot;18S Illumina Amplicon Protocol : earthmicrobiome&quot;,&quot;url&quot;:&quot;https://earthmicrobiome.org/protocols-and-standards/18s/&quot;},{&quot;title&quot;:&quot;De novo identification of microbial contaminants in low microbial biomass microbiomes with Squeegee | Nature Communications&quot;,&quot;url&quot;:&quot;https://www.nature.com/articles/s41467-022-34409-z&quot;},{&quot;title&quot;:&quot;Contamination in Low Microbial Biomass Microbiome Studies: Issues and Recommendations - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/30497919/&quot;},{&quot;title&quot;:&quot;Blanking on blanks: few insect microbiota studies control for contaminants - PMC&quot;,&quot;url&quot;:&quot;https://pmc.ncbi.nlm.nih.gov/articles/PMC11980574/&quot;},{&quot;title&quot;:&quot;Reagent and laboratory contamination can critically impact sequence-based microbiome analyses | BMC Biology | Full Text&quot;,&quot;url&quot;:&quot;https://bmcbiol.biomedcentral.com/articles/10.1186/s12915-014-0087-z&quot;},{&quot;title&quot;:&quot;Frontiers | micRoclean: an R package for decontaminating low-biomass 16S-rRNA microbiome data&quot;,&quot;url&quot;:&quot;https://www.frontiersin.org/journals/bioinformatics/articles/10.3389/fbinf.2025.1556361/full&quot;},{&quot;title&quot;:&quot;Contamination in Low Microbial Biomass Microbiome Studies: Issues and Recommendations - ScienceDirect&quot;,&quot;url&quot;:&quot;https://www.sciencedirect.com/science/article/abs/pii/S0966842X18302531&quot;},{&quot;title&quot;:&quot;Reviews &amp; Analysis | Nature Microbiology&quot;,&quot;url&quot;:&quot;https://www.nature.com/nmicrobiol/reviews-and-analysis?type=consensus-statement&amp;year=2025&quot;}]


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T22-42-01-038Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T22-42-01-038Z" class="timestamp-link"><time datetime="2025-12-14T22:42:01.038Z" data-timestamp="2025-12-14T22:42:01.038Z">2025-12-14T22:42:01.038Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;PNA LNA blocking oligonucleotides microbiome host DNA depletion 2025&quot;

Links: [{&quot;title&quot;:&quot;Does peptide-nucleic acid (PNA) clamping of host plant DNA benefit ITS1 amplicon-based characterization of the fungal endophyte community? - ScienceDirect&quot;,&quot;url&quot;:&quot;https://www.sciencedirect.com/science/article/abs/pii/S1754504822000423&quot;},{&quot;title&quot;:&quot;ATDBio - Nucleic Acids Book - Chapter 11: Nucleic acid analogues&quot;,&quot;url&quot;:&quot;https://atdbio.com/nucleic-acids-book/Nucleic-acid-analogues&quot;},{&quot;title&quot;:&quot;Locked Analog Bases (LNA-N) Oligo Modifications from Gene Link&quot;,&quot;url&quot;:&quot;https://www.genelink.com/newsite/products/mod_detail.asp?modid=482&quot;},{&quot;title&quot;:&quot;(PDF) Application of Blocking Oligonucleotides to Improve Signal-to-Noise Ratio in a PCR&quot;,&quot;url&quot;:&quot;https://www.researchgate.net/publication/47521290_Application_of_Blocking_Oligonucleotides_to_Improve_Signal-to-Noise_Ratio_in_a_PCR&quot;},{&quot;title&quot;:&quot;LNA blockers for improved amplification selectivity - PMC&quot;,&quot;url&quot;:&quot;https://pmc.ncbi.nlm.nih.gov/articles/PMC10038989/&quot;},{&quot;title&quot;:&quot;Artificial genetic polymers against human pathologies | Biology Direct | Full Text&quot;,&quot;url&quot;:&quot;https://biologydirect.biomedcentral.com/articles/10.1186/s13062-022-00353-7&quot;},{&quot;title&quot;:&quot;Modified version from (9). Different mechanisms of blocking oligos. (a)... | Download Scientific Diagram&quot;,&quot;url&quot;:&quot;https://www.researchgate.net/figure/Modified-version-from-9-Different-mechanisms-of-blocking-oligos-a-Annealing_fig1_47521290&quot;},{&quot;title&quot;:&quot;Peptide nucleic acid (PNA) clamps reduce amplification of host chloroplast and mitochondria rRNA gene sequences and increase detected diversity in 16S rRNA gene profiling analysis of oak-associated microbiota | Environmental Microbiome | Full Text&quot;,&quot;url&quot;:&quot;https://environmentalmicrobiome.biomedcentral.com/articles/10.1186/s40793-025-00674-w&quot;},{&quot;title&quot;:&quot;Peptide nucleic acid (PNA) clamps reduce amplification of host chloroplast and mitochondria rRNA gene sequences and increase detected diversity in 16S rRNA gene profiling analysis of oak-associated microbiota - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/39875992/&quot;},{&quot;title&quot;:&quot;Peptide nucleic acid - Wikipedia&quot;,&quot;url&quot;:&quot;https://en.wikipedia.org/wiki/Peptide_nucleic_acid&quot;}]

Based on my search, here&#x27;s what I found about PNA and LNA blocking oligonucleotides for microbiome host DNA depletion:

## PNA and LNA Blocking Oligonucleotides for Microbiome Studies

### Recent 2025 Research

A January 2025 study in Environmental Microbiome (volume 20, Article number: 14) addressed how acquiring representative bacterial 16S rRNA gene community profiles in plant microbiome studies can be challenging due to excessive co-amplification of host chloroplast and mitochondrial rRNA gene sequences. Peptide Nucleic Acid (PNA) clamps prevent this by blocking PCR primer binding or binding within the amplified region of non-target DNA to stop the function of DNA polymerase.(no content)The study applied a universal chloroplast (p)PNA clamp and a newly designed mitochondria (m)PNA clamp to minimise host chloroplast and mitochondria amplification in 16S rRNA gene amplicon profiles of leaf, bark and root tissue of two oak species. Adding PNA clamps to PCR led to an overall reduction of host chloroplast and mitochondrial 16S rRNA gene sequences of 79%, 46% and 99% in leaf, bark and root tissues, respectively.

### How PNA Clamps Work

PNA clamps are synthetic probes comprising high sequence-specific binding affinity toward DNA. The binding of the PNA clamp prevents DNA polymerase from moving along the target DNA.(no content)PNA oligomers show greater specificity in binding to complementary DNAs, with a PNA/DNA base mismatch being more destabilizing than a similar mismatch in a DNA/DNA duplex. This binding strength and specificity also applies to PNA/RNA duplexes. PNAs are not easily recognized by either nucleases or proteases, making them resistant to degradation by enzymes.

### LNA Blocking Oligonucleotides

When a desired DNA is present at low concentrations relative to nearly identical undesired DNAs, LNAs can block amplification of unwanted DNAs. Researchers have studied the length, number, and positioning of LNA bases to improve blocker effectiveness.(no content)Oligonucleotides 18–24 bases long with LNAs at every other position were most effective. Mismatches at LNA ends had little impact on blocking activity. Single and double mismatches were tolerated with longer blockers, especially if the mismatches were near LNA ends. Shorter LNAs were more selective, with &gt;1 mismatch preventing effective blocking.

### Comparison of Methods

Published host signal reduction (HSR) methods include restriction enzyme digestion, peptide nucleic acid (PNA) clamps, blocking oligonucleotides, and nested blocking primers, each with advantages and disadvantages.(no content)Although PNA clamps have been shown to significantly increase the microbial/plant DNA ratio, there are also indications that application of PNA clamps negatively affects PCR efficiency reducing an overall number of reads. However, other studies have shown that suppression of host DNA amplification using PNA clamps results in less biased microbial community analysis than the application of blocking primers and increases the chance of detecting rare microbial taxa.(no content)PNAs can be used to improve high-throughput 16S ribosomal RNA gene sequencing of plant and soil samples by blocking amplification of contaminant plastid and mitochondrial sequences.


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T22-42-09-656Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T22-42-09-656Z" class="timestamp-link"><time datetime="2025-12-14T22:42:09.656Z" data-timestamp="2025-12-14T22:42:09.656Z">2025-12-14T22:42:09.656Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;cpn60 chaperonin primer vaginal microbiome 2025&quot;

Links: [{&quot;title&quot;:&quot;Optimizing a PCR protocol for cpn60-based microbiome profiling of samples variously contaminated with host genomic DNA - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/26092180/&quot;},{&quot;title&quot;:&quot;A Study of the Vaginal Microbiome in Healthy Canadian Women Utilizing cpn60-Based Molecular Profiling Reveals Distinct Gardnerella Subgroup Community State Types - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/26266808/&quot;},{&quot;title&quot;:&quot;Resolution and Characterization of Distinct cpn60-Based Subgroups of Gardnerella vaginalis in the Vaginal Microbiota - PMC&quot;,&quot;url&quot;:&quot;https://ncbi.nlm.nih.gov/pmc/articles/PMC3416817&quot;},{&quot;title&quot;:&quot;Resolution and Characterization of Distinct cpn60-Based Subgroups of Gardnerella vaginalis in the Vaginal Microbiota | PLOS One&quot;,&quot;url&quot;:&quot;https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0043009&quot;},{&quot;title&quot;:&quot;Comparative analysis of DNA extraction and PCR product purification methods for cervicovaginal microbiome analysis using cpn60 microbial profiling - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/35025956/&quot;},{&quot;title&quot;:&quot;Pyrosequencing of the chaperonin-60 universal target as a tool for determining microbial community composition - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/19270139/&quot;},{&quot;title&quot;:&quot;A Study of the Vaginal Microbiome in Healthy Canadian Women Utilizing cpn60-Based Molecular Profiling Reveals Distinct Gardnerella Subgroup Community State Types | PLOS One&quot;,&quot;url&quot;:&quot;https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0135620&quot;},{&quot;title&quot;:&quot;Comparative analysis of DNA extraction and PCR product purification methods for cervicovaginal microbiome analysis using cpn60 microbial profiling | PLOS One&quot;,&quot;url&quot;:&quot;https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0262355&quot;},{&quot;title&quot;:&quot;Rapid and accurate taxonomic classification of cpn60 amplicon sequence variants | ISME Communications | Oxford Academic&quot;,&quot;url&quot;:&quot;https://academic.oup.com/ismecommun/article/3/1/77/7584927?login=false&quot;},{&quot;title&quot;:&quot;Update on cpnDB: a reference database of chaperonin sequences | Database | Oxford Academic&quot;,&quot;url&quot;:&quot;https://academic.oup.com/database/article/doi/10.1093/database/baz033/5367323&quot;}]

Here are the search results for &quot;cpn60 chaperonin primer vaginal microbiome 2025&quot;:

## Overview

The search results provide information about cpn60 (chaperonin-60) as a molecular target for vaginal microbiome profiling. Here are the key findings:

### What is cpn60?

The type I chaperonins (60 kDa chaperonin, CPN60, also known as GroEL or HSP60) are found in bacteria and a few archaea and in the mitochondria and chloroplasts of eukaryotes.(no content)The discovery that a 549–567 bp region of the cpn60 gene termed the &#x27;universal target&#x27; (UT) could be PCR amplified with degenerate primers provided the foundation for development of numerous applications exploiting cpn60 sequences.

### Advantages Over 16S rRNA

Microbial profiling using the chaperonin60 (cpn60) universal target (UT) improves resolution of vaginal species associated with negative health outcomes compared to the more commonly used 16S ribosomal DNA target.(no content)An approximately 555 bp region corresponding to nucleotides 274–828 of the E. coli cpn60 gene can be amplified with degenerate, universal PCR primers. This universal target (UT) region is phylogenetically informative, providing more discriminating power than 16S rRNA to differentiate organisms, even at the sub-species or strain level.

### Application to Vaginal Microbiome Studies

Detailed profiles of vaginal microbiomes were generated by pyrosequencing of the chaperonin-60 universal target. Six community state types (CST) were delineated by hierarchical clustering, including three Lactobacillus-dominated CST (L. crispatus, L. iners, L. jensenii), two Gardnerella-dominated (subgroups A and C) and an &quot;intermediate&quot; CST.(no content)The results support previous observations of genotypic and phenotypic diversity within G. vaginalis, and cpn60 UT sequences were successful for robust classification of available G. vaginalis strains into four subgroups, providing evidence that supports the eventual reclassification of subgroups as different species of Gardnerella.

### Recent 2025 Research

A recent publication in BMC Urol. 2025 Feb 28;25(1):41 describes &quot;A highly accurate nanopore-based sequencing workflow for culture and PCR-free microbial metagenomic profiling of urogenital samples.&quot;(no content)A review article in J Assist Reprod Genet. 2025 Jan;42(1):15-37 was published (Epub 2024 Oct 21) related to this field.

### PCR Protocol Considerations

The current recommended protocol for chaperonin-60 (cpn60) universal target based microbiome profiling includes universal PCR of microbiome samples across an annealing temperature gradient to maximize the diversity of sequences amplified. However, the value of including this gradient approach has not been formally evaluated since the optimization of a modified universal PCR primer cocktail for cpn60 PCR.(no content)Higher annealing temperatures resulted in larger amounts of PCR product and lower amounts of non-target sequence amplification, especially in samples containing proportionally large amounts of host DNA. These results provide important information to guide decisions about experimental design for cpn60 based microbiome studies.


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T22-42-38-411Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T22-42-38-411Z" class="timestamp-link"><time datetime="2025-12-14T22:42:38.411Z" data-timestamp="2025-12-14T22:42:38.411Z">2025-12-14T22:42:38.411Z</time></a></div><div class="message-content">
<div class="tool-use" data-tool-id="toolu_01PNnmC9GEHYj2UUzN6ZNGns"><div class="tool-header"><span class="tool-icon">⚙</span> WebFetch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;url&#34;: &#34;https://www.nature.com/articles/s41564-025-02035-2&#34;,
  &#34;prompt&#34;: &#34;What are the key guidelines for preventing contamination in low-biomass microbiome studies? What specific recommendations are made for primer design, controls, and best practices?&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div>
<div class="tool-use" data-tool-id="toolu_01AWuRbjvmHEguMqHJUTF4k4"><div class="tool-header"><span class="tool-icon">⚙</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;long-read amplicon sequencing PacBio nanopore full length 16S cpn60 2025&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div>
<div class="tool-use" data-tool-id="toolu_017DcJvHtJ9aWps886Dzhcjs"><div class="tool-header"><span class="tool-icon">⚙</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;unique molecular identifiers UMI amplicon sequencing PCR bias correction 2025&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T22-42-39-277Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T22-42-39-277Z" class="timestamp-link"><time datetime="2025-12-14T22:42:39.277Z" data-timestamp="2025-12-14T22:42:39.277Z">2025-12-14T22:42:39.277Z</time></a></div><div class="message-content"><div class="tool-result tool-error"><div class="truncatable"><div class="truncatable-content"><pre>Request failed with status code 303</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T22-43-02-919Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T22-43-02-919Z" class="timestamp-link"><time datetime="2025-12-14T22:43:02.919Z" data-timestamp="2025-12-14T22:43:02.919Z">2025-12-14T22:43:02.919Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;long-read amplicon sequencing PacBio nanopore full length 16S cpn60 2025&quot;

Links: [{&quot;title&quot;:&quot;Full-length 16S rRNA gene sequencing by PacBio improves taxonomic resolution in human microbiome samples | BMC Genomics&quot;,&quot;url&quot;:&quot;https://link.springer.com/article/10.1186/s12864-024-10213-5&quot;},{&quot;title&quot;:&quot;High-accuracy long-read amplicon sequences using unique molecular identifiers with Nanopore or PacBio sequencing | Nature Methods&quot;,&quot;url&quot;:&quot;https://www.nature.com/articles/s41592-020-01041-y&quot;},{&quot;title&quot;:&quot;[PDF] High-accuracy long-read amplicon sequences using unique molecular identifiers with Nanopore or PacBio sequencing | Semantic Scholar&quot;,&quot;url&quot;:&quot;https://www.semanticscholar.org/paper/High-accuracy-long-read-amplicon-sequences-using-or-Karst-Ziels/347b7508e019e3c157e345d4b69a908f5e8e9b4b&quot;},{&quot;title&quot;:&quot;High accuracy meets high throughput for near full-length 16S ribosomal RNA amplicon sequencing on the Nanopore platform | PNAS Nexus | Oxford Academic&quot;,&quot;url&quot;:&quot;https://academic.oup.com/pnasnexus/article/3/10/pgae411/7816023&quot;},{&quot;title&quot;:&quot;High-throughput amplicon sequencing of the full-length 16S rRNA gene with single-nucleotide resolution | Nucleic Acids Research | Oxford Academic&quot;,&quot;url&quot;:&quot;https://academic.oup.com/nar/article/47/18/e103/5527971&quot;},{&quot;title&quot;:&quot;High-accuracy long-read amplicon sequences using unique molecular identifiers with Nanopore or PacBio sequencing - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/33432244/&quot;},{&quot;title&quot;:&quot;Enabling high-accuracy long-read amplicon sequences using unique molecular identifiers with Nanopore or PacBio sequencing | bioRxiv&quot;,&quot;url&quot;:&quot;https://www.biorxiv.org/content/10.1101/645903v3.full&quot;},{&quot;title&quot;:&quot;Nanopore Is Preferable over Illumina for 16S Amplicon Sequencing of the Gut Microbiota When Species-Level Taxonomic Classification, Accurate Estimation of Richness, or Focus on Rare Taxa Is Required - PMC&quot;,&quot;url&quot;:&quot;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059749/&quot;},{&quot;title&quot;:&quot;Highly-multiplexed and efficient long-amplicon PacBio and Nanopore sequencing of hundreds of full mitochondrial genomes | BMC Genomics | Full Text&quot;,&quot;url&quot;:&quot;https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-023-09277-6&quot;},{&quot;title&quot;:&quot;High-throughput amplicon sequencing of the full-length 16S rRNA gene with single-nucleotide resolution | bioRxiv&quot;,&quot;url&quot;:&quot;https://www.biorxiv.org/content/10.1101/392332v2.full&quot;}]

Here are the search results for long-read amplicon sequencing with PacBio and Nanopore for full-length 16S and related markers:

## Key Findings

### Full-Length 16S rRNA Amplicon Sequencing

Sequencing variable regions of the 16S rRNA gene (≃300 bp) with Illumina technology is commonly used to study the composition of human microbiota. Unfortunately, short reads are unable to differentiate between highly similar species.(no content)A high-throughput amplicon sequencing approach combining unique molecular identifiers (UMIs) with Oxford Nanopore Technologies (ONT) or Pacific Biosciences circular consensus sequencing yields high-accuracy single-molecule consensus sequences of large genomic regions. This approach has been applied to sequence ribosomal RNA operon amplicons (~4,500 bp) and genomic sequences (&gt;10,000 bp) of reference microbial communities with a chimera rate &lt;0.02%.

### Accuracy Comparisons

To reach a mean UMI consensus error rate &lt;0.01%, a UMI read coverage of 15× (ONT R10.3), 25× (ONT R9.4.1) and 3× (Pacific Biosciences circular consensus sequencing) is needed, which provides a mean error rate of 0.0042%, 0.0041% and 0.0007%, respectively.(no content)Applying a final round of Racon polishing after Medaka led to a significant reduction in error rate, producing a mean sequence accuracy of 99.99%.

### ssUMI Workflow (2024)

The ssUMI workflow for high-throughput UMI-based error correction of near full-length 16S rRNA amplicons provided higher sequence accuracy than was observed for PacBio HiFi long reads and Illumina short reads, and reached a similar accuracy to LoopSeq synthetic long reads sequenced on Illumina.

### Nanopore vs. Illumina

The Nanopore data outperformed the Illumina data with respect to the proportion of reads from the faecal samples that could be classified to species. This highlights the improved taxonomic resolution of the long reads.(no content)Nanopore sequencing technology has two crucial properties: long reads and a low up-front cost. It can sequence the full 16S rRNA gene retrieving the information content of all nine hypervariable regions. The cost of a MinION sequencer is a small fraction of that of any Illumina or PacBio sequencing system.

### Full rRNA Operon Sequencing

Using only the full-length 16S rRNA gene, 11.3% of the sequences could be matched at the strain level to a database, and 38.4% assigned at the species level. By using both the 16S and 23S rRNA genes within an operon, 22% could be assigned at the strain level and 72.2% at the species level.

### Cost Considerations

The current projected price per sequence for &gt;Q40 data from rRNA operons is: 0.015 USD (ONT UMI), 0.012 USD (PB CCS), 0.007 USD (PB UMI).

**Note:** The search did not return specific results about cpn60 (chaperonin-60) long-read amplicon sequencing. The results were primarily focused on 16S rRNA gene sequencing. If you need information specifically about cpn60 sequencing with long-read technologies, I can perform an additional search.


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T22-43-03-670Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T22-43-03-670Z" class="timestamp-link"><time datetime="2025-12-14T22:43:03.670Z" data-timestamp="2025-12-14T22:43:03.670Z">2025-12-14T22:43:03.670Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;unique molecular identifiers UMI amplicon sequencing PCR bias correction 2025&quot;

Links: [{&quot;title&quot;:&quot;Correcting PCR amplification errors in unique molecular identifiers to generate accurate numbers of sequencing molecules | Nature Methods&quot;,&quot;url&quot;:&quot;https://www.nature.com/articles/s41592-024-02168-y&quot;},{&quot;title&quot;:&quot;AmpUMI: design and analysis of unique molecular identifiers for deep amplicon sequencing - PMC&quot;,&quot;url&quot;:&quot;https://pmc.ncbi.nlm.nih.gov/articles/PMC6022702/&quot;},{&quot;title&quot;:&quot;Correcting PCR amplification errors in unique molecular identifiers to generate absolute numbers of sequencing molecules | bioRxiv&quot;,&quot;url&quot;:&quot;https://www.biorxiv.org/content/10.1101/2023.04.06.535911v1.full&quot;},{&quot;title&quot;:&quot;Unique Molecular Identifiers (UMIs) | For sequencing accuracy&quot;,&quot;url&quot;:&quot;https://www.illumina.com/techniques/sequencing/ngs-library-prep/multiplexing/unique-molecular-identifiers.html&quot;},{&quot;title&quot;:&quot;AmpUMI: design and analysis of unique molecular identifiers for deep amplicon sequencing | Bioinformatics | Oxford Academic&quot;,&quot;url&quot;:&quot;https://academic.oup.com/bioinformatics/article/34/13/i202/5045706&quot;},{&quot;title&quot;:&quot;Ultrasensitive amplicon barcoding for next-generation sequencing facilitating sequence error and amplification-bias correction - PMC&quot;,&quot;url&quot;:&quot;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324614/&quot;},{&quot;title&quot;:&quot;Unique Molecular Identifiers reveal a novel sequencing artefact with implications for RNA-Seq based gene expression analysis | Scientific Reports&quot;,&quot;url&quot;:&quot;https://www.nature.com/articles/s41598-018-31064-7&quot;},{&quot;title&quot;:&quot;Correcting PCR amplification errors in unique molecular identifiers to generate accurate numbers of sequencing molecules - PMC&quot;,&quot;url&quot;:&quot;https://pmc.ncbi.nlm.nih.gov/articles/PMC10927542/&quot;},{&quot;title&quot;:&quot;(PDF) AmpUMI: design and analysis of unique molecular identifiers for deep amplicon sequencing&quot;,&quot;url&quot;:&quot;https://www.researchgate.net/publication/326100826_AmpUMI_design_and_analysis_of_unique_molecular_identifiers_for_deep_amplicon_sequencing&quot;},{&quot;title&quot;:&quot;Accurate estimation of molecular counts from amplicon sequence data with unique molecular identifiers - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/36610988/&quot;}]

Here are the search results for your query on unique molecular identifiers (UMI) for amplicon sequencing and PCR bias correction:

## Key Findings

### Recent Research (2024)

A Nature Methods paper from February 2024 addresses how unique molecular identifiers are random oligonucleotide sequences that remove PCR amplification biases. However, the impact that PCR associated sequencing errors have on the accuracy of generating absolute counts of RNA molecules is underappreciated. The researchers show that PCR errors are a source of inaccuracy in both bulk and single-cell sequencing data, and synthesizing unique molecular identifiers using homotrimeric nucleotide blocks provides an error-correcting solution that allows absolute counting of sequenced molecules.(no content)UMIs distinguish molecules in sequencing, enabling correction for biases in sampling and PCR amplification across next-generation and third-generation sequencing methods, including bulk RNA, single-cell RNA, and DNA approaches. However, the accuracy of molecular quantification can be affected by the varying sequencing quality of different platforms.

### Computational Tools and Methods

**AmpUMI** - UMIs are added to DNA fragments before PCR amplification to discriminate between alleles arising from the same genomic locus and sequencing reads produced by PCR amplification. While computational methods have been developed for genome-wide and single-cell sequencing studies, they are not designed for modern amplicon-based sequencing experiments, especially in cases of high allelic diversity. AmpUMI presents a model for determining the minimum UMI length required to prevent UMI collisions and reduce allelic distortion.

**DAUMI** - Amplicon sequencing is widely applied to explore heterogeneity and rare variants in genetic populations. Measured abundances are distorted by stochasticity and bias in amplification, plus errors during PCR and sequencing. One solution attaches UMIs to sample sequences before amplification. Counting UMIs instead of sequences provides unbiased estimates of abundance. DAUMI is a probabilistic framework to detect true biological amplicon sequences and accurately estimate their deduplicated abundance.

### Error Correction Approaches

Unlike sample barcodes for multiplexing or cell barcodes in single-cell sequencing, which can be whitelisted due to a limited pool of barcodes, UMIs cannot be corrected using this approach as their synthesis is random. Therefore, UMIs are often corrected using computational approaches, concatemeric consensus sequencing, or by bespoke UMI designs. Despite several computational approaches that leverage Hamming distances, graph networks, or thresholding on UMI frequency, experimental validation of these solutions is lacking.

### Ultrasensitive Amplicon Barcoding (sUMI-seq)

Amplicon sequencing is often the basis for characterizing DNA variant proportions, used in areas including tumor heterogeneity, 16S microbiome, viral, CRISPR/Cas9 library screens, and immune receptor sequencing. However, the ability to accurately quantify proportions of DNA variants is hampered by amplification biases that lead to inflation/deflation of some DNA amplicons. To overcome this, researchers developed a novel generalizable ultrasensitive amplicon barcoding approach that significantly reduces the inflation/deflation of DNA variant proportions from PCR amplification biases and sequencing errors.

### Applications

Sequencing with UMIs can reduce the rate of false-positive variant calls and increase sensitivity of variant detection. Since each nucleic acid in the starting material is tagged with a unique molecular barcode, bioinformatics software can filter out duplicate reads and PCR errors with a high level of accuracy.


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T22-43-06-739Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T22-43-06-739Z" class="timestamp-link"><time datetime="2025-12-14T22:43:06.739Z" data-timestamp="2025-12-14T22:43:06.739Z">2025-12-14T22:43:06.739Z</time></a></div><div class="message-content">
<div class="tool-use" data-tool-id="toolu_01Ctrvh1RHH8eN7Mr2Kds3t7"><div class="tool-header"><span class="tool-icon">⚙</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;\&#34;PrimeGen\&#34; LLM primer design amplicon sequencing 2025&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T22-43-07-404Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T22-43-07-404Z" class="timestamp-link"><time datetime="2025-12-14T22:43:07.404Z" data-timestamp="2025-12-14T22:43:07.404Z">2025-12-14T22:43:07.404Z</time></a></div><div class="message-content">
<div class="tool-use" data-tool-id="toolu_01FrxkArmbZUWBQMb9kZhbtQ"><div class="tool-header"><span class="tool-icon">⚙</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;degenerate primer optimization microbiome coverage bias 2025&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T22-43-20-369Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T22-43-20-369Z" class="timestamp-link"><time datetime="2025-12-14T22:43:20.369Z" data-timestamp="2025-12-14T22:43:20.369Z">2025-12-14T22:43:20.369Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;&quot;PrimeGen&quot; LLM primer design amplicon sequencing 2025&quot;

Links: [{&quot;title&quot;:&quot;Accelerating primer design for amplicon sequencing using large language model-powered agents - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/40738975/&quot;},{&quot;title&quot;:&quot;Accelerating primer design for amplicon sequencing using large language model-powered agents | Nature Biomedical Engineering&quot;,&quot;url&quot;:&quot;https://www.nature.com/articles/s41551-025-01455-z&quot;},{&quot;title&quot;:&quot;GitHub - melobio/PrimeGen&quot;,&quot;url&quot;:&quot;https://github.com/melobio/PrimeGen&quot;}]

Based on the search results, here&#x27;s what I found about PrimeGen:

## PrimeGen: LLM-Powered Primer Design for Amplicon Sequencing

PrimeGen is an orchestrated multi-agent system powered by large language models, designed to streamline labour-intensive primer design tasks for targeted next-generation sequencing.

### Key Features

PrimeGen uses GPT-4o as a central controller to engage with experimentalists for task planning and decomposition, coordinating various specialized agents to execute distinct subtasks.(no content)These include an interactive search agent for retrieving gene targets from databases, a primer agent for designing primer sequences across multiple scenarios, a protocol agent for generating executable robot scripts through retrieval-augmented generation and prompt engineering, and an experiment agent equipped with a vision language model for detecting and reporting anomalies.

### Performance

The researchers experimentally demonstrated the effectiveness of PrimeGen across a variety of applications. PrimeGen can accommodate up to 955 amplicons, ensuring high amplification uniformity and minimizing dimer formation.

### Publication Details

The research was published on July 30, 2025 (doi: 10.1038/s41551-025-01455-z), online ahead of print in Nature Biomedical Engineering.(no content)The study was authored by Yi Wang, Yuejie Hou, Lin Yang, Shisen Li, and many other collaborators from institutions including MGI Tech in Shenzhen, China and αLab AI department at MGI Tech R&amp;D in Hong Kong.

### Code Availability

The code is available on GitHub (melobio/PrimeGen), where users can set up the environment with DATA_PATH for storing project files, including static, database files, and upload files, using MySQL and Redis from official Docker hub images.


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T22-43-43-323Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T22-43-43-323Z" class="timestamp-link"><time datetime="2025-12-14T22:43:43.323Z" data-timestamp="2025-12-14T22:43:43.323Z">2025-12-14T22:43:43.323Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;degenerate primer optimization microbiome coverage bias 2025&quot;

Links: [{&quot;title&quot;:&quot;Frontiers | Unveiling the impact of 16S rRNA gene intergenomic variation on primer design and gut microbiome profiling&quot;,&quot;url&quot;:&quot;https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2025.1573920/full&quot;},{&quot;title&quot;:&quot;Developing the script “degenerate primer 111” to enhance the coverage of universal primers for the small subunit rRNA gene on target microorganisms - PMC&quot;,&quot;url&quot;:&quot;https://pmc.ncbi.nlm.nih.gov/articles/PMC11409422/&quot;},{&quot;title&quot;:&quot;Comprehensive Metagenomic Profiling of Diverse Microbiomes | bioRxiv&quot;,&quot;url&quot;:&quot;https://www.biorxiv.org/content/10.1101/2025.02.13.638056v1.full&quot;},{&quot;title&quot;:&quot;DegePrime, a Program for Degenerate Primer Design for Broad-Taxonomic-Range PCR in Microbial Ecology Studies | Applied and Environmental Microbiology&quot;,&quot;url&quot;:&quot;https://journals.asm.org/doi/abs/10.1128/aem.01403-14&quot;},{&quot;title&quot;:&quot;ARDEP, a Rapid Degenerate Primer Design Pipeline Based on k-mers for Amplicon Microbiome Studies - PMC&quot;,&quot;url&quot;:&quot;https://pmc.ncbi.nlm.nih.gov/articles/PMC7459862/&quot;},{&quot;title&quot;:&quot;Measuring and mitigating PCR bias in microbiota datasets | PLOS Computational Biology&quot;,&quot;url&quot;:&quot;https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1009113&quot;},{&quot;title&quot;:&quot;(PDF) ARDEP, a Rapid Degenerate Primer Design Pipeline Based on k-mers for Amplicon Microbiome Studies&quot;,&quot;url&quot;:&quot;https://www.researchgate.net/publication/343714996_ARDEP_a_Rapid_Degenerate_Primer_Design_Pipeline_Based_on_k-mers_for_Amplicon_Microbiome_Studies&quot;},{&quot;title&quot;:&quot;PCR Bias Impacts Microbiome Ecological Analyses | bioRxiv&quot;,&quot;url&quot;:&quot;https://www.biorxiv.org/content/10.1101/2025.07.31.667904v1.full&quot;},{&quot;title&quot;:&quot;The Use of Degenerate Primers in qPCR Analysis of Functional Genes Can Cause Dramatic Quantification Bias as Revealed by Investigation of nifH Primer Performance - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/28389727/&quot;},{&quot;title&quot;:&quot;DeGenPrime provides robust primer design and optimization unlocking the biosphere | bioRxiv&quot;,&quot;url&quot;:&quot;https://www.biorxiv.org/content/10.1101/2023.08.11.553048v1.full&quot;}]

Here are the search results for degenerate primer optimization and microbiome coverage bias in 2025:

## Recent Studies (2025)

### 16S rRNA Primer Evaluation for Gut Microbiome
A study from Frontiers in Microbiology (April 2025) notes that the 16S rRNA gene is crucial for bacterial identification, but primer biases and intergenomic variation can compromise its effectiveness, especially in complex ecosystems like the human gut microbiome. This study systematically evaluated 57 commonly used 16S rRNA primer sets through in silico PCR simulations against the SILVA database and identified three promising primer sets (V3_P3, V3_P7, and V4_P10) that offer balanced coverage and specificity across 20 key genera of the core gut microbiome.(no content)The study revealed significant limitations in widely used &quot;universal&quot; primers, often failing to capture microbial diversity due to unexpected variability in conserved regions. The results challenge assumptions about 16S rRNA gene conservation and emphasize the need for tailored primer design informed by comprehensive sequence databases. The authors advocate for a multi-primer strategy to improve coverage and mitigate biases.

### PCR Bias Impacts on Ecological Analyses
A bioRxiv preprint from July 2025 addresses how PCR introduces amplification bias, where some DNA sequences are preferentially amplified over others due to factors such as primer-template mismatches, sequence GC content, and secondary structures. The study evaluates how PCR-bias influences both within-samples (α-diversity) and between-sample (β-diversity) analyses, showing that perturbation-invariant diversity measures remain unaffected by PCR bias, but widely used metrics such as Shannon diversity and Weighted-Unifrac are sensitive.(no content)The results prove that PCR bias alters both α- and β-diversity estimates, with the magnitude and direction of distortion depending strongly on the underlying community composition. For α-diversity, bias is greatest in communities with even taxonomic structures, whereas highly skewed communities show minimal distortion.

### Metagenomic Profiling and Primer Comparisons
A February 2025 bioRxiv study evaluated three 16S primer sets—standard ONT (V1–V9), PacBio full-length 16S, and modified ONT with degenerate bases—applied to mock communities and real fecal samples. While degenerate primers have improved Bifidobacterium detection, this direct comparison quantifies primer-induced biases and identifies opportunities to refine microbiome profiling accuracy.

## Tools and Methods for Degenerate Primer Design

### Degenerate Primer 111 Tool
Universal primers sometimes omit target microorganisms due to inadequate primer coverage. Adding degenerate bases to primers can help, but existing methods are complex and time-consuming. A tool called &quot;Degenerate primer 111&quot; was developed for adding degenerate bases to existing universal primers by aligning one universal primer with one uncovered target microorganism&#x27;s SSU rRNA gene, iteratively generating a new primer to maximize coverage for target microorganisms.

### ARDEP Pipeline
The ARDEP (Rapid Degenerate Primer Design Pipeline) is based on the k-mer algorithm, which can bypass the time-consuming step of sequence alignment to greatly reduce run times while ensuring accuracy. The platform can calculate amplification product length, GC content, annealing temperature (Tm), and ΔG of primer self-folding, and identify covered species and functional groups. Newly designed primers using this platform achieved higher coverage than commonly used primers for all tested genes.

### DegePrime
The DegePrime program finds, for each position of a multiple sequence alignment, a degenerate oligomer of as high coverage as possible and outputs its coverage among taxonomic divisions. The novel heuristic, called weighted randomized combination, performs better than previously described algorithms for solving the maximum coverage degenerate primer design problem.

## Key Insights on Primer Bias

Degenerate PCR primers have been demonstrated to cause template-specific bias in PCR applications. Studies using nifH gene standards found significant template-specific bias in multiple primer sets, with template-specific bias causing more than 1000-fold mis-estimation of gene copy number for three primer sets and more than 10,000-fold mis-estimation for one primer set.(no content)A reduction in bias was achieved by increasing the primer concentration. Researchers conclude that degenerate primers should be evaluated across a range of templates, annealing temperatures, and primer concentrations to evaluate the potential for template-specific bias prior to their use in qPCR.


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T22-43-46-984Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T22-43-46-984Z" class="timestamp-link"><time datetime="2025-12-14T22:43:46.984Z" data-timestamp="2025-12-14T22:43:46.984Z">2025-12-14T22:43:46.984Z</time></a></div><div class="message-content">
<div class="tool-use" data-tool-id="toolu_01JQHMo6yKTDEFVuKQwPN5m4"><div class="tool-header"><span class="tool-icon">⚙</span> WebFetch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;url&#34;: &#34;https://www.nature.com/articles/s41551-025-01455-z&#34;,
  &#34;prompt&#34;: &#34;What is PrimeGen and how does it work? What are the key innovations for primer design? What performance metrics are reported?&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T22-43-47-876Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T22-43-47-876Z" class="timestamp-link"><time datetime="2025-12-14T22:43:47.876Z" data-timestamp="2025-12-14T22:43:47.876Z">2025-12-14T22:43:47.876Z</time></a></div><div class="message-content">
<div class="tool-use" data-tool-id="toolu_01U5mTqR5MB7PnrcyNMo5cpY"><div class="tool-header"><span class="tool-icon">⚙</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;rpoB primer bacterial species identification lactobacillus 2024 2025&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T22-43-48-205Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T22-43-48-205Z" class="timestamp-link"><time datetime="2025-12-14T22:43:48.205Z" data-timestamp="2025-12-14T22:43:48.205Z">2025-12-14T22:43:48.205Z</time></a></div><div class="message-content"><div class="tool-result tool-error"><div class="truncatable"><div class="truncatable-content"><pre>Request failed with status code 303</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T22-44-08-486Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T22-44-08-486Z" class="timestamp-link"><time datetime="2025-12-14T22:44:08.486Z" data-timestamp="2025-12-14T22:44:08.486Z">2025-12-14T22:44:08.486Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;rpoB primer bacterial species identification lactobacillus 2024 2025&quot;

Links: [{&quot;title&quot;:&quot;Broad-range amplification and sequencing of the rpoB gene: a novel assay for bacterial identification in clinical microbiology | Journal of Clinical Microbiology&quot;,&quot;url&quot;:&quot;https://journals.asm.org/doi/10.1128/jcm.00266-24&quot;},{&quot;title&quot;:&quot;rpoB sequence analysis as a novel basis for bacterial identification - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/9426137/&quot;},{&quot;title&quot;:&quot;Genome-based species-specific primers for rapid identification of six species of Lactobacillus acidophilus group using multiplex PCR - PMC&quot;,&quot;url&quot;:&quot;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083307/&quot;},{&quot;title&quot;:&quot;Antibacterial activity of Lactobacillus species against some ...&quot;,&quot;url&quot;:&quot;https://updatepublishing.com/journal/index.php/fb/article/download/9224/6496&quot;},{&quot;title&quot;:&quot;The rpoB gene as a tool for clinical microbiologists - ScienceDirect&quot;,&quot;url&quot;:&quot;https://www.sciencedirect.com/science/article/abs/pii/S0966842X08002679&quot;},{&quot;title&quot;:&quot;Partial rpoB Gene Sequencing Identification and Probiotic Potential of Floricoccus penangensis ML061-4 Isolated from Assam Tea (Camellia sinensis var. assamica) | Scientific Reports&quot;,&quot;url&quot;:&quot;https://www.nature.com/articles/s41598-019-52979-9&quot;},{&quot;title&quot;:&quot;Rapid identification of probiotic Lactobacillus species by multiplex PCR using species-specific primers based on the region extending from 16S rRNA through 23S rRNA - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/15476976/&quot;},{&quot;title&quot;:&quot;rpoB, a promising marker for analyzing the diversity of bacterial communities by amplicon sequencing | BMC Microbiology&quot;,&quot;url&quot;:&quot;https://link.springer.com/article/10.1186/s12866-019-1546-z&quot;},{&quot;title&quot;:&quot;Genome-based species-specific primers for rapid identification of six species of Lactobacillus acidophilus group using multiplex PCR | PLOS One&quot;,&quot;url&quot;:&quot;https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0230550&quot;},{&quot;title&quot;:&quot;rpoB sequence analysis as a novel basis for bacterial identification&quot;,&quot;url&quot;:&quot;https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2958.1997.6382009.x&quot;}]

Based on the search results, here&#x27;s what I found regarding rpoB primers for bacterial species identification, including for Lactobacillus:

## Key Findings

### Recent 2024 Research on rpoB for Bacterial Identification

The rpoB gene has been proposed as a promising phylogenetic marker for bacterial identification, providing theoretically improved species-level resolution compared to the 16S rRNA gene for a range of clinically important taxa.

A 2024 study published in the Journal of Clinical Microbiology presents a novel assay:
- The researchers present an assay for broad-range partial amplification and Sanger sequencing of the rpoB gene. To reduce cross-reactivity and allow for rpoB amplification directly from patient samples, primers were based on the dual priming oligonucleotide principle. The resulting amplicon is ~550 base pairs in length and appropriate for species-level identification.

- Systematic in silico evaluation of a wide selection of taxa demonstrated improved resolution within multiple important genera, including Enterococcus, Fusobacterium, Mycobacterium, Streptococcus, and Staphylococcus species.

### rpoB Advantages Over 16S rRNA

The rpoB gene, encoding the β-subunit of RNA polymerase, has emerged as a core gene candidate for phylogenetic analyses and identification of bacteria, especially when studying closely related isolates. Together with the 16S rRNA gene, rpoB has helped to delineate new bacterial species and refine bacterial community analysis.(no content)Previous reports have shown this marker to be suitable for phylogenetic analyses, as it provides a better resolution at species level than the 16S rRNA gene.

### Lactobacillus-Specific Methods

For Lactobacillus identification specifically, molecular methods based on 16S ribosomal DNA gene sequencing are widely used to identify bacteria at the species level. However, the L. acidophilus group is genotypically closely related and these sequences are highly similar among species. Therefore, a reliable and rapid method is needed to classify the L. acidophilus group.(no content)Researchers developed a multiplex PCR method to distinguish six closely related species in the Lactobacillus acidophilus group (L. gasseri, L. acidophilus, L. helveticus, L. jensenii, L. crispatus, and L. gallinarum), which is based on species-specific primer sets.

### rpoB for Lactic Acid Bacteria

Partial rpoB gene sequence has been demonstrated as a molecular tool for lactic acid bacteria identification.(no content)Researchers compared specificity and sensitivity between a portion of the rpoB gene and the V3 V4 hypervariable region of the 16S rRNA gene. They designed universal primers for rpoB suitable for use with Illumina sequencing-based technology and constructed a reference rpoB database of 45,000 sequences.


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T22-44-12-292Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T22-44-12-292Z" class="timestamp-link"><time datetime="2025-12-14T22:44:12.292Z" data-timestamp="2025-12-14T22:44:12.292Z">2025-12-14T22:44:12.292Z</time></a></div><div class="message-content">
<div class="tool-use" data-tool-id="toolu_01HYs3fyM71s7Z6jvVkxZCMk"><div class="tool-header"><span class="tool-icon">⚙</span> WebFetch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;url&#34;: &#34;https://journals.asm.org/doi/10.1128/jcm.00266-24&#34;,
  &#34;prompt&#34;: &#34;What are the details of this rpoB assay? What primers are used? What is the amplicon size? How does it compare to 16S? What is the dual priming oligonucleotide principle?&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T22-44-13-817Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T22-44-13-817Z" class="timestamp-link"><time datetime="2025-12-14T22:44:13.817Z" data-timestamp="2025-12-14T22:44:13.817Z">2025-12-14T22:44:13.817Z</time></a></div><div class="message-content">
<div class="tool-use" data-tool-id="toolu_01CuST73k4Vu176DnnDGpd7q"><div class="tool-header"><span class="tool-icon">⚙</span> WebFetch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;url&#34;: &#34;https://link.springer.com/article/10.1186/s12866-019-1546-z&#34;,
  &#34;prompt&#34;: &#34;What are the rpoB primers described for microbiome profiling? What is the amplicon size? How does it compare to 16S for species resolution?&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T22-44-14-371Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T22-44-14-371Z" class="timestamp-link"><time datetime="2025-12-14T22:44:14.371Z" data-timestamp="2025-12-14T22:44:14.371Z">2025-12-14T22:44:14.371Z</time></a></div><div class="message-content"><div class="tool-result tool-error"><div class="truncatable"><div class="truncatable-content"><pre>Request failed with status code 403</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T22-44-14-422Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T22-44-14-422Z" class="timestamp-link"><time datetime="2025-12-14T22:44:14.422Z" data-timestamp="2025-12-14T22:44:14.422Z">2025-12-14T22:44:14.422Z</time></a></div><div class="message-content"><div class="tool-result tool-error"><div class="truncatable"><div class="truncatable-content"><pre>Request failed with status code 303</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T22-44-17-549Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T22-44-17-549Z" class="timestamp-link"><time datetime="2025-12-14T22:44:17.549Z" data-timestamp="2025-12-14T22:44:17.549Z">2025-12-14T22:44:17.549Z</time></a></div><div class="message-content">
<div class="tool-use" data-tool-id="toolu_01X5WgDLhaHxz7kdi8Gka5T5"><div class="tool-header"><span class="tool-icon">⚙</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;dual priming oligonucleotide DPO primer specificity contamination reduction&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T22-44-18-558Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T22-44-18-558Z" class="timestamp-link"><time datetime="2025-12-14T22:44:18.558Z" data-timestamp="2025-12-14T22:44:18.558Z">2025-12-14T22:44:18.558Z</time></a></div><div class="message-content">
<div class="tool-use" data-tool-id="toolu_01SE7YWF51uPbuqfJK418268"><div class="tool-header"><span class="tool-icon">⚙</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;synthetic spike-in controls amplicon sequencing quantification absolute abundance 2025&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T22-44-40-951Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T22-44-40-951Z" class="timestamp-link"><time datetime="2025-12-14T22:44:40.951Z" data-timestamp="2025-12-14T22:44:40.951Z">2025-12-14T22:44:40.951Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;synthetic spike-in controls amplicon sequencing quantification absolute abundance 2025&quot;

Links: [{&quot;title&quot;:&quot;Synthetic DNA spike-in standards for cross-domain absolute quantification of microbiomes by rRNA gene amplicon sequencing | ISME Communications | Oxford Academic&quot;,&quot;url&quot;:&quot;https://academic.oup.com/ismecommun/article/5/1/ycaf028/8008921&quot;},{&quot;title&quot;:&quot;Synthetic spike-in standards for high-throughput 16S rRNA gene amplicon sequencing - PMC&quot;,&quot;url&quot;:&quot;https://pmc.ncbi.nlm.nih.gov/articles/PMC5389483/&quot;},{&quot;title&quot;:&quot;Synthetic spike-in standards for high-throughput 16S rRNA gene amplicon sequencing | Nucleic Acids Research | Oxford Academic&quot;,&quot;url&quot;:&quot;https://academic.oup.com/nar/article/45/4/e23/2605843&quot;},{&quot;title&quot;:&quot;Synthetic spike-in standards for high-throughput 16S rRNA gene amplicon sequencing - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/27980100/&quot;},{&quot;title&quot;:&quot;(PDF) Synthetic spike-in standards for high-throughput 16S rRNA gene amplicon sequencing&quot;,&quot;url&quot;:&quot;https://www.researchgate.net/publication/311704133_Synthetic_spike-in_standards_for_high-throughput_16S_rRNA_gene_amplicon_sequencing&quot;},{&quot;title&quot;:&quot;Spike-in: An Internal Standard For Absolute Quantification In NGS Applications – mBioWorks Copenhagen&quot;,&quot;url&quot;:&quot;https://mbioworks.com/?p=8825&quot;},{&quot;title&quot;:&quot;Quantitative Amplicon Sequencing Is Necessary to Identify Differential Taxa and Correlated Taxa Where Population Sizes Differ - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/37563275/&quot;},{&quot;title&quot;:&quot;A quantitative sequencing method using synthetic internal standards including functional and phylogenetic marker genes - PMC&quot;,&quot;url&quot;:&quot;https://pmc.ncbi.nlm.nih.gov/articles/PMC10667660/&quot;},{&quot;title&quot;:&quot;Frontiers | Absolute abundance calculation enhances the significance of microbiome data in antibiotic treatment studies&quot;,&quot;url&quot;:&quot;https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2025.1481197/full&quot;},{&quot;title&quot;:&quot;synDNA—a Synthetic DNA Spike-in Method for Absolute Quantification of Shotgun Metagenomic Sequencing - PMC&quot;,&quot;url&quot;:&quot;https://pmc.ncbi.nlm.nih.gov/articles/PMC9765022/&quot;}]

Here are the search results for synthetic spike-in controls for amplicon sequencing quantification of absolute abundance:

## Key Findings

### Recent 2025 Publications

A January 2025 study by Tourlousse and Sekiguchi published in ISME Communications describes the design and experimental validation of a set of 12 unique synthetic rRNA operons, called &quot;rDNA-mimics,&quot; to serve as spike-in standards for quantitative profiling of fungal/eukaryotic and bacterial microbiomes.(no content)The rDNA-mimics consist of conserved sequence regions from natural rRNA genes to act as binding sites for common universal PCR primers, and bioinformatically designed variable regions that allow their robust identification in any microbiome sample. All constructs cover multiple rRNA operon regions commonly targeted in fungal/eukaryotic microbiome studies (SSU-V9, ITS1, ITS2, and LSU-D1D2), and two of them also include an artificial segment of the bacterial 16S rRNA gene (SSU-V4) for cross-domain application.(no content)The researchers demonstrated that rDNA-mimics added to extracted DNA or directly to samples prior to DNA extraction precisely reflects the total amount of fungal and/or bacterial rRNA genes in the samples, allowing accurate estimation of differences in microbial loads between samples.

### Another 2025 Study

A February 2025 study in Frontiers in Microbiology supports the significance of precise determination of absolute cell numbers, noting that the spike-in method based on adding synthetic DNA to samples ahead of DNA isolation requires less effort than flow cytometry (FACS). The researchers observed a high degree of comparability between the two methods for calculating absolute abundances.

### Background and Rationale

An important limitation of current 16S-seq procedures is that only relative abundance data are generated. Interpretation of microbial community dynamics based solely on relative abundances can be misleading because fluctuations in the absolute abundance of one species may cause an apparent change in the measured (relative) abundance of other species.(no content)Recently, sequencing has been combined with Q-PCR to generate &quot;Quantitative Sequencing&quot; (QSeq) data. QSeq more accurately estimates the true abundance of taxa, is a more reliable basis for inferring correlation, and can be more reliably related to environmental data to infer community assembly processes.

### Technical Approaches

The spike-in nucleic acid approach facilitates absolute quantification of total bacterial cell count with high precision and consistency. Absolute quantification proves more precise when a pool of multiple synthetic DNA molecules serves as a reference compared to using a singular synthetic DNA molecule.(no content)Obtaining absolute abundance measurements is still technically challenging. Researchers have developed synthetic DNA (synDNA) spike-ins that enable precise and cost-effective absolute quantification of microbiome data by adding defined amounts of synDNAs to the samples.(no content)By combining the total gene abundance obtained from qPCR with the relative proportion of individual taxonomy obtained from amplicon sequencing, the gene abundance of individual taxonomy can be estimated. This method is widely used to elucidate microbial dynamics but is limited by the time required due to different workflows for quantitation and sequencing.


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T22-44-42-061Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T22-44-42-061Z" class="timestamp-link"><time datetime="2025-12-14T22:44:42.061Z" data-timestamp="2025-12-14T22:44:42.061Z">2025-12-14T22:44:42.061Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;dual priming oligonucleotide DPO primer specificity contamination reduction&quot;

Links: [{&quot;title&quot;:&quot;Dual priming oligonucleotide system for the multiplex detection of respiratory viruses and SNP genotyping of CYP2C19 gene - PMC&quot;,&quot;url&quot;:&quot;https://pmc.ncbi.nlm.nih.gov/articles/PMC1874606/&quot;},{&quot;title&quot;:&quot;Dual priming oligonucleotide system for the multiplex detection of respiratory viruses and SNP genotyping of CYP2C19 gene - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/17287288/&quot;},{&quot;title&quot;:&quot;Dual priming oligonucleotide system for the multiplex detection of respiratory viruses and SNP genotyping of CYP2C19 gene | Nucleic Acids Research | Oxford Academic&quot;,&quot;url&quot;:&quot;https://academic.oup.com/nar/article/35/6/e40/1033152&quot;},{&quot;title&quot;:&quot;Dual priming oligonucleotide (DPO)‐based multiplex PCR assay for specific detection of four diarrhoeagenic Escherichia coli in food - Xu - 2015 - Letters in Applied Microbiology - Wiley Online Library&quot;,&quot;url&quot;:&quot;https://sfamjournals.onlinelibrary.wiley.com/doi/full/10.1111/lam.12426&quot;},{&quot;title&quot;:&quot;Seegene Inc&quot;,&quot;url&quot;:&quot;https://www.seegene.com/technologies/dpo&quot;},{&quot;title&quot;:&quot;CN103952483A - DPO (Dual Priming Oligonucleotide) primer sequences and detection kit for detecting Vibrio alginolyticus by DPO-PCR (Polymerase Chain Reaction) method - Google Patents&quot;,&quot;url&quot;:&quot;https://patents.google.com/patent/CN103952483A/en&quot;},{&quot;title&quot;:&quot;Dual priming oligonucleotide (DPO)-based real-time RT-PCR assay for accurate differentiation of four major viruses causing porcine viral diarrhea - PMC&quot;,&quot;url&quot;:&quot;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127266/&quot;},{&quot;title&quot;:&quot;Use of dual priming oligonucleotide system-based multiplex RT-PCR assay to detect five diarrhea viruses in pig herds in South China | AMB Express | Full Text&quot;,&quot;url&quot;:&quot;https://amb-express.springeropen.com/articles/10.1186/s13568-021-01255-z&quot;},{&quot;title&quot;:&quot;Establishment of dual priming oligonucleotide (DPO)-based real-time RT-PCR method for detecting infectious hematopoietic necrosis virus - ScienceDirect&quot;,&quot;url&quot;:&quot;https://www.sciencedirect.com/science/article/abs/pii/S0044848625003199?dgcid=rss_sd_all&quot;},{&quot;title&quot;:&quot;DPO multiplex PCR as an alternative to culture and susceptibility testing to detect Helicobacter pylori and its resistance to clarithromycin | BMC Gastroenterology&quot;,&quot;url&quot;:&quot;https://link.springer.com/article/10.1186/1471-230X-11-112&quot;}]

Based on my search, here&#x27;s what I found about Dual Priming Oligonucleotide (DPO) technology and its role in primer specificity and contamination reduction:

## Dual Priming Oligonucleotide (DPO) Technology

### Structure
DPO is a novel dual priming oligonucleotide which contains two separate priming regions joined by a polydeoxyinosine linker.(no content)The linker assumes a bubble-like structure which itself is not involved in priming, but rather delineates the boundary between the two parts of the primer. This structure results in two primer segments with distinct annealing properties: a longer 5′-segment that initiates stable priming, and a short 3′-segment that determines target-specific extension.(no content)The poly(I) linker inserted between two stretches of natural bases forms a bubble-like structure and separates a single primer into two functional regions at a certain annealing temperature: a 5′-segment 18–25 nt in length and a 3′-segment 6–12 nt in length.

### Mechanism for Specificity
The longer 5′-segment preferentially binds to the template DNA and initiates stable annealing, whereas the short 3′-segment selectively binds to its target site and blocks non-specific annealing.(no content)The short 3&#x27;-end portion selectively binds to a target site and determines &quot;target-specific extension&quot;. DPO™ primer does not generate any false positive signal by blocking the extension of primer on non-target template, thus provides unparalleled specificity in high multiplex PCR.

### Advantages for Contamination/Non-specific Amplification Reduction
This DPO-based system is a fundamental tool for blocking extension of non-specifically primed templates, and thereby generates consistently high PCR specificity even under less than optimal PCR conditions.(no content)The false positive results can be effectively eliminated by the DPO primers due to the bubble-like structure of the poly I linker in DPO, while conventional primers showed a lower specificity than DPO primers, possibly due to primer competition, primer dimers or different melting temperatures for different primer pairs.(no content)Any mismatch of three or more bases in either the 5′ or 3′ primer regions will prevent the PCR reaction.

### Temperature Flexibility
The DPO primer allowed a wider annealing temperature range (40–65 °C) and had a higher priming specificity compared to conventional primer.(no content)DPO primer can reduce the competitive effects between different primers during multiplex PCR, enabling simple and efficient detection with high specificity.

### Applications
DPO technology has been successfully applied in:
- Multiplex PCR of respiratory viruses and single nucleotide polymorphism (SNP) genotyping PCR in CYP2C19 gene.
- Detection of four foodborne diarrhoeagenic Escherichia coli (DEC) in food, including enterotoxigenic E. coli (ETEC), enteropathogenic E. coli (EPEC), enterohemorrhagic E. coli (EHEC) O157:H7 and enteroinvasive E. coli (EIEC).
- Simultaneous detection of transmissible gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV), porcine rotavirus A (PRV-A), porcine delta coronavirus (PDCoV), and swine acute diarrhea syndrome coronavirus (SADS-CoV).


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T22-45-49-965Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T22-45-49-965Z" class="timestamp-link"><time datetime="2025-12-14T22:45:49.965Z" data-timestamp="2025-12-14T22:45:49.965Z">2025-12-14T22:45:49.965Z</time></a></div><div class="message-content">
<div class="assistant-text"><p>Good, I've gathered comprehensive information. Let me synthesize this into a coherent response.</p>
<h2>Primer Design: State of the Art and Novel Enhancements</h2>
<p>Based on my search, here are the key developments and strategies to consider:</p>
<hr />
<h3>1. Published Primer Sets vs. De Novo Design</h3>
<p><strong>For your core amplicons:</strong></p>
<table>
<thead>
<tr>
<th>Amplicon</th>
<th>Published primers</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>16S V4</td>
<td>515F/806R (Earth Microbiome Project)</td>
<td>Use established - cross-study compatibility</td>
</tr>
<tr>
<td>16S V1-V3</td>
<td>27F/534R variants</td>
<td>Consider optimization for Lactobacillus</td>
</tr>
<tr>
<td>cpn60 UT</td>
<td>H279p/H280p (Hill lab)</td>
<td>Use established, validated for vaginal</td>
</tr>
<tr>
<td>rpoB</td>
<td>Multiple options, <a href="https://journals.asm.org/doi/10.1128/jcm.00266-24">new 2024 DPO-based assay</a></td>
<td>Promising - ~550bp, improved species resolution</td>
</tr>
</tbody>
</table>
<p><strong>For functional genes:</strong> You'll likely need de novo design since these are less standardized.</p>
<hr />
<h3>2. Key Technical Enhancements to Consider</h3>
<h4>A. Dual Priming Oligonucleotide (DPO) Technology</h4>
<p>This is compelling for your application:</p>
<pre><code>Standard primer:     5'------------------3'
                     (entire sequence primes)

DPO primer:          5'-----[poly-I linker]-----3'
                     18-25nt              6-12nt
                     (stable annealing)   (specificity gate)
</code></pre>
<p><strong>Advantages:</strong>
- Dramatically reduces non-specific amplification
- Works across wide annealing temperature range (40-65°C)
- Better multiplexing (less primer competition)
- The <a href="https://journals.asm.org/doi/10.1128/jcm.00266-24">2024 rpoB paper</a> uses this for direct clinical samples</p>
<p><strong>Application for you:</strong> Design DPO versions of your functional gene primers to reduce off-target amplification.</p>
<hr />
<h4>B. Unique Molecular Identifiers (UMIs)</h4>
<p><a href="https://www.nature.com/articles/s41592-020-01041-y">High-accuracy long-read amplicons with UMIs</a> can achieve <strong>&gt;99.99% accuracy</strong>:</p>
<pre><code>Standard amplicon:
[Primer]---[Target sequence]---[Primer]

UMI amplicon:
[Primer]-[UMI]-[Target sequence]-[UMI]-[Primer]
          ↓
    Random 8-12nt barcode tags each original molecule
          ↓
    Post-sequencing: group reads by UMI → consensus → error correction
</code></pre>
<p><strong>What this gives you:</strong>
- True absolute quantification (count molecules, not reads)
- PCR bias correction
- Chimera elimination (&lt;0.02% rate)
- Strain-level accuracy</p>
<p><strong>Recent advance:</strong> <a href="https://www.nature.com/articles/s41592-024-02168-y">Nature Methods 2024</a> showed that homotrimeric UMI blocks (AAA, TTT, CCC, GGG repeats) provide error-correcting capability.</p>
<p><strong>Recommendation:</strong> Add UMIs to your cpn60 and rpoB primers for strain-level work.</p>
<hr />
<h4>C. Synthetic Spike-in Standards for Absolute Quantification</h4>
<p><a href="https://academic.oup.com/ismecommun/article/5/1/ycaf028/8008921">January 2025 paper in ISME Communications</a> describes "rDNA-mimics":</p>
<pre><code>Spike-in design:
[Conserved primer binding sites] + [Unique synthetic variable region]
           ↓
Add known copy number to sample before DNA extraction
           ↓
Sequencing reads of spike-in calibrate total microbial load
           ↓
Convert relative → absolute abundance
</code></pre>
<p><strong>For your application:</strong>
- Design cpn60 and rpoB spike-ins with your primer binding sites
- Add defined copies before extraction
- Enables cross-sample comparison of absolute loads
- No separate qPCR needed</p>
<hr />
<h4>D. PNA/LNA Blocking Oligos for Host Reduction</h4>
<p><a href="https://pubmed.ncbi.nlm.nih.gov/39875992/">2025 paper on PNA clamps</a> shows 46-99% reduction in host amplification:</p>
<pre><code>Without blocker:
Human mitochondrial 16S ←──── Primers bind ────→ Amplified (waste)

With PNA clamp:
Human mitochondrial 16S ←── PNA binds, blocks polymerase ──→ NOT amplified
</code></pre>
<p><strong>FGT relevance:</strong> Your samples have high host DNA. PNA blockers against human mitochondrial sequences could improve bacterial signal for 16S. Less relevant for cpn60/rpoB (bacteria-specific).</p>
<hr />
<h4>E. Long-Read Amplicon Sequencing</h4>
<p><a href="https://academic.oup.com/pnasnexus/article/3/10/pgae411/7816023">Full-length 16S with Nanopore + UMIs</a> now achieves Illumina-level accuracy:</p>
<table>
<thead>
<tr>
<th>Approach</th>
<th>Accuracy</th>
<th>Strain resolution</th>
<th>Cost/sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>Illumina V4 (250bp)</td>
<td>99.9%</td>
<td>Poor</td>
<td>$15-20</td>
</tr>
<tr>
<td>Nanopore full 16S + UMI</td>
<td>99.99%</td>
<td>Good</td>
<td>$20-30</td>
</tr>
<tr>
<td>PacBio HiFi full 16S</td>
<td>99.99%</td>
<td>Excellent</td>
<td>$25-40</td>
</tr>
<tr>
<td>Full rRNA operon (16S+23S)</td>
<td>99.99%</td>
<td>Excellent</td>
<td>$30-50</td>
</tr>
</tbody>
</table>
<p><strong>For cpn60:</strong> The ~550bp amplicon is perfect for long-read - you'd get the full universal target with no assembly required.</p>
<hr />
<h4>F. AI-Assisted Primer Design</h4>
<p><a href="https://www.nature.com/articles/s41551-025-01455-z">PrimeGen</a> (Nature Biomedical Engineering, July 2025):
- LLM-powered multi-agent system for primer design
- Handles up to 955 amplicons with uniform amplification
- Minimizes dimer formation
- Could be useful for your functional gene panel design</p>
<hr />
<h3>3. Contamination Control: 2025 Guidelines</h3>
<p>The <a href="https://www.nature.com/articles/s41564-025-02035-2">new Nature Microbiology consensus statement</a> on low-biomass studies recommends:</p>
<ol>
<li><strong>Extraction blanks</strong> at every batch</li>
<li><strong>PCR no-template controls</strong> on every plate</li>
<li><strong>Positive controls</strong> (mock community) for each run</li>
<li><strong>Computational decontamination</strong> (e.g., <a href="https://www.frontiersin.org/journals/bioinformatics/articles/10.3389/fbinf.2025.1556361/full">micRoclean</a> R package)</li>
<li><strong>Report contaminant profiles</strong> - don't just filter silently</li>
</ol>
<hr />
<h3>4. Recommended Enhanced Primer Strategy</h3>
<p>Here's what I'd propose for your multi-amplicon panel:</p>
<pre><code>┌────────────────────────────────────────────────────────────────────────┐
│                    ENHANCED PRIMER DESIGN STRATEGY                     │
├────────────────────────────────────────────────────────────────────────┤
│                                                                        │
│  TAXONOMIC AMPLICONS                                                   │
│  ──────────────────                                                    │
│  16S V4:        Standard 515F/806R (cross-study compatibility)         │
│                 + PNA blocker for human mitochondria                   │
│                                                                        │
│  16S V1-V3:     Optimized for Lactobacillus (evaluate published sets)  │
│                 Consider long-read (Nanopore/PacBio) for full V1-V9   │
│                                                                        │
│  cpn60:         H279p/H280p (established)                              │
│                 + UMI tags for strain resolution                       │
│                 + Spike-in standard for absolute quantification        │
│                                                                        │
│  rpoB:          New DPO-based primers (~550bp)                         │
│                 + UMI tags                                             │
│                 + Spike-in standard                                    │
│                                                                        │
│  FUNCTIONAL AMPLICONS                                                  │
│  ────────────────────                                                  │
│  All functional genes:                                                 │
│                 De novo design using comparative genomics              │
│                 DPO format for specificity                             │
│                 Degenerate positions optimized with ARDEP/DegePrime    │
│                 Validate in silico against South African MAGs          │
│                                                                        │
│  CONTROLS                                                              │
│  ────────────────                                                      │
│  Spike-ins:     Synthetic cpn60/rpoB mimics (known copy number)        │
│  Mock:          Defined community (commercial + custom FGT isolates)   │
│  Blanks:        Extraction + PCR negatives every batch                 │
│                                                                        │
└────────────────────────────────────────────────────────────────────────┘
</code></pre>
<hr />
<h3>5. Development Workflow</h3>
<pre><code>Phase 1: Primer Design (3-4 months)
├── Compile reference genomes for FGT taxa
├── Download/generate South African MAGs (if available)
├── Use DegePrime/ARDEP for degenerate optimization
├── Design DPO versions for functional genes
├── Add UMI sequences to cpn60/rpoB primers
├── Design synthetic spike-in standards
└── In silico validation (coverage, specificity)

Phase 2: Wet Lab Validation (3-4 months)
├── Test on mock communities (defined composition)
├── Test on archived samples with known 16S profiles
├── Optimize multiplexing pools
├── Validate spike-in quantification against qPCR
├── Establish SOP for each primer pool
└── Cross-validate between Wash U and Ragon

Phase 3: Pipeline Development (concurrent)
├── Multi-amplicon demultiplexing
├── UMI-based error correction
├── Spike-in normalization
├── Taxonomic integration across markers
└── Functional gene quantification
</code></pre>
<hr />
<h3>Questions to Refine</h3>
<ol>
<li>
<p><strong>Long-read vs. short-read?</strong> For cpn60/rpoB, long-read (Nanopore or PacBio) would give you the full amplicon without assembly. Worth the extra cost?</p>
</li>
<li>
<p><strong>UMI complexity?</strong> Full UMI workflow adds cost and bioinformatics complexity. Essential for strain work, maybe overkill for community profiling.</p>
</li>
<li>
<p><strong>How many functional genes?</strong> I listed 6-8 candidates. Want to prioritize based on mechanistic hypotheses?</p>
</li>
<li>
<p><strong>Spike-in design?</strong> Would you want to design these in-house or use commercial options (Zymo, ATCC)?</p>
</li>
</ol>
<p>Sources:
- <a href="https://www.nature.com/articles/s41551-025-01455-z">PrimeGen - Nature Biomedical Engineering 2025</a>
- <a href="https://www.nature.com/articles/s41592-020-01041-y">UMI long-read amplicons - Nature Methods</a>
- <a href="https://www.nature.com/articles/s41592-024-02168-y">UMI error correction - Nature Methods 2024</a>
- <a href="https://academic.oup.com/ismecommun/article/5/1/ycaf028/8008921">rDNA-mimics spike-ins - ISME Communications 2025</a>
- <a href="https://www.nature.com/articles/s41564-025-02035-2">Low-biomass contamination guidelines - Nature Microbiology 2025</a>
- <a href="https://pubmed.ncbi.nlm.nih.gov/39875992/">PNA clamps - Environmental Microbiome 2025</a>
- <a href="https://academic.oup.com/pnasnexus/article/3/10/pgae411/7816023">Nanopore full 16S - PNAS Nexus 2024</a>
- <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC1874606/">DPO technology</a>
- <a href="https://journals.asm.org/doi/10.1128/jcm.00266-24">rpoB for clinical microbiology 2024</a></p></div></div></div>
<div class="message user" id="msg-2025-12-14T22-55-05-022Z"><div class="message-header"><span class="role-label">User</span><a href="#msg-2025-12-14T22-55-05-022Z" class="timestamp-link"><time datetime="2025-12-14T22:55:05.022Z" data-timestamp="2025-12-14T22:55:05.022Z">2025-12-14T22:55:05.022Z</time></a></div><div class="message-content">
<div class="user-content"><p>Here is the content of a grant I have to do this work. Would you recommend any changes to our approach including what functional genes to address: SPECIFIC AIMS
The female genital tract (FGT) plays a pivotal role in the acquisition of HIV infection in women and heterosexual transmission to men. Although the majority of new infections globally occur in women following exposure to HIV through the mucosal membranes of the FGT, there remain significant gaps in our understanding of the local mucosal factors influencing susceptibility. Our previous work demonstrated that relative to vaginal communities dominated by Lactobacillus crispatus, high diversity vaginal bacterial communities comprised of mixed anaerobes with low Lactobacillus abundance were associated with elevated levels of inflammatory chemokines and cytokines in genital secretions, increased numbers of activated CD4+ T cells (“HIV target cells”) in the cervix, and a greater than four-fold increased risk of HIV acquisition2,3. Importantly, these high risk vaginal bacterial communities were present in two-thirds of young, healthy, black South African women in our FRESH (Females Rising through Education, Support and Health) cohort, suggesting that this risk factor is highly prevalent among South African women of reproductive age3. Furthermore, vaginal microbiota and genital inflammation have been shown to significantly reduce the efficacy of vaginal microbicides for preventing HIV4,5. These findings underscore the critical need to understand the mechanisms by which vaginal microbiota increase genital inflammation and HIV acquisition risk, particularly for women living in sub-Saharan Africa.
To address these knowledge gaps, we will utilize 3600 samples from 1200 FRESH participants with longitudinal blood and genital sampling, including pre-infection samples from 102 women who went on to acquire HIV. In Aim 1.1 we will generate multi-omics datasets characterizing vaginal microbiota utilizing metagenomics, metatranscriptomics, fungal internally transcribed spacer (ITS) sequencing, culturomics, microbial whole genome sequencing (WGS), and metabolomics. We will complement this in Aim 1.2 with a comprehensive characterization of the host FGT by assessing genital inflammatory chemokines and cytokines, cervical flow cytometric cell phenotype, and cervical single cell RNA sequencing (scRNAseq) profiles, combined with in-depth behavioral and demographic metadata. These complex multi-omics datasets will then be integrated in Aim 1.3 following critical quality control, transformation, and imputation of data from each modality. Modern supervised integration techniques will be used to identify multi-omics profiles predictive of genital inflammation and HIV acquisition. Candidate vaginal bacterial strains, functions, and/or metabolites will then be validated in Aim 2 using innovative in vitro and in vivo models, including an organ-on-a-chip model co-developed by the co-PI, cervical and vaginal organoids, and a humanized mouse model. Our preliminary data indicate promising candidates that can already be tested directly. Overall, this project will identify specific bacterial strains and molecules, along with host cellular lineages and sensing pathways, that mediate microbiota-induced genital inflammation and increased HIV acquisition risk. It will also validate much needed novel model systems that test the interactions of microbiota, host, and HIV to provide critical resources to develop the mechanistic understanding needed to advance the field. 
This proposal leverages the complementary expertise of Drs. Doug Kwon and Scott Handley to define the role of vaginal microbiota in genital inflammation and HIV acquisition. Dr. Kwon has studied the vaginal microbiome, mucosal immunology, and HIV pathogenesis, and has extensive experience working with clinical cohorts in sub-Saharan Africa, including over 10 years as the co-PI of the FRESH study. Dr. Handley is an expert in using microbial genomics and metagenomics to understand the impact of microbiota on human diseases. The co-PIs have a long history of productive collaboration, including multiple R01s together and seminal findings on the role of the microbiome in HIV2,6,7. They will work with Drs. Kris Sankaran and Laura Symul, biostatisticians with extensive expertise with latent variable modeling, visualization of multi-omics data, and multi-resolution analysis of the microbiome. In this proposal, we will build on our prior work and utilize an integrated multi-omics approach to address critical questions: 1) what are the specific bacterial strains, mediators and/or functions that induce host genital inflammation, 2) what are the host cellular lineages that sense bacteria in the FGT, 3) what host pathways are triggered by inflammatory bacteria in the FGT, and 4) can inhibitors of host microbial sensing be used to reduce HIV acquisition risk. We will answer these questions using samples from a unique clinical cohort of South African women living in an area of extraordinarily high HIV incidence and prevalence, innovative multi-omic approaches, advance biostatistical methods, a library of primary FGT bacterial isolates, and novel in vitro and in vivo models. This research has the potential to inform strategies for reducing new HIV infections in women, particularly for those living in sub-Saharan Africa. In this proposal, the following Aims will be addressed:
Aim 1: Utilize integrated multi-omics characterization of the female genital tract to identify drivers of genital inflammation and HIV acquisition risk
Aim 2: Investigate candidate pathways of microbiota-mediated genital inflammation and HIV acquisition risk using novel in vitro and in vivo models 
RESEARCH STRATEGY
    SIGNIFICANCE
The central role of the female genital tract (FGT) in HIV transmission. In the over four decades since the identification of HIV as the causative agent of AIDS, HIV has caused over 40 million deaths and left nearly 39 million living with disease8. Of the 1.2 million new infections each year, almost 70% occur in sub-Saharan Africa and most occur in young women of reproductive age. Heterosexual intercourse is responsible for the majority of global HIV transmission, with women being twice as likely to contract HIV through heterosexual sex as men9. Mucosal tissues in the FGT therefore represent the frontline of transmission in most incident infections. Understanding the mucosal environment of the FGT is critical for developing strategies to prevent HIV transmission. Studies in nonhuman primates have shown that soon after HIV exposure, viral replication occurs within tissue resident CD4+ T cells (“HIV target cells”) in the mucosa of the cervix and vagina for 5-7 days prior to systemic dissemination10,11. This early phase has been referred to as a “window of opportunity”, since interventions which reduce the viral reproductive rate (R0) to &lt;1 could prevent systemic viral dissemination12. Effective strategies to prevent HIV in women will require a detailed understanding of the critical mucosal factors in the FGT that modulate HIV susceptibility.
The cervicovaginal microbiome, genital inflammation, and HIV susceptibility. Inflammation in the FGT is associated with an increased risk of HIV infection3,13,14. Cervicovaginal bacteria have been shown to be closely associated with genital inflammation3, but the mechanisms by which specific bacteria increase inflammation and HIV risk remain unclear. We characterized vaginal microbiota in FRESH (Females Rising through Education, Support, and Health), a prospective cohort study of healthy HIV-uninfected South African women monitored for nine months with twice weekly HIV testing. Sequencing of the bacterial 16S rRNA gene from vaginal swabs revealed four cervicovaginal bacterial community types, or “cervicotypes” (CTs), two of which had low diversity and were dominated by either Lactobacillus crispatus (CT1, 9% of participants) or Lactobacillus iners (CT2, 28%), and two high diversity CTs dominated by mixed anaerobes, including Gardnerella vaginalis (CT3, 28%) or other mixed anaerobes (CT4, 35%) (Fig. 1A)2,3. The most abundant taxa in CT4 were Prevotella, Gardnerella, Sneathia and Megasphaera. Individuals with CT3 and CT4 communities were at over 4-fold higher risk of acquiring HIV compared to those with L. crispatus dominance (Fig. 1B)2. This risk was associated with elevated genital cytokine levels3 (Fig. 1C) and a 17-fold increase in the number of cervical HIV target cells (activated tissue resident CD4+ T cells) (Fig. 1D)2, providing a potential biologic mechanism for the observed increase in infection. We identified specific bacterial taxa linked with HIV infection, showing that Prevotella melaninogenica, P. bivia and Sneathia sanguinegens, among other anaerobes, were significantly more abundant in individuals who subsequently acquired HIV2. The specific mechanisms by which FGT bacteria induce genital inflammation and increased HIV risk are unknown. 
The lack of robust testing in model systems. Mechanistic understanding of FGT biology has been limited by the lack of robust testing in model systems. Existing models of host-microbiota interactions in the FGT range from epithelial cells alone in a simple monolayer15 or polarized in a transwell16 to murine models of herpes infection17,18 and a nonhuman primate model of IUD insertion19. Each of these models has critical limitations, and none successfully recapitulate the complex conditions of the genital tract in women20. We propose the use of multiple complementary and innovative models to evaluate mechanisms underlying observed phenotypes in women in FRESH to better understand the most important biological interactions between microbiota, host cells, and HIV infection. Validation of these model systems will lead to much needed mechanistic insight and provide a significant advance for the field.</p>
<pre><code>INNOVATION
</code></pre>
<p>Utilization of longitudinal samples from the FRESH study. This proposal utilizes multiple innovative approaches, starting with the use of 3600 longitudinal samples from a unique cohort of 1200 participants in the FRESH study21,22. FRESH has been highly effective at engaging women in research and has previously provided valuable insights into factors impacting HIV acquisition risk and early immune responses against HIV2,3,22-26. Among these samples are those from 102 women who later became HIV-infected, providing a unique opportunity to investigate how vaginal microbiota contribute to genital inflammation and HIV acquisition. Comprehensive multi-omic approaches. This proposal employs multiple innovative ‘omics approaches to comprehensively characterize vaginal microbiota and the host environment. This includes the application of metagenomics, metatranscriptomics, culturomics, bacterial whole genome sequencing (WGS), and metabolomics. Additionally, Seq-Well, a newly developed single cell sequencing method, will allow the agnostic identification of specific host lineages in the FGT that respond to vaginal microbiota using small input cell numbers. Cutting-edge biostatistical data integration. Our comprehensive multi-omics datasets will be integrated using modern techniques for multi-omics quality control, supervised dimensionality reduction, and interaction network inference resulting in a statistically rigorous, unified description of specific features underlying genital inflammation and HIV acquisition. These innovative methods leverage newly developed statistical approaches, including those developed by the co-investigators, Drs. Kris Sankaran and Laura Symul. Novel in vitro and in vivo models. Importantly, we will validate and mechanistically explore identified features using innovative model systems, including a vagina-on-a-chip co-developed by Dr. Kwon27, cervical and vaginal organoids, and humanized mice. Overall, these highly innovative approaches promise to move beyond associations to define specific mechanisms by which vaginal microbiota impact the tissue environments of the FGT and adverse women’s health outcomes.</p>
<pre><code>APPROACH
</code></pre>
<p>Aim 1: Utilize integrated multi-omics characterization of the female genital tract to identify drivers of genital inflammation and HIV acquisition risk
We hypothesize that vaginal microbiota communities with low Lactobacillus abundance and high diversity are sensed by multiple cellular lineages in the FGT and that these interactions result in alterations in the frequency, phenotype, and function of these cells in ways which lead to elevated levels of genital inflammation and increased biological susceptibility to HIV infection. These responding host cells may include components of the innate and adaptive immune system, as well as mucosal epithelial and stromal cells, which are responding to specific bacterial products, metabolites, and/or functions. In Aim 1, we will address these hypotheses by comprehensively characterizing vaginal microbiota communities using multi-omics approaches (Aim 1.1). We will complement this with an assessment of the host genital inflammation (Aim 1.2), measuring soluble cytokines and chemokines in genital secretions, cellular phenotypes with flow cytometry, and performing scRNAseq using methods optimized for small cellular input (SeqWell). These multi-omic datasets will then be integrated using supervised dimensionality reduction and interaction network inference to identify specific features that predict genital inflammation and HIV acquisition (Aim 1.3).  These features will then be validated and further tested using novel in vitro and in vivo model systems that capture the complex interactions between microbiota, host cells, and HIV in Aim 2 (Fig. 2).</p>
<p>Aim 1.1: Characterize FGT bacterial and fungal communities and microbial expression profiles in women living in sub-Saharan Africa
Patient cohort, clinical characterization, and sample collection. The FRESH cohort consists of HIV-uninfected young women aged 18-23 living in Umlazi, South Africa21,22. In this region, &lt;1% of 14-year-old girls are HIV positive but over 60% of 24-year-old women are HIV infected28. FRESH combines a behavioral program along with basic science research examining HIV acquisition and hyperacute HIV infection. Participants in FRESH engage in an intensive poverty alleviation program that provides job skills training, education on self-esteem, and classes on HIV prevention and health maintenance. Women participate in classes twice a week for three hours per visit over the course of nine months. At each visit, HIV viral load testing is performed through finger prick blood PCR. Paired blood and genital mucosal sampling occurs every three months with specific collection of plasma, PBMCs, cervical and vaginal swabs, cervical cytobrush, and cervicovaginal lavage (CVL). Questionnaires are collected at each visit detailing symptomatic and sexual behavior data, diet, vaginal hygiene practices, contraceptive use, medical history, last menstrual period, and demographic factors. All participants undergo regular STI testing. This proposal will utilize stored samples from 1200 FRESH participant who have samples from three longitudinal time points at 3-month intervals, including samples from 102 women who acquired HIV during the study. This proposal leverages an existing major investment to collect and store these unique samples. The quality of these samples has been validated extensively in published work2,3,6,29-31 and in our preliminary data.
Characterization of bacterial communities in the FGT of FRESH participants. We will use a combination of both 16S rRNA gene amplicon and metagenomic sequencing to classify bacterial communities of 3600 genital tract samples (1200 participants with three timepoints each). While metagenomic sequencing provides lower-level taxonomic resolution and gene-level functional profiles, 16S sequencing is an efficient and cost-effective tool to rapidly characterize genital microbiota. The combination of both tools will enable both rapid community classification as well as rich metagenome data generation useful for strain-level and gene content investigation. Both 16S and metagenomic data will be used in Aim 1.3 for signature identification with host inflammatory and HIV acquisition readouts.
16S rRNA amplicon surveys. Bacterial community profiles will be characterized using 16S rRNA amplicon sequencing (see Fig. 1). We will amplify a region of 16S rRNA using the 515F-806R primer set32 and sequence to a depth of approximately 50-60,000 paired-end reads using the Illumina MiSeq 2x225 protocol. Reads will be demultiplexed and resolved into sequence variants using DADA233 and taxonomically classified using GreenGenes v234. Taxonomic assignments and per sample abundances will be combined with sample data into a phyloseq object35 to facilitate analysis of bacterial presence and absence, relative abundance and diversity.
Metagenomic sequencing. Libraries for metagenomic sequencing will be prepared using Illumina Nextera XT kits and sequenced on the Illumina NovaSeq X Plus instrument using the 10B flow cell at the GTAC@MGI sequencing facility at Washington University with the goal of generating approximately 100 million 2x150 reads per sample. Raw metagenomic sequencing data will undergo adapter removal using fastp36. Human reads will be removed using DeconSeq37. Taxonomic abundances will be calculated using MetaPhlAn438 supplemented with strain-level analysis using StrainPhlAn39. Initial shotgun metagenomic data from FRESH shows geographic distribution of strains of L. crispatus between South Africa and North America (Fig. 3).
Assessment of metatranscriptomes in the FGT of women living in sub-Saharan Africa. A metatranscriptome represents the collective transcriptomes of a given environment40. Metatranscriptomic data can be used to study gene expression of a community and identify active elements. Alterations in microbial responses and activities can be revealed by comparing gene expression across conditions, clinical parameters, and over time. To assess the metatranscriptomes of the FGT of women living in sub-Saharan Africa we will first isolate RNA and remove contaminating rRNA from samples using the protocol detailed in Deng et al.41. RNA will be converted to cDNA and prepared for sequencing using the Illumina TruSeq RNA sample prep kit. Libraries will be sequenced on the Illumina NovaSeq X Plus instrument using the 10B flow cell at the GTAC@MGI sequencing facility at Washington University with the goal of generating approximately 100 million 2x150 reads per sample. Metatranscriptomic functional profiles will be determined using HUMAnN242 with differential abundances tested with edgeR43.
Creation of bacterial strain library. Swabs collected at quarterly visits are also frozen in 10% glycerol solution. Upon thawing, isolates will be grown in a variety of media to allow broad propagation of multiple species. Once pure isolates have been obtained, DNA will be extracted and submitted to WGS. Isolates will be identified based on alignment to universal single copy marker genes. As part of this proposal, we will culture, sequence, and store 600 primary bacterial strains. Strains that demonstrate differences in inflammatory potential in the model systems described below will undergo comparative genomic analysis to identify genetic differences that may be the source of altered host-microbe interactions. Our preliminary data (Fig. 4) indicate sub-species structure within isolates from different geographies and support the utility and feasibility of this approach. 
Characterization of fungal communities in the FGT of women living in sub-Saharan Africa. The FGT is commonly colonized by fungal species, most frequently by species of Candida44. In women from Western countries, approximately 30-50% of women are affected by vulvovaginal candidiasis (VVC) at least once during their lifetime44. While Candida is the dominant fungal genera of the female genital tract, cultivation-independent sequencing efforts have identified previously hidden species diversity45. Fungal colonization of the female genital tract has been associated with changes to resident bacterial communities46 with C. glabrata detection correlated with bacteria from the genus Prevotella. Fungal colonization is also associated with vaginal inflammation with Interleukin (IL)-17 responses thought to play a major role in controlling colonization in mouse models of VVC47. Studies using Gram-staining have associated VVC with increased HIV risk48 and persistent, asymptomatic VVC is associated with elevated cervical Th17-like cells and cytokines49. Understanding fungal colonization patterns in women living in sub-Saharan Africa is required for a full understanding of how the microbiome influences genital inflammation and HIV acquisition risk.
ITS2 rRNA amplicon surveys. Fungal community profiles will be characterized using ITS2 rRNA amplicon sequencing. We will amplify a region of ITS2 using the ITS1f-ITS2 primer set50 and sequence to a depth of approximately 50-60,000 paired-end reads using the Illumina MiSeq 2x225 protocol. Reads will be demultiplexed and resolved into sequence variants using DADA233 and taxonomically classified using the UNITE database51. Taxonomic assignments and per sample abundances will be combined with sample data into a phyloseq object35 to facilitate analysis of fungal presence and absence, relative abundance and diversity. Preliminary ITS sequencing from 220 FRESH participants shows high relative abundance of diverse fungal taxa (Fig. 5). 
Measurement of the vaginal metabolome. The vaginal metabolome is inextricably linked to both microbiota and host function. Metabolome shifts in bacterial vaginosis (BV) have been widely recognized for decades15,16, but detailed understanding of how these metabolic disturbance impact the host are lacking. In preliminary data from 143 FRESH participants, we used ultra-high-performance liquid chromatograph/tandem mass spectrometry (in collaboration with Metabolon, Inc.) and found marked metabolomic differences by vaginal microbiota composition, including alterations of metabolites known to have well-documented adverse host effects at other body sites (Fig. 6). For this proposal, metabolomics data will be generated on all 3600 FRESH CVL samples with Metabolon and then used in Aim 1.3 for feature identification with host inflammatory and HIV acquisition endpoints.</p>
<p>Aim 1.2: Identify specific host genital cellular lineages and microbial sensing pathways that mediate microbiota-associated inflammation and HIV acquisition risk
Assessment of inflammation in the FGT. Luminex will be used to assess the level of inflammation in the FGT of women, using a panel of 28 cytokines validated in our prior work (Fig. 1)2,3. We will also measure other soluble mucosal immune markers, such as human defensins, secretory leukocyte peptidase inhibitor (SLPI), lactoferrin, myeloperoxidase and human neutrophil peptides (HNPs), which have been reported to be differentially expressed in the FGT and may represent important readouts of genital inflammation52,53.
Quantitation of reproductive hormone levels. Reproductive hormones have been reported to alter both the vaginal microbiome and HIV acquisition risk54 and a study of the temporal dynamics of the vaginal microbiome across the menstrual cycle demonstrated a subset of women have significant variation in the bacterial communities55. These observations suggest a possible linkage between reproductive hormones, the vaginal microbiome, and HIV acquisition risk, and suggest that more detailed studies are needed to understand the relationships between these factors. Systemic progesterone, estradiol, and MPA (medroxyprogesterone acetate, found in DMPA) will be measured by liquid chromatography-mass spectrometry (LC-MS) performed by the Massachusetts General Hospital Clinical Pathology Core. This will allow us to accurately assess the stage in the menstrual cycle sampling was performed for all women56. We will integrate these levels with metadata regarding days since last menstrual period (LMP) and use of hormonal contraception. 
Characterization of frequency, activation state and co-receptor expression of cervical cells. Cervical cytobrush samples from FRESH participants will be phenotypically characterized by flow cytometry for subset frequency (CD4+ and CD8+ T cells, CD14+ macrophages, CD11c+ and CD123+ DCs, EpCAM+ epithelial cells, and neutrophils), activation state (HLA-DR, CD38, CD69), and HIV co-receptor expression (i.e. CD4 and CCR5) (Fig. 1). These panels have been utilized before in over 300 FRESH cytobrush samples.
Use of Seq-Well to perform agnostic high throughput single cell profiling of FGT cellular subsets in women with defined cervicovaginal microbiota. In collaboration with Dr. Alex Shalek at MIT  (see LOS), we will utilize a new high throughput microwell technology called Seq-Well to perform single cell RNA sequencing57 (Fig. 7A) from cytobrush samples from the FRESH Study. Seq-Well confines uniquely barcoded mRNA capture beads and single cells in a PDMS microwell array (containing ~ 100,000 wells) sealed with a semi-permeable membrane. Cytobrush, cells are distributed in the plate; the plate is then sealed and frozen for storage. To date, we have successfully captured and generated high quality sequencing libraries from up to 5,000 cells from frozen cervical cytobrushes from participants in the FRESH study from women with both L. crispatus (CT1) and highly diverse (CT4) vaginal microbial communities (Fig. 7B). Using a single device, an average of 40,000-50,000 transcripts per cell can be captured. Once single cell RNAseq has been performed, linear models using the Bioconductor package LIMMA will be utilized for transcriptional profile analyses (i.e. to identify genes which are differentially expressed between specific cell lineages in women with distinct vaginal microbial communities). Differentially expressed genes will be identified based on false discovery rate (FDR) adjusted p value using empirical Bayes moderated tests. The FDR will be controlled using the Benjamini Hochberg procedure. Pathways and interactive networks analysis will be performed on differentially expressed genes using Ingenuity Pathway Analysis, gene set enrichment analysis, and protein interaction databases (STRING58 and FunctionalNet59) to identify candidate host pathways that mediate sensing of inflammatory cervicovaginal microbiota. These candidate pathways will be validated using in vitro and in vivo models in Aim 2. Additionally, exponential random graph models (ERGM) will be used to identify networks of interacting cellular lineages, displayed as an “interactome” of differentially regulated pathways that are predicted to interact between distinct lineages (Fig. 7C). Due to cost, not all cytobrush samples can be analyzed with Seq-Well. We will guide the selection of an informative subset using available microbiome and host data. Specifically, we will embed the non-Seq-Well data into a lower dimensional space and use archetypal analysis to identify representatives for Seq-Well analysis. Since samples with more extreme inflammation (i.e. very high or very low) or microbiome profiles (i.e. L. crispatus dominant or non-dominant) are expected to contain stronger signals, we will adjust the loss function to increase their probability of selection.</p>
<p>Aim 1.3: Clarify disease profiles and candidate mechanisms through integrated multi-omics analysis
The data generated by Aims 1.1 and 1.2 have the potential to identify the host-microbiota interactions leading to genital inflammation and HIV acquisition. However, care must be taken to address the challenges of multi-omics data integration. Our approach considers the following challenges: 
    Preprocessing and quality assurance: Careful preprocessing is needed to reduce biases and enhance biological signals in downstream analysis.
    Characterization of longitudinal changes:  Within patient trends in relevant features may provide additional information than their absolute expression levels.
    Defining disease profiles using integrative dimensionality reduction: The number and high dimensionality of the data modalities complicate the definition of disease profiles.
    Identifying disease pathways using multi-omics networks: Forming a mechanistic description of disease development requires reasoning about integrated network interactions and causality.
Our approach first preprocesses each modality with normalization, batch effect correction, and temporal featurization methods. This boosts true signals and accounts for dependence between samples. Next, we will fit multiblock Partial Least Squares (PLS)60 and iterative Random Forest (iRF)61,62 models to learn integrated disease profiles and interaction networks. For longitudinal samples we will define summary variables for each feature to quantify the longitudinal variability and trends for each participant. Finally, we will share intermediate data and modeling artifacts through web and code interfaces, ensuring that our analysis effort is transparent and can be reused by the community. Our approach will be applied to integrate and interrogate data generated in Aim 1.1 and Aim 1.2 with the goal of identifying microbes, microbial products, host cell and host-responses that define genital inflammation and HIV acquisition. These features will serve as substrate for Aim 2.
Preliminary Data: We previously completed an integrative, multi-omics analysis to evaluate a probiotic intervention, Lactin-V, which is intended to reduce the rate of recurrent BV (rBV) after antibiotic treatment63. We quantified feature and block importance from host demographic, behavioral, immunological, and microbiome data using PLS (Fig. 8). Since all blocks were included in the model simultaneously, the effect of any one block can be interpreted as conditional on all others being held fixed. We found that past microbiota composition and perturbations (e.g., vaginal hygiene practices) of the vaginal environment are more predictive of treatment success than all demographic or sexual behavioral characteristics. Further, a Canonical Correlation Analysis (CCA)64,65 found a strong association between microbiome subcommunity composition and host cytokine activity (Fig. 9), with the top two canonical dimensions having correlations of 0.7 and 0.32.
Research Design:
Protocols for preprocessing and quality assurance. Distinguishing technical from biological variation is a central difficulty in multi-omics analysis, and careful data preparation is vital for valid inference. To facilitate this analysis, we will sequence negative control samples across modalities. Negative controls represent background variation due to sample preparation and assay noise. If batch effects are detected, these negative controls can be input to either CellAnova66 or RUV467,68 for correction, depending on whether the assay is sequencing-based. Further, we must be mindful of missing data, especially for metabolomics, which will be processed with a peak-detection pipeline. Different mechanisms can lead to missingness – for example, falling below the lower limit of quantification or peak-detection failure during alignment – and we will impute values in a way that respects these differences69. We will apply variance stabilizing transformations to 16S/ITS, metagenomic, metatranscriptomics, cytokine, cellular phenotype, and scRNAseq data to improve the statistical efficiency of downstream analysis. We will compute quality metrics on these normalized data using Scater70 and will exclude low-quality outliers from analysis. These sample-level checks will be coupled with cohort-level visualization of sampling times to flag inconsistencies. Finally, beyond sample processing, errors can result from inaccurate sample tracking. We will link metadata to digital metadata files that are curated and QC’d, mitigating the risks associated with manual data entry and transfer. 
Characterizing longitudinal changes. Each participant of the FRESH study provided samples approximately every three months for three time points. Because of the low sampling frequency relative to the typical dynamics of microbiota composition in individuals (previous studies have shown that the microbiota composition can drastically change over a few days or weeks71) dynamical models of the vaginal ecosystems are unlikely to accurately describe temporal changes between visits. Instead, we will define summary variables for each feature to quantify the longitudinal variability and trends for each participant. Specifically, each feature will be summarized for each participant by its mean value and trend. Trends will be computed as the slope of the line regressed over the available time points and considered missing for participants with a single time point. If we observe many features with large variances but small trends (e.g., a sequence of high-low-high values), we will include the variance in the summary variables. Since this increases the number of features (but not the number of samples), we would then use regularization in downstream analyses to impose sparsity in the profiles associated with genital inflammation or HIV acquisition (see below). 
Defining disease profiles using integrative dimensionality reduction. Given the preprocessed data, we will generate an integrated, exploratory overview of disease-associated features using PLS or sparse PLS (sPLS). PLS is a foundational method in multi-omics analysis72-74 and has been applied to a variety of settings, including childhood asthma75, diabetes76, and COVID-1977. In our context, it will produce latent profiles of genital inflammation and HIV acquisition across modalities. Specifically, we will apply the mixOmics60 R package with longitudinally summarized 16S/ITS, metagenomic, metatranscriptomic, cytokine, cellular phenotypic, metabolomic, scRNAseq, demographic, and behavioral data as input blocks and inflammation and HIV infection status as the response variables. The number of factors will be tuned by cross-validation. This supervised dimensionality reduction mirrors the approach used on the preliminary data but with inflammation and HIV status. By including demographic and behavioral features as inputs, we will control for them, helping illuminate microbiological and immunological effects beyond superficial host differences. The model will output latent profiles ─ patterns of features that are predictive of the inflammatory and infection response variables ─ for each input block. Features with strong associations (i.e., factor loadings with large magnitudes) may play a direct role in disease development and are natural candidates for follow up studies in Aim 2. Of particular interest are the latent profiles associated with immunological activity. From prior work, we expect these profiles to be highly predictive of HIV infection risk. If these findings are replicated, the resulting profiles will be reliable proxies for infection risk that could be used during model-system experiments. Further, the PLS analysis will return importance scores for each modality. These scores will prioritize relevant disease-associated features, since large effects tend to be proximate to underlying disease mechanisms.
Identifying disease pathways using multi-omics networks. The PLS analysis provides an exploratory view of disease associations. However, a more precise description of cellular interactions is necessary to guide experimental investigation. Multi-omics interaction networks, which are analogs to gene expression networks that tie modalities together, can reveal specific pathways of disease development. To build these networks, we will apply iRF61,62, a random forest-based interaction discovery method. Our input and response will be formatted as in the PLS; however, the output of the iRF model are feature-level interactions that are predictive of either inflammatory or HIV state. For example, a bacterial taxon (16S data) may increase the levels of an immune cell type (scRNAseq data or cell phenotyping) that is targeted by HIV, ultimately resulting in increased disease risk. This mechanism would systematically elevate the expression of that pair of taxonomic and immunological features within HIV-infected women. The feature pair defines a predictive association rule and hence can be learned by iRF. We can subsequently build a general interaction network by combining association rules from across the model.
One limitation of this analysis is that the learned iRF interactions are associational, not causal. In the example above, an interaction between a bacterial taxon and an immune cell type may be visible, but we would not be able to conclude that the taxon leads to alterations in immune cell frequency. In general, causal discovery is a challenging statistical problem. However, the diversity of our multi-omics data allows us to apply a causal invariance analysis to the network, helping to screen away non-causal effects. Specifically, for each node in the undirected association network, we will apply stabilized regression78 with that node as the response, direct neighbors as candidate causal features, and all other nodes as the background environment. Stabilized regression is built on the observation that upstream causal nodes in a biological pathway maintain consistent associations even in shifting environments, while noncausal, downstream associations tend to be sensitive to environmental perturbation. By iterating this procedure across neighborhoods in the estimated network, we can identify and prioritize stable directed edges (i.e. pointing at specific microbial taxa or immune cells) for experimental follow-up.
Enhancing Transparency and Reproducibility. We will prepare data, model outputs, and code notebooks so that they can become a resource for the microbiome multi-omics research community. We will host raw data on a permanent URL through our library system, except for sequencing reads, which we will deposit in the Sequence Read Archive. Preprocessed data will be shared as an R Bioconductor ExperimentData package and in a language-agnostic form through Zenodo79,80.Estimated model parameters, including the learned PLS profiles and iRF network, will be hosted publicly as RData objects and CSV files. A helper R package will encapsulate the low-level operations of our analysis. These functions will be called in compiled Rmarkdown reports that discuss the analysis, allow others to reproduce it, and support adaptation to new data81. These notebooks will be hosted on GitHub, and we will document the repository to clarify the workflow and engage the community. 
Power analysis for Aim 1. To ensure sufficient power to identify meaningful multi-omic signatures given the collected number of samples, we relied on simulations. We generated synthetic data associated with each modality, introduced hypothetical HIV-associated shifts, and measured recovery of the true effect. We used the sparseDOSSA282 and ZINB-WaVE83 models to simulate baseline vaginal 16S rRNA and metagenomic sequencing data. Though ZINB-WaVE was designed for scRNAseq data, it uses a low-rank negative binomial factorization that has been competitive in metagenomics benchmarks84. We simulated metabolomics and behavioral data from gamma and categorical distributions, respectively. We then defined a sparse regression model where 10% of features from each modality relate to the response, fixed the signal-to-noise ratio to 3, and calculated error rates across sample sizes. When enforcing a False Discovery Rate control level of 0.15, a sample with 1200 subjects has an average power of 88.7% across assays (75% power for the simulated survey, 90% for the 16S, 90% for the metagenomic, and 100% for the metabolomic data). In contrast, applying the analysis with a sample of size 600 had low average power (55.0%), and a larger sample size of 1800 yielded diminishing returns (93.8% average power). Hence, the intended sample size balances efficacy with economy.
Potential pitfalls and alternative approaches for Aim 1. Multi-omics analysis can be sensitive to specific preprocessing hyperparameters, like the choice of variance stabilization function or the selection of confounding variables during batch effect correction. Though the large sample size of the proposed study partially mitigates these risks, we must still guard against potential spurious associations that preprocessing can introduce. To this end, we will measure the concordance of selected candidate features/interactions on different data splits when using different hyperparameter choices. Our final analysis will only incorporate hyperparameter selections with high between-split concordance. A second potential pitfall is that imbalance between the number of FRESH participants who do and do not acquire HIV may degrade model performances. Since we will use supervised methods to predict the binary variable flagging HIV acquisition, we may address this class imbalance by increasing the weight of samples (participants) from the minority class, or, equivalently, by altering the loss function. Another potential pitfall is computational rather than statistical. If the learned interaction network is dense with many potential connections, then stabilizing regression can become computationally challenging, even after parallelization across the high-performance computer cluster used by our team. In this case, we will restrict the causal invariance analysis to the subset of edges with the strongest associations, sacrificing the completeness of the causal characterization for improved computational efficiency.</p>
<p>Aim 2: Investigate candidate pathways of microbiota-mediated genital inflammation and HIV acquisition risk using novel in vitro and in vivo models
A significant technical problem in the field is the lack of a single accepted model for the human FGT20, particularly one that incorporates microbiota, host cells, and HIV infection. We have developed three model systems that we will use to test candidate bacterial strains and metabolites chosen based upon our preliminary work as well as from features identified in Aim 1: 1) a 3D vagina-on-a-chip (“V-Chip”), 2) vaginal organoids, and 3) humanized mice. These complementary systems will allow us to characterize mechanistic relationships between candidate mediators and readouts of host inflammation and/or HIV acquisition. To begin with, we will define a set of candidate mediators based upon our prior work and published literature while work described in Aim 1 occurs in parallel to define additional candidate features.</p>
<p>Candidate mediators of genital inflammation and HIV acquisition risk to test in model systems. Our preliminary results have already identified several candidate bacterial species, metabolites, and host inflammatory pathways to test in model systems. This includes biogenic amines, such as the metabolites putrescine and cadaverine, which are highly enriched in the vagina of women with CT3 and CT4 microbiota and have been described as having pro-viral effects at other body sites (Fig. 10A). Putrescine has small molecule synthesis inhibitors that can also be tested using our model systems. In addition, RNA transcriptional analysis of cervical antigen presenting cells (APCs) demonstrated strong upregulation of bacterial lipopolysaccharide (LPS) signaling via toll-like receptor 4 (TLR4) pathways (Fig. 10B). This coincides with significant increases in LPS in CT3 and CT4 communities based upon bacterial metagenomic analysis. Regarding candidate vaginal bacterial species that may mediate increased HIV acquisition, we previously identified Prevotella melaninogenica, Veillonella montpellierensis, Mycoplasma, Sneathia sanguinegens, and two strains of Prevotella bivia as being associated with both increased genital inflammation and HIV acquisition in FRESH (Fig. 10C). These candidate metabolites, host pathways, and bacterial species will be used initially in model systems to explore mechanistic relationships to genital inflammation and HIV infection.
3D organ-on-a-chip vaginal epithelial model (V-Chip). One of the challenges in the vaginal microbiome field is that there has not been a robust way to study how living human vaginal epithelium interacts directly with living microbes because conventional co-cultures lead to bacterial overgrowth and cell death85-88. In addition, they fail to recapitulate physiologically relevant tissue-tissue interfaces and critical physical cues89. Organ-on-a-chip models provide more robust options for in vitro testing of complex interactions with multifaceted microbial communities27,89,90. The V-Chip is a novel, 3D microfluidic organ-on-a-chip model of the vaginal epithelium, which supports testing of hypotheses regarding microbe-host interactions27. Developed in collaboration with Dr. Don Ingber, the V-Chip is created by co-culturing primary human vaginal epithelium on the top surface of an extracellular matrix-coated porous membrane within the top channel of a two-channel microfluidic chip with primary human uterine fibroblasts on the lower surface of the same membrane in the bottom parallel channel to recreate the vaginal epithelial-stromal interface (Fig. 11A-C). The V-Chip model allows integration of microbial and host characteristics, and the microfluidic platform allows for long-term co-culture, introduction of varying exposures, and frequent sampling of the community composition and metabolic output of the system. When co-cultured with L. crispatus strain consortia, the V-Chips maintain vaginal epithelial cell viability, low pH, and the bacterial production of D-lactate, while downregulating proinflammatory cytokines, all of which recapitulate findings in women (Fig. 11D-F). V-Chips are commercially available from Enumeral (see LOS from Dr. Don Ingber) and will be used to test candidate microbial strains, host pathways, and metabolites that are identifed from Aim 1 and/or our preliminary findings. V-Chips will be evaluated for bacterial composition (for those colonized with bacterial strains and/or consortia), metabolites production (metabolomics), and host response (immunological markers and transcriptional analysis).
Vaginal organoids with autologous tissue resident T cells. To complement the V-Chip model, we will use vaginal organoids with autologous tissue resident T cells derived from excess hysterectomy tissue (Fig. 12). These organoids can be expanded in vitro and co-cultured with bacteria (for short term culture &lt;24 hours), metabolites, and small molecule inhibitors. We will also develop the model so that we can infect the tissue resident CD4+ T cells with HIV and measure the impact of candidate features on HIV viral replication at low multiplicity of infection (MOI) using HIV p24 ELISA over the first 10 days after infection. 
Assessment of candidate features in a humanized mouse model of intravaginal HIV acquisition. We will utilize the humanized mouse model, which is an established model for vaginal HIV infection91-93, to assess the impact of candidate features on genital inflammation and HIV susceptibility. We have shown that vaginal inoculation of these mice with P. bivia, but not L. crispatus, induces a similar genital inflammatory cytokine response and increases in FGT CD4+ T cell as observed in women in FRESH (Fig. 13A, B)2. Additionally, vaginal inoculation with P. bivia also resulted in increased HIV acquisition with repeated low dose vaginal HIV challenge (Fig. 13C, D). 
To test candidate features, mice will be intravaginally inoculated each week on days 0 and 2 with microbes (bacterial and/or fungal strains, alone or as consortia), metabolites, or other molecules of interest, including potential inflammation inhibitors. On day 3, mice will undergo vaginal low dose HIV challenge with 2500 TCID50/mL JRCSF; the challenge dose is chosen such that 10-15% of saline inoculated control mice are infected with each challenge. The series of weekly vaginal inoculation and HIV challenge will be repeated for 10 weeks. We will compare HIV infection rates in treated mice vs saline inoculated control mice (12 mice per group). Blood viral load (VL) will be assessed weekly and time to infection compared between mice receiving different vaginal inocula and treatments. Animals will be sacrificed once HIV is detected or after 10 weeks, when CVL, blood, and the FGT tissue will be collected. Half of the FGT will be used for flow cytometry the same day, while the other half will be digested and loaded on Seq-Well for scRNAseq. Flow cytometry will be performed to assess cellular markers of genital inflammation as described above. Secondarily, CVL fluid and plasma (control) will be used to examine local and systemic cytokines and chemokines using Luminex. CVL fluid will further be used to assess the presence of live bacteria and the bacterial composition.<br />
Statistical analysis for Aim 2: Measures of inflammation and pathway activation will be compared in each model system between different conditions using t-test, ANOVA, or nonparametric methods as appropriate. scRNAseq results will be analyzed as described in Aim 1.2 and will be compared to findings generated from cervical samples from FRESH participants. For the organoid experiments we will conduct at least 3 experiments per condition, each with technical replicates. In preliminary experiments, our standard deviation for IL-8 values across donors and bacterial treatments is 0.35 log10, thus with 4 donors per comparison we would have at least 80% power to detect a 1.5 log10 difference between conditions. For mouse experiments with at least 4 mice per group in each of 3 experiments (i.e., 12 mice per group), analyzed using a two-sided Wilcoxon rank sum test (level α=0.05) stratified by experiment, there would be at least 80% power to detect a true standardized difference (stdiff) of 1.23 in numbers of activated CD4+ T cells between conditions, which is smaller than the observed stdiff of 1.48 for CD4+ T cells seen in our prior work2. We will compare p24 quantity between conditions in organoids and mice using student’s t-test. For mouse experiments, the number of mice suggested is based on a 10-15% infection rate with the indicated dose of virus, assuming that some conditions would increase the infection rate 3-fold and inhibition would decrease that by at least half, to 45%.  We will test the proportion of infected mice between treatment conditions using a one-sided Fisher exact test with a cut-off of 0.05.
Potential pitfalls and alternative approaches for Aim 2. There are caveats to the use of any model system. However, we propose comparing results directly to those obtained from women in FRESH to make sure that the models recapitulate important observations identified in Aim 1.  Discrepancies will be used to inform in vitro model improvements, and only after its fidelity can be guaranteed will we move forward with mechanistic work in the model. Given the lack of animal models for the human vagina, this type of modeling, which uses multiple complementary approaches and calibrates model system parameters using real-world omics data sources, is likely to be the best way to reach an understanding of the mechanistic relationships between vaginal microbiota, genital inflammation, and HIV acquisition risk.  
BIBLIOGRAPHY AND REFERENCES CITED
1    France, M. T. et al. VALENCIA: a nearest centroid classification method for vaginal microbial communities based on composition. Microbiome 8, 166, doi:10.1186/s40168-020-00934-6 (2020).PMC7684964 translating microbiome research into live biotherapeutics drugs for women's health. All other authors declare that they have no competing interests.
2    Gosmann, C. et al. Lactobacillus-Deficient Cervicovaginal Bacterial Communities Are Associated with Increased HIV Acquisition in Young South African Women. Immunity 46, 29-37, doi:10.1016/j.immuni.2016.12.013 (2017).PMC5270628
3    Anahtar, M. N. et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity 42, 965-976, doi:10.1016/j.immuni.2015.04.019 (2015).PMC4461369
4    Klatt, N. R. et al. Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. Science 356, 938-945, doi:10.1126/science.aai9383 (2017)
5    McKinnon, L. R. et al. Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. Nat Med 24, 491-496, doi:10.1038/nm.4506 (2018).PMC5893390
6    Byrne, E. H. et al. Antigen Presenting Cells Link the Female Genital Tract Microbiome to Mucosal Inflammation, With Hormonal Contraception as an Additional Modulator of Inflammatory Signatures. Front Cell Infect Microbiol 11, 733619, doi:10.3389/fcimb.2021.733619 (2021).PMC8482842
7    Monaco, C. L. et al. Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome. Cell Host Microbe 19, 311-322, doi:10.1016/j.chom.2016.02.011 (2016).PMC4821831
8    WHO, U. UNAIDS Global AIDS Update. (Geneva, 2023).
9    Boily, M. C. et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 9, 118-129, doi:10.1016/S1473-3099(09)70021-0 (2009)
10    Haase, A. T. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 62, 127-139, doi:10.1146/annurev-med-080709-124959 (2011)
11    Tebit, D. M., Ndembi, N., Weinberg, A. &amp; Quinones-Mateu, M. E. Mucosal transmission of human immunodeficiency virus. Curr HIV Res 10, 3-8 (2012)
12    Haase, A. T. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464, 217-223, doi:10.1038/nature08757 (2010)
13    Masson, L. et al. Genital inflammation and the risk of HIV acquisition in women. Clin Infect Dis 61, 260-269, doi:10.1093/cid/civ298 (2015).PMC4565995
14    Anahtar, M. N., Gootenberg, D. B., Mitchell, C. M. &amp; Kwon, D. S. Cervicovaginal Microbiota and Reproductive Health: The Virtue of Simplicity. Cell Host Microbe 23, 159-168, doi:10.1016/j.chom.2018.01.013 (2018)
15    Fichorova, R. N., Yamamoto, H. S., Delaney, M. L., Onderdonk, A. B. &amp; Doncel, G. F. Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action. MBio 2, e00168-00111, doi:mBio.00168-11 [pii]10.1128/mBio.00168-11 (2011).3202752
16    Eade, C. R. et al. Identification and characterization of bacterial vaginosis-associated pathogens using a comprehensive cervical-vaginal epithelial coculture assay. PLoS One 7, e50106, doi:10.1371/journal.pone.0050106PONE-D-12-19131 [pii] (2012).3499514
17    Yim, K. C. et al. The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies. J Virol 79, 14632-14639, doi:10.1128/JVI.79.23.14632-14639.2005 (2005).PMC1287570
18    Kutle, I., Dittrich, A. &amp; Wirth, D. Mouse Models for Human Herpesviruses. Pathogens 12, doi:10.3390/pathogens12070953 (2023).PMC10384569
19    Hashway, S. A. et al. Impact of a hormone-releasing intrauterine system on the vaginal microbiome: a prospective baboon model. J Med Primatol 43, 89-99, doi:10.1111/jmp.12090 (2014).PMC3954920
20    Herbst-Kralovetz, M. M., Pyles, R. B., Ratner, A. J., Sycuro, L. K. &amp; Mitchell, C. New Systems for Studying Intercellular Interactions in Bacterial Vaginosis. J Infect Dis 214 Suppl 1, S6-S13, doi:10.1093/infdis/jiw130 (2016).PMC4957508
21    Ndung'u, T., Dong, K. L., Kwon, D. S. &amp; Walker, B. D. A FRESH approach: Combining basic science and social good. Sci Immunol 3, doi:10.1126/sciimmunol.aau2798 (2018).PMC7593829
22    Dong, K. L. et al. Detection and treatment of Fiebig stage I HIV-1 infection in young at-risk women in South Africa: a prospective cohort study. Lancet HIV 5, e35-e44, doi:10.1016/S2352-3018(17)30146-7 (2018).PMC6506720
23    Byrne, E. H. et al. Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study. Lancet Infect Dis 16, 441-448, doi:10.1016/S1473-3099(15)00429-6 (2016).PMC5294917
24    Ndhlovu, Z. M. et al. Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection. Science translational medicine 11, doi:10.1126/scitranslmed.aau0528 (2019)
25    Kloverpris, H. N. et al. Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV-1 Infection in the Absence of Viral Suppression. Immunity 44, 391-405, doi:10.1016/j.immuni.2016.01.006 (2016)
26    Ndhlovu, Z. M. et al. Magnitude and Kinetics of CD8+ T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point. Immunity 43, 591-604, doi:10.1016/j.immuni.2015.08.012 (2015).PMC4575777
27    Mahajan, G. et al. Vaginal microbiome-host interactions modeled in a human vagina-on-a-chip. Microbiome 10, 201, doi:10.1186/s40168-022-01400-1 (2022).PMC9701078 holder in Emulate, Inc. G.M. is current employee of Emulate Inc. and may hold equity interest in Emulate, Inc. J.R. is co-founder of LUCA Biologics, a biotechnology company focusing on translating microbiome research into live biotherapeutics drugs for women's health. The other authors declare that they have no competing interests.
28    Wong, E. B. et al. Convergence of infectious and non-communicable disease epidemics in rural South Africa: a cross-sectional, population-based multimorbidity study. Lancet Glob Health 9, e967-e976, doi:10.1016/S2214-109X(21)00176-5 (2021).PMC8220132 Academy of Sciences, and the South African National Research Foundation, during the conduct of the study. ADG reports grants from the Wellcome Trust, during the conduct of the study. All other authors declare no competing interests.
29    Bloom, S. M. et al. Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol 7, 434-450, doi:10.1038/s41564-022-01070-7 (2022).PMC10473153
30    Munoz, A. et al. Modeling the temporal dynamics of cervicovaginal microbiota identifies targets that may promote reproductive health. Microbiome 9, 163, doi:10.1186/s40168-021-01096-9 (2021).PMC8314590
31    Piantadosi, A. et al. Metagenomic Sequencing of HIV-1 in the Blood and Female Genital Tract Reveals Little Quasispecies Diversity during Acute Infection. J Virol 93, doi:10.1128/JVI.00804-18 (2019).PMC6321908
32    Caporaso, J. G. et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci U S A 108 Suppl 1, 4516-4522, doi:10.1073/pnas.1000080107 (2011).PMC3063599
33    Callahan, B. J. et al. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods 13, 581-583, doi:10.1038/nmeth.3869 (2016).PMC4927377
34    McDonald, D. et al. Greengenes2 unifies microbial data in a single reference tree. Nat Biotechnol, doi:10.1038/s41587-023-01845-1 (2023)
35    McMurdie, P. J. &amp; Holmes, S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One 8, e61217, doi:10.1371/journal.pone.0061217 (2013).PMC3632530
36    Chen, S., Zhou, Y., Chen, Y. &amp; Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884-i890, doi:10.1093/bioinformatics/bty560 (2018).PMC6129281
37    Schmieder, R. &amp; Edwards, R. Fast identification and removal of sequence contamination from genomic and metagenomic datasets. PLoS One 6, e17288, doi:10.1371/journal.pone.0017288 (2011).PMC3052304
38    Blanco-Miguez, A. et al. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nat Biotechnol, doi:10.1038/s41587-023-01688-w (2023)
39    Truong, D. T., Tett, A., Pasolli, E., Huttenhower, C. &amp; Segata, N. Microbial strain-level population structure and genetic diversity from metagenomes. Genome Res 27, 626-638, doi:10.1101/gr.216242.116 (2017).PMC5378180
40    Filiatrault, M. J. Progress in prokaryotic transcriptomics. Curr Opin Microbiol 14, 579-586, doi:10.1016/j.mib.2011.07.023 (2011)
41    Deng, Z. L. et al. Metatranscriptome Analysis of the Vaginal Microbiota Reveals Potential Mechanisms for Protection against Metronidazole in Bacterial Vaginosis. mSphere 3, doi:10.1128/mSphereDirect.00262-18 (2018).PMC5990888
42    Franzosa, E. A. et al. Species-level functional profiling of metagenomes and metatranscriptomes. Nat Methods 15, 962-968, doi:10.1038/s41592-018-0176-y (2018).PMC6235447
43    Robinson, M. D., McCarthy, D. J. &amp; Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140, doi:10.1093/bioinformatics/btp616 (2010).PMC2796818
44    Foxman, B., Muraglia, R., Dietz, J. P., Sobel, J. D. &amp; Wagner, J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis 17, 340-345, doi:10.1097/LGT.0b013e318273e8cf (2013)
45    Drell, T. et al. Characterization of the vaginal micro- and mycobiome in asymptomatic reproductive-age Estonian women. PLoS One 8, e54379, doi:10.1371/journal.pone.0054379 (2013).PMC3553157 LCC. The company partly financed and provided sequencing service for the project as part of their workflow development for metagenomic sequencing service. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
46    Zhao, C. et al. Mycobiome Study Reveals Different Pathogens of Vulvovaginal Candidiasis Shape Characteristic Vaginal Bacteriome. Microbiol Spectr 11, e0315222, doi:10.1128/spectrum.03152-22 (2023).PMC10269694
47    Jin, Y. M., Liu, S. S., Xu, T. M., Guo, F. J. &amp; Chen, J. Impaired Th17 cell proliferation and decreased pro-inflammatory cytokine production in CXCR3/CXCR4 double-deficient mice of vulvovaginal candidiasis. J Cell Physiol 234, 13894-13905, doi:10.1002/jcp.28071 (2019)
48    Hester, R. A. &amp; Kennedy, S. B. Candida infection as a risk factor for HIV transmission. J Womens Health (Larchmt) 12, 487-494, doi:10.1089/154099903766651612 (2003)
49    Happel, A. U. et al. Persistent, Asymptomatic Colonization with Candida is Associated with Elevated Frequencies of Highly Activated Cervical Th17-Like Cells and Related Cytokines in the Reproductive Tract of South African Adolescents. Microbiol Spectr 10, e0162621, doi:10.1128/spectrum.01626-21 (2022).PMC9045181
50    Bokulich, N. A. &amp; Mills, D. A. Improved selection of internal transcribed spacer-specific primers enables quantitative, ultra-high-throughput profiling of fungal communities. Appl Environ Microbiol 79, 2519-2526, doi:10.1128/AEM.03870-12 (2013).PMC3623200
51    Nilsson, R. H. et al. The UNITE database for molecular identification of fungi: handling dark taxa and parallel taxonomic classifications. Nucleic Acids Res. 47, D259-D264, doi:10.1093/nar/gky1022 (2019).PMC6324048
52    Murphy, K. et al. Levels of Genital Tract Defensins and Cytokines Differ between HIV-Uninfected US and African Women. Am J Reprod Immunol 74, 313-322, doi:10.1111/aji.12411 (2015).PMC4573314
53    Jais, M., Younes, N., Chapman, S., Cu-Uvin, S. &amp; Ghosh, M. Reduced levels of genital tract immune biomarkers in postmenopausal women: implications for HIV acquisition. Am J Obstet Gynecol 215, 324 e321-324 e310, doi:10.1016/j.ajog.2016.03.041 (2016)
54    Wira, C. R. &amp; Fahey, J. V. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. Aids 22, 1909-1917, doi:10.1097/QAD.0b013e3283060ea4 (2008).2647143
55    Gajer, P. et al. Temporal dynamics of the human vaginal microbiota. Sci Transl Med 4, 132ra152, doi:10.1126/scitranslmed.3003605 (2012)
56    Maybin, J. A. &amp; Critchley, H. O. Progesterone: a pivotal hormone at menstruation. Ann N Y Acad Sci 1221, 88-97, doi:10.1111/j.1749-6632.2011.05953.x (2011)
57    Gierahn, T. M. et al. Seq-Well: portable, low-cost RNA sequencing of single cells at high throughput. Nat Methods 14, 395-398, doi:10.1038/nmeth.4179 (2017).PMC5376227
58    Szklarczyk, D. et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43, D447-452, doi:10.1093/nar/gku1003 (2015).PMC4383874
59    Moignard, V. et al. Characterization of transcriptional networks in blood stem and progenitor cells using high-throughput single-cell gene expression analysis. Nat Cell Biol 15, 363-372, doi:10.1038/ncb2709 (2013).PMC3796878
60    Rohart, F., Gautier, B., Singh, A. &amp; Le Cao, K. A. mixOmics: An R package for 'omics feature selection and multiple data integration. Plos Comput Biol 13, doi:ARTN e100575210.1371/journal.pcbi.1005752 (2017)
61    Basu, S., Kumbier, K., Brown, J. B. &amp; Yu, B. Iterative random forests to discover predictive and stable high-order interactions. P Natl Acad Sci USA 115, 1943-1948, doi:10.1073/pnas.1711236115 (2018)
62    Walker, A. M. et al. Evaluating the performance of random forest and iterative random forest based methods when applied to gene expression data. Comput Struct Biotec 20, 3372-3386, doi:10.1016/j.csbj.2022.06.0372001-0370 (2022)
63    Cohen, C. R. et al. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. N Engl J Med 382, 1906-1915, doi:10.1056/NEJMoa1915254 (2020).PMC7362958
64    Callahan, B. J., Sankaran, K., Fukuyama, J. A., McMurdie, P. J. &amp; Holmes, S. P. Bioconductor Workflow for Microbiome Data Analysis: from raw reads to community analyses. F1000Res 5, 1492, doi:10.12688/f1000research.8986.2 (2016).PMC4955027
65    Hastie, T., Tibshirani, R. &amp; Friedman, J. H. The elements of statistical learning : data mining, inference, and prediction. 2nd edn,  (Springer, 2009).
66    Zhang, Z. et al. Signal recovery in single cell batch integration. bioRxiv, doi:10.1101/2023.05.05.539614 (2023).PMC10197537
67    Gagnon-Bartsch, J. A. &amp; Speed, T. P. Using control genes to correct for unwanted variation in microarray data. Biostatistics 13, 539-552, doi:10.1093/biostatistics/kxr034 (2012)
68    Wang, J. S., Zhao, Q. Y., Hastie, T. &amp; Owen, A. B. Confounder Adjustment in Multiple Hypothesis Testing. Ann Stat 45, 1863-1894, doi:10.1214/16-Aos1511 (2017)
69    Dekermanjian, J. P., Shaddox, E., Nandy, D., Ghosh, D. &amp; Kechris, K. Mechanism-aware imputation: a two-step approach in handling missing values in metabolomics. BMC Bioinformatics 23, 179, doi:10.1186/s12859-022-04659-1 (2022).PMC9109373
70    McCarthy, D. J., Campbell, K. R., Lun, A. T. &amp; Wills, Q. F. Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics 33, 1179-1186, doi:10.1093/bioinformatics/btw777 (2017).PMC5408845
71    David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559-563, doi:10.1038/nature12820 (2014).PMC3957428
72    Sankaran, K. &amp; Holmes, S. P. Multitable Methods for Microbiome Data Integration. Front Genet 10, doi:ARTN 62710.3389/fgene.2019.00627 (2019)
73    Rappoport, N. &amp; Shamir, R. Multi-omic and multi-view clustering algorithms: review and cancer benchmark (vol 46, pg 10546, 2018). Nucleic Acids Res 47, 1044-1044, doi:10.1093/nar/gky1226 (2019)
74    Misra, B. B., Langefeld, C., Olivier, M. &amp; Cox, L. A. Integrated omics: tools, advances and future approaches. J Mol Endocrinol 62, R21-R45, doi:10.1530/Jme-18-0055 (2019)
75    Stokholm, J. et al. Maturation of the gut microbiome and risk of asthma in childhood (vol 9, 2018). Nat Commun 9, doi:ARTN 70410.1038/s41467-018-03150-x (2018)
76    Liu, Z. G. et al. Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment. Nat Commun 11, doi:ARTN 85510.1038/s41467-020-14676-4 (2020)
77    Bergamaschi, L. et al. Longitudinal analysis reveals that delayed bystander CD8(+) T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity 54, 1257-+, doi:10.1016/j.immuni.2021.05.010 (2021)
78    Pfister, N., Williams, E. G., Peters, J., Aebersold, R. &amp; Buhlmann, P. Stabilizing Variable Selection and Regression. Ann Appl Stat 15, 1220-1246, doi:10.1214/21-Aoas1487 (2021)
79    Huber, W. et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods 12, 115-121, doi:10.1038/Nmeth.3252 (2015)
80    Stodden, V., Leisch, F. &amp; Peng, R. D. Implementing reproducible research.  (CRC Press, Taylor &amp; Francis Group, 2014).
81    Xie, Y., Allaire, J. J. &amp; Grolemund, G.     1 online resource (CRC Press, Taylor and Francis Group,, Boca Raton, 2019).
82    Ma, S. et al. A statistical model for describing and simulating microbial community profiles. Plos Comput Biol 17, e1008913, doi:10.1371/journal.pcbi.1008913 (2021).PMC8491899
83    Risso, D., Perraudeau, F., Gribkova, S., Dudoit, S. &amp; Vert, J. P. A general and flexible method for signal extraction from single-cell RNA-seq data. Nat Commun 9, 284, doi:10.1038/s41467-017-02554-5 (2018).PMC5773593
84    Calgaro, M., Romualdi, C., Waldron, L., Risso, D. &amp; Vitulo, N. Assessment of statistical methods from single cell, bulk RNA-seq, and metagenomics applied to microbiome data. Genome Biol 21, 191, doi:10.1186/s13059-020-02104-1 (2020).PMC7398076
85    Huh, D. et al. Reconstituting organ-level lung functions on a chip. Science 328, 1662-1668, doi:10.1126/science.1188302 (2010).PMC8335790
86    Jalili-Firoozinezhad, S. et al. A complex human gut microbiome cultured in an anaerobic intestine-on-a-chip. Nat Biomed Eng 3, 520-531, doi:10.1038/s41551-019-0397-0 (2019).PMC6658209
87    Kim, H. J., Huh, D., Hamilton, G. &amp; Ingber, D. E. Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. Lab Chip 12, 2165-2174, doi:10.1039/c2lc40074j (2012)
88    Kim, H. J., Li, H., Collins, J. J. &amp; Ingber, D. E. Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. Proc Natl Acad Sci U S A 113, E7-15, doi:10.1073/pnas.1522193112 (2016).PMC4711860
89    Ingber, D. E. Is it Time for Reviewer 3 to Request Human Organ Chip Experiments Instead of Animal Validation Studies? Adv Sci (Weinh) 7, 2002030, doi:10.1002/advs.202002030 (2020).PMC7675190
90    Gazzaniga, F. S. et al. Harnessing Colon Chip Technology to Identify Commensal Bacteria That Promote Host Tolerance to Infection. Front Cell Infect Microbiol 11, 638014, doi:10.3389/fcimb.2021.638014 (2021).PMC7996096
91    Brainard, D. M. et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol 83, 7305-7321, doi:JVI.02207-08 [pii]10.1128/JVI.02207-08 (2009)
92    Deruaz, M. et al. Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo. J Infect Dis 214, 612-616, doi:10.1093/infdis/jiw203 (2016).PMC4957443
93    Deruaz, M. &amp; Tager, A. M. Humanized mouse models of latent HIV infection. Curr Opin Virol 25, 97-104, doi:10.1016/j.coviro.2017.07.027 (2017)</p></div></div></div>
<div class="message assistant" id="msg-2025-12-14T22-56-12-486Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T22-56-12-486Z" class="timestamp-link"><time datetime="2025-12-14T22:56:12.486Z" data-timestamp="2025-12-14T22:56:12.486Z">2025-12-14T22:56:12.486Z</time></a></div><div class="message-content">
<div class="assistant-text"><p>This is an excellent, well-designed grant. The multi-omics approach combined with the FRESH cohort's unique longitudinal pre-seroconversion samples is powerful. Let me provide a critical assessment and recommendations.</p>
<h2>Overall Assessment</h2>
<p><strong>Strengths:</strong>
- Exceptional sample resource (3600 samples, 102 seroconverters)
- Strong preliminary data supporting the central hypothesis
- Excellent integration of discovery (Aim 1) and validation (Aim 2)
- Innovative model systems (V-Chip, organoids, humanized mice)
- Strong biostatistics/integration plan</p>
<p><strong>Areas for Enhancement:</strong></p>
<hr />
<h2>Recommended Changes to Approach</h2>
<h3>1. 16S Sequencing Strategy: Add cpn60</h3>
<p>Your current plan uses only 16S V4 (515F-806R). This is limiting for your key taxa:</p>
<p><strong>Problem:</strong> 16S V4 cannot reliably distinguish:
- Gardnerella species (G. vaginalis, G. leopoldii, G. swidsinskii, G. piotii) - all &gt;98.5% identical
- Lactobacillus species resolution is marginal
- Your preliminary data shows Gardnerella subgroups matter (Fig. 1, 4)</p>
<p><strong>Recommendation:</strong> Add cpn60 amplicon sequencing on a subset or all samples</p>
<pre><code>Current:     16S V4 (all 3600 samples)
             ↓
Proposed:    16S V4 (all 3600 samples) + cpn60 (all or subset)
             ↓
Benefit:     Gardnerella species-level resolution
             Better Lactobacillus discrimination
             Validation of metagenomic strain calls
</code></pre>
<p>This complements rather than replaces your metagenomic StrainPhlAn analysis, providing an independent validation layer.</p>
<hr />
<h3>2. Absolute Quantification Gap</h3>
<p><strong>Problem:</strong> Your current approach generates only relative abundance data from 16S. You state that CT3/CT4 communities increase HIV risk, but you can't distinguish:
- True increase in inflammatory bacteria
- Decrease in total Lactobacillus (with same absolute anaerobe load)
- Overall bacterial load differences</p>
<p><strong>Recommendation:</strong> Add quantitative component</p>
<p><strong>Option A: qPCR panel (recommended)</strong></p>
<pre><code>Targets:
- Total bacterial load (universal 16S)
- L. crispatus (species-specific)
- L. iners (species-specific)  
- Gardnerella (genus or species)
- Total Lactobacillus

Run on all samples: ~$15-20/sample additional
</code></pre>
<p><strong>Option B: Spike-in standards</strong>
- Add synthetic DNA spike-ins before extraction
- Enables conversion of relative → absolute from existing sequencing
- <a href="https://academic.oup.com/ismecommun/article/5/1/ycaf028/8008921">Recent 2025 methods</a> show this works well</p>
<p>This is fundable as a minor budget addition and addresses a key mechanistic question.</p>
<hr />
<h3>3. Functional Gene Amplicons: Missing Opportunity</h3>
<p>Your preliminary data (Fig. 10) identifies specific mechanistic candidates:
- LPS/TLR4 signaling in APCs
- Biogenic amines (putrescine, cadaverine)</p>
<p><strong>Problem:</strong> You're relying entirely on metagenomics/metatranscriptomics for functional readouts. These are expensive and may miss strain-level variation in key genes.</p>
<p><strong>Recommendation:</strong> Add targeted functional gene amplicons</p>
<p>Based on your hypotheses and preliminary data, I recommend these specific genes:</p>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Target organism(s)</th>
<th>Rationale from your data</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>nanH</strong> (sialidase)</td>
<td>Gardnerella, Prevotella</td>
<td>Mucin degradation, epithelial barrier disruption - directly relevant to HIV target cell exposure</td>
</tr>
<tr>
<td><strong>vly</strong> (vaginolysin)</td>
<td>Gardnerella</td>
<td>Cytolysin causing epithelial damage - your APC TLR4 data suggests PAMP sensing</td>
</tr>
<tr>
<td><strong>ily</strong> (inerolysin)</td>
<td>L. iners</td>
<td>Distinguishes "good" vs "bad" Lactobacillus - L. iners is 28% of your cohort</td>
</tr>
<tr>
<td><strong>speA/speB</strong> (ornithine decarboxylase)</td>
<td>Multiple BV-associated</td>
<td>Putrescine synthesis - you identified this in metabolomics (Fig. 10A)</td>
</tr>
<tr>
<td><strong>ldcC</strong> (lysine decarboxylase)</td>
<td>Enterobacteriaceae, others</td>
<td>Cadaverine synthesis - also in your Fig. 10A</td>
</tr>
<tr>
<td><strong>ldhD</strong> (D-lactate dehydrogenase)</td>
<td>L. crispatus</td>
<td>Protective D-lactic acid - mechanistic marker of CT1</td>
</tr>
</tbody>
</table>
<p><strong>Why this matters:</strong>
- Direct PCR quantification of functional genes is cheaper than metatranscriptomics
- Captures strain-level variation (not all Gardnerella have equal sialidase activity)
- Provides validation targets for your model systems
- Can be run on all 3600 samples affordably</p>
<hr />
<h3>4. UMI-Based Error Correction for Strain Work</h3>
<p><strong>Problem:</strong> You're planning StrainPhlAn for strain-level analysis from metagenomics. This works but has limitations with strain mixtures and low-abundance strains.</p>
<p><strong>Recommendation:</strong> For your cpn60 amplicons (if added), use UMI-tagged primers</p>
<pre><code>Standard cpn60:     [Primer]--[cpn60 target]--[Primer]

UMI-tagged cpn60:   [Primer]-[UMI]--[cpn60 target]--[UMI]-[Primer]
                              ↓
                    Enables true strain deconvolution
                    Eliminates PCR chimeras (&lt;0.02% rate)
                    Provides molecule counting (absolute)
</code></pre>
<p>This is particularly valuable for your L. crispatus geographic strain analysis (Fig. 3) - UMIs would let you confidently call strain mixtures within samples.</p>
<hr />
<h3>5. Host DNA Contamination Strategy</h3>
<p><strong>Problem:</strong> FGT samples are host-heavy. You mention DeconSeq for metagenomics, but no strategy for amplicon work.</p>
<p><strong>Recommendation:</strong> Add PNA blocking oligos for 16S</p>
<p><a href="https://pubmed.ncbi.nlm.nih.gov/39875992/">Recent 2025 data</a> shows PNA clamps against human mitochondrial 16S reduce host contamination by 46-99%. This increases effective bacterial read depth without additional sequencing cost.</p>
<hr />
<h3>6. South African Reference Database Gap</h3>
<p><strong>Critical issue not addressed in grant:</strong> Your strain-level analyses rely on existing databases (GreenGenes, MetaPhlAn, cpnDB), which are heavily biased toward North American/European populations.</p>
<p>Your Fig. 3 already shows geographic strain structure. You're likely missing population-specific taxa.</p>
<p><strong>Recommendation:</strong> Add explicit aim or sub-aim for reference building</p>
<pre><code>From your culturomics (600 isolates):
├── Whole genome sequence all isolates
├── Extract 16S, cpn60, rpoB, functional genes
├── Build FRESH reference database
├── Deposit publicly (major contribution to field)
└── Use for improved taxonomic assignment
</code></pre>
<p>This transforms your culturomics from a validation resource into a discovery resource.</p>
<hr />
<h2>Revised Technical Approach</h2>
<p>Here's how I'd restructure Aim 1.1:</p>
<pre><code>┌────────────────────────────────────────────────────────────────────────┐
│                    REVISED AIM 1.1 APPROACH                            │
├────────────────────────────────────────────────────────────────────────┤
│                                                                        │
│  TIER 1: All 3600 samples                                              │
│  ├── 16S V4 amplicon (cross-study compatibility)        [current]     │
│  ├── cpn60 amplicon (species resolution)                [ADD]         │
│  ├── qPCR panel (absolute quantification)               [ADD]         │
│  │   └── Total bacteria, L. crispatus, L. iners, Gardnerella          │
│  ├── ITS2 amplicon (fungi)                              [current]     │
│  └── Metabolomics                                       [current]     │
│                                                                        │
│  TIER 2: Subset (n=500-1000, prioritized)                             │
│  ├── Metagenomics                                       [current]     │
│  ├── Metatranscriptomics                                [current]     │
│  └── Functional gene amplicons                          [ADD]         │
│      └── nanH, vly, ily, speA/ldcC, ldhD                              │
│                                                                        │
│  TIER 3: Discovery subset (n=100-200)                                  │
│  ├── Seq-Well scRNAseq                                  [current]     │
│  └── Deep metagenomics for MAG recovery                 [ENHANCE]     │
│                                                                        │
│  REFERENCE BUILDING: From culturomics                                  │
│  ├── WGS all 600 isolates                               [current]     │
│  ├── Build South African FGT reference database         [ADD]         │
│  └── Public deposition                                  [ADD]         │
│                                                                        │
└────────────────────────────────────────────────────────────────────────┘
</code></pre>
<hr />
<h2>Functional Genes: Final Recommendations</h2>
<p>Based on your specific hypotheses and preliminary data, here's my prioritized list:</p>
<h3>Must Include (directly supported by your data):</h3>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Why (from your grant)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>nanH</strong> (sialidase)</td>
<td>Gardnerella virulence factor; mucin degradation exposes epithelium; multiple variants exist</td>
</tr>
<tr>
<td><strong>vly</strong> (vaginolysin)</td>
<td>Your APC data shows TLR4/LPS pathway activation; vaginolysin causes epithelial lysis releasing PAMPs</td>
</tr>
<tr>
<td><strong>speA/odc</strong> (ornithine decarboxylase)</td>
<td>Putrescine synthesis - you identified this metabolite as elevated in CT3/4 (Fig 10A)</td>
</tr>
<tr>
<td><strong>ldcC</strong> (lysine decarboxylase)</td>
<td>Cadaverine synthesis - same rationale</td>
</tr>
<tr>
<td><strong>ldhD</strong> (D-LDH)</td>
<td>L. crispatus marker; D-lactate is protective; distinguishes from L. iners</td>
</tr>
</tbody>
</table>
<h3>Strongly Consider:</h3>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ily</strong> (inerolysin)</td>
<td>L. iners-specific cytolysin; L. iners is your CT2 (28% of cohort); strain variation matters</td>
</tr>
<tr>
<td><strong>hdc</strong> (histidine decarboxylase)</td>
<td>Histamine production - inflammatory; biogenic amine pathway</td>
</tr>
<tr>
<td><strong>prtS/prtP</strong> (proteases)</td>
<td>Prevotella tissue degradation; your data shows P. bivia, P. melaninogenica in HIV+</td>
</tr>
</tbody>
</table>
<h3>Lower Priority but Interesting:</h3>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>bsh</strong> (bile salt hydrolase)</td>
<td>Metabolic activity marker</td>
</tr>
<tr>
<td><strong>tetM/ermB</strong></td>
<td>AMR genes - not in your hypotheses but opportunistic data collection</td>
</tr>
</tbody>
</table>
<hr />
<h2>Budget Implications</h2>
<p>Rough cost additions for a 3600-sample study:</p>
<table>
<thead>
<tr>
<th>Addition</th>
<th>Per sample</th>
<th>Total</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>cpn60 amplicon</td>
<td>~$30-40</td>
<td>~$120K</td>
<td>Can multiplex with 16S</td>
</tr>
<tr>
<td>qPCR panel (5 targets)</td>
<td>~$15-20</td>
<td>~$60K</td>
<td>Could do subset</td>
</tr>
<tr>
<td>Functional amplicons (6 genes)</td>
<td>~$40-50</td>
<td>~$150K</td>
<td>On metagenomics subset only</td>
</tr>
<tr>
<td>UMI-tagged primers</td>
<td>~$5</td>
<td>~$18K</td>
<td>Marginal cost</td>
</tr>
<tr>
<td>Spike-in standards</td>
<td>~$2</td>
<td>~$7K</td>
<td>One-time synthesis + per-sample</td>
</tr>
</tbody>
</table>
<p><strong>Total addition: ~$200-350K depending on scope</strong></p>
<p>This is fundable within an R01 budget, especially if you tier the approach (all samples get qPCR + cpn60, subset gets functional amplicons).</p>
<hr />
<h2>Questions for You</h2>
<ol>
<li>
<p><strong>Budget flexibility?</strong> The additions I'm suggesting add $200-350K. Is there room, or should I prioritize?</p>
</li>
<li>
<p><strong>Metagenomics on all samples?</strong> Your grant says 100M reads per sample on all 3600. That's enormous (~$500/sample × 3600 = $1.8M just for metagenomics). Is this accurate, or is metagenomics on a subset? If subset, cpn60 becomes even more important for comprehensive coverage.</p>
</li>
<li>
<p><strong>Timeline for culturomics?</strong> If your 600 isolates are sequenced early, they can inform your functional gene primer design. Is this feasible?</p>
</li>
<li>
<p><strong>Interest in making the reference database a formal deliverable?</strong> This could be a significant contribution to the field and would strengthen the grant's impact statement.</p>
</li>
</ol></div></div></div>
<div class="message user" id="msg-2025-12-14T22-59-37-051Z"><div class="message-header"><span class="role-label">User</span><a href="#msg-2025-12-14T22-59-37-051Z" class="timestamp-link"><time datetime="2025-12-14T22:59:37.051Z" data-timestamp="2025-12-14T22:59:37.051Z">2025-12-14T22:59:37.051Z</time></a></div><div class="message-content">
<div class="user-content"><p>we already have the zymogen spike-in, 16S v4 primers (the earth microbiome ones) and a V1-V3 validated primer set we obtrained from Jacuqe Ravell. One of the reasons I am having this discussion with you is to work on cost reduction. I would like to implement the highest quality, most data rich approach that DOES NOT require any metagenomic sequencing. We will do some low pass metagenomics on sample subsets with a colleauge, but I want my lab to innovate on multi-gene amplicon surveys and the targetted functional assays with novel tech and informatic dev</p></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-00-51-615Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-00-51-615Z" class="timestamp-link"><time datetime="2025-12-14T23:00:51.615Z" data-timestamp="2025-12-14T23:00:51.615Z">2025-12-14T23:00:51.615Z</time></a></div><div class="message-content">
<div class="assistant-text"><p>Now I understand your vision much better. You want to build a <strong>next-generation amplicon platform</strong> that extracts metagenomic-level insights without metagenomics costs. This is a compelling technical innovation space.</p>
<h2>Reframed Goal</h2>
<p><strong>Build a multi-amplicon platform that delivers:</strong>
- Species/strain-level taxonomic resolution
- Functional gene quantification
- Absolute abundance
- Cross-study compatibility</p>
<p><strong>Without:</strong>
- Metagenomics costs ($300-500/sample)
- Massive sequencing depth
- Complex assembly pipelines</p>
<hr />
<h2>The Platform Architecture</h2>
<pre><code>┌─────────────────────────────────────────────────────────────────────────┐
│           MULTI-AMPLICON FGT PROFILING PLATFORM                        │
├─────────────────────────────────────────────────────────────────────────┤
│                                                                         │
│  EXISTING ASSETS                                                        │
│  ├── 16S V4 (515F/806R) - Earth Microbiome Project                     │
│  ├── 16S V1-V3 (Ravel validated)                                       │
│  ├── Zymo spike-ins (absolute quantification)                          │
│  └── ITS2 (fungal - already running)                                   │
│                                                                         │
│  NEW DEVELOPMENT                                                        │
│  ├── cpn60 UT (species resolution, Gardnerella)                        │
│  ├── rpoB (orthogonal validation, Lactobacillus)                       │
│  └── Functional gene panel (mechanistic readouts)                      │
│                                                                         │
│  NOVEL TECH/INFORMATICS                                                 │
│  ├── UMI integration for strain deconvolution                          │
│  ├── Multi-marker taxonomic concordance                                │
│  ├── Functional scoring algorithms                                     │
│  └── South African reference database                                  │
│                                                                         │
└─────────────────────────────────────────────────────────────────────────┘
</code></pre>
<hr />
<h2>Amplicon Selection: Final Recommendations</h2>
<h3>Taxonomic Amplicons</h3>
<table>
<thead>
<tr>
<th>Amplicon</th>
<th>Status</th>
<th>Purpose</th>
<th>Innovation opportunity</th>
</tr>
</thead>
<tbody>
<tr>
<td>16S V4</td>
<td>Have</td>
<td>Cross-study compatibility</td>
<td>None needed</td>
</tr>
<tr>
<td>16S V1-V3</td>
<td>Have (Ravel)</td>
<td>Lactobacillus resolution</td>
<td>None needed</td>
</tr>
<tr>
<td>cpn60 UT</td>
<td>Need primers</td>
<td>Gardnerella species, strain hints</td>
<td>UMI-tagged version</td>
</tr>
<tr>
<td>rpoB</td>
<td>Need primers</td>
<td>Orthogonal validation</td>
<td>DPO design for specificity</td>
</tr>
</tbody>
</table>
<p><strong>Why rpoB in addition to cpn60?</strong>
- Independent validation (if cpn60 and rpoB disagree, you've found something interesting)
- Better Lactobacillus resolution than cpn60 in some cases
- Less database bias (you'll build your own reference)
- The <a href="https://journals.asm.org/doi/10.1128/jcm.00266-24">2024 JCM paper</a> shows ~550bp amplicon with excellent species discrimination</p>
<h3>Functional Gene Amplicons</h3>
<p>Based on your grant's mechanistic hypotheses, here's my curated list:</p>
<p><strong>Tier 1: Must have (directly from your preliminary data)</strong></p>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Target</th>
<th>Your data support</th>
<th>Primer status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>nanH1/nanH2</strong></td>
<td>Gardnerella sialidases</td>
<td>Mucin degradation → epithelial exposure → HIV target cells</td>
<td>Need design</td>
</tr>
<tr>
<td><strong>vly</strong></td>
<td>Gardnerella vaginolysin</td>
<td>APC TLR4 activation (Fig 10B); PAMP release</td>
<td>Need design</td>
</tr>
<tr>
<td><strong>speA/odc</strong></td>
<td>Multiple (ornithine decarboxylase)</td>
<td>Putrescine elevated in CT3/4 (Fig 10A)</td>
<td>Need design</td>
</tr>
<tr>
<td><strong>ldcC</strong></td>
<td>Multiple (lysine decarboxylase)</td>
<td>Cadaverine elevated in CT3/4 (Fig 10A)</td>
<td>Need design</td>
</tr>
<tr>
<td><strong>ldhD</strong></td>
<td>L. crispatus D-LDH</td>
<td>Protective D-lactate; mechanistic marker of CT1</td>
<td>Need design</td>
</tr>
</tbody>
</table>
<p><strong>Tier 2: Strong biological rationale</strong></p>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Target</th>
<th>Rationale</th>
<th>Primer status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ily</strong></td>
<td>L. iners inerolysin</td>
<td>L. iners is 28% of cohort; strain variation in cytolysin activity matters</td>
<td>Need design</td>
</tr>
<tr>
<td><strong>ldhL</strong></td>
<td>All Lactobacillus L-LDH</td>
<td>L-lactate (less protective than D); ratio to ldhD informative</td>
<td>Need design</td>
</tr>
</tbody>
</table>
<p><strong>Tier 3: Consider</strong></p>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Target</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>hdc</strong></td>
<td>Histidine decarboxylase</td>
<td>Histamine production; inflammatory</td>
</tr>
<tr>
<td><strong>aguA</strong></td>
<td>Agmatine deiminase</td>
<td>Polyamine pathway; complements speA/ldcC</td>
</tr>
<tr>
<td><strong>prtS</strong></td>
<td>Prevotella proteases</td>
<td>Tissue degradation; P. bivia in your HIV+ samples</td>
</tr>
</tbody>
</table>
<hr />
<h2>The Innovation Layer</h2>
<p>Here's where your lab differentiates:</p>
<h3>1. UMI-Tagged Amplicons for Strain Deconvolution</h3>
<pre><code>Standard amplicon workflow:
  Sample → PCR → Sequence → ASVs → Can't resolve strain mixtures

UMI workflow:
  Sample → PCR with UMI primers → Sequence → Group by UMI → Consensus per molecule
         ↓
  True molecule counting (absolute)
  Strain mixture deconvolution
  PCR chimera elimination
  PCR bias correction
</code></pre>
<p><strong>Apply to:</strong> cpn60, rpoB (your strain-resolution amplicons)</p>
<p><strong>Innovation:</strong> Nobody has done UMI-tagged cpn60 for vaginal microbiome. This is publishable methods work.</p>
<h3>2. Multi-Marker Taxonomic Integration</h3>
<pre><code>Current state of field:
  16S → taxonomy
  Done.

Your innovation:
  16S V4    ─┐
  16S V1-V3 ─┼─→ Concordance analysis ─→ Confidence-weighted taxonomy
  cpn60     ─┤                         ─→ Novel taxa flagging
  rpoB      ─┘                         ─→ Database gap identification
</code></pre>
<p><strong>Informatics development:</strong>
- Concordance scoring: Do all markers agree? If not, why?
- Weighted consensus: Trust cpn60 for Gardnerella, V1-V3 for Lactobacillus
- Discordance flagging: Samples where markers disagree get prioritized for your collaborator's metagenomics</p>
<h3>3. Functional Scoring from Amplicons</h3>
<p>This is the killer innovation. Instead of metagenomics for functional inference, you directly measure:</p>
<pre><code>Inflammation Potential Score = f(nanH, vly, speA, ldcC, hdc)

Protection Score = f(ldhD, total_Lactobacillus, L.crispatus_abundance)

Risk Index = Inflammation_Score / Protection_Score
</code></pre>
<p><strong>Validation:</strong> Correlate with your Luminex cytokine data, CD4+ T cell counts, and ultimately HIV acquisition.</p>
<p><strong>This becomes a predictive biomarker panel</strong> - clinically translatable, deployable in Durban.</p>
<h3>4. South African Reference Database</h3>
<p>Your culturomics (600 isolates) + amplicon data = population-specific reference</p>
<pre><code>From each isolate:
├── Full 16S (Sanger or long-read)
├── Full cpn60
├── Full rpoB  
├── Functional genes present/absent
└── Phenotypic characterization

Output:
├── FRESH-DB: South African FGT reference
├── Primer validation against local strains
├── Novel taxa documentation
└── Public resource (citable, impactful)
</code></pre>
<hr />
<h2>Cost Model</h2>
<p>Let's price this out for 3600 samples:</p>
<h3>Sequencing Costs (per sample)</h3>
<table>
<thead>
<tr>
<th>Component</th>
<th>Reads needed</th>
<th>Cost estimate</th>
</tr>
</thead>
<tbody>
<tr>
<td>16S V4</td>
<td>50K</td>
<td>Already budgeted</td>
</tr>
<tr>
<td>16S V1-V3</td>
<td>50K</td>
<td>~$10-15</td>
</tr>
<tr>
<td>cpn60 + UMI</td>
<td>50K</td>
<td>~$15-20</td>
</tr>
<tr>
<td>rpoB</td>
<td>30K</td>
<td>~$8-12</td>
</tr>
<tr>
<td>Functional panel (6-8 genes)</td>
<td>100K total</td>
<td>~$20-30</td>
</tr>
<tr>
<td><strong>Total per sample</strong></td>
<td></td>
<td><strong>~$55-75 additional</strong></td>
</tr>
</tbody>
</table>
<h3>Multiplexing Strategy</h3>
<p>You can dramatically reduce costs by pooling:</p>
<pre><code>Option A: Separate libraries, pooled sequencing
├── More flexible
├── Easier troubleshooting
├── Higher cost

Option B: Multiplexed PCR pools
├── Pool 1: 16S V4 + V1-V3 (same gene, different regions)
├── Pool 2: cpn60 + rpoB (both ~500bp, bacteria-specific)
├── Pool 3: Functional genes (all ~300-500bp)
├── Lower cost
├── Requires careful primer design to avoid cross-reactivity
</code></pre>
<h3>Total Platform Cost Estimate</h3>
<table>
<thead>
<tr>
<th>Item</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primer synthesis (including UMI versions)</td>
<td>~$5-10K</td>
</tr>
<tr>
<td>Validation/optimization</td>
<td>~$20-30K</td>
</tr>
<tr>
<td>3600 samples × $60/sample (new amplicons)</td>
<td>~$216K</td>
</tr>
<tr>
<td>Spike-in calibration</td>
<td>Using Zymo (have)</td>
</tr>
<tr>
<td>Bioinformatics development</td>
<td>Personnel time</td>
</tr>
<tr>
<td><strong>Total new costs</strong></td>
<td><strong>~$250K</strong></td>
</tr>
</tbody>
</table>
<p>Compare to metagenomics on 3600 samples: <strong>$1.5-2M+</strong></p>
<hr />
<h2>Primer Design Strategy</h2>
<h3>For Published Primers (cpn60)</h3>
<p><strong>cpn60 UT primers (H279p/H280p from Hill lab):</strong></p>
<pre><code>H279p: 5'-GAIIIIGCIGGIGAYGGIACIACIAC-3'
H280p: 5'-YKIYKITCICCRAAICCIGGIGCYTT-3'
</code></pre>
<p><strong>Enhancement:</strong> Add UMI + Illumina adapter tails</p>
<pre><code>UMI-H279p: 5'-[Illumina adapter]-[8N UMI]-GAIIIIGCIGGIGAYGGIACIACIAC-3'
UMI-H280p: 5'-[Illumina adapter]-[8N UMI]-YKIYKITCICCRAAICCIGGIGCYTT-3'
</code></pre>
<h3>For De Novo Design (functional genes)</h3>
<p><strong>Workflow:</strong>
1. Download all available sequences for target gene from NCBI/UniProt
2. Include your isolate sequences as they become available
3. Align with MUSCLE/MAFFT
4. Use DegePrime or ARDEP for degenerate primer design
5. Validate coverage in silico against FGT taxa
6. Consider DPO format for specificity</p>
<p><strong>Example: nanH (sialidase)</strong></p>
<pre><code>Multiple nanH variants exist:
├── nanH1 (Gardnerella vaginalis type)
├── nanH2 (Gardnerella other species)
├── nanH3 (Prevotella)

Design strategy:
├── Conserved regions that capture all variants? OR
├── Variant-specific primers for each?

Recommendation: Start with broad capture, resolve computationally
</code></pre>
<hr />
<h2>Bioinformatics Pipeline Architecture</h2>
<pre><code>┌─────────────────────────────────────────────────────────────────────────┐
│                    MULTI-AMPLICON ANALYSIS PIPELINE                     │
├─────────────────────────────────────────────────────────────────────────┤
│                                                                         │
│  INPUT: Multiplexed amplicon reads                                      │
│         ↓                                                               │
│  DEMULTIPLEXING                                                         │
│  ├── By sample (dual index)                                            │
│  ├── By amplicon (primer sequence)                                     │
│  └── By molecule (UMI, for cpn60/rpoB)                                 │
│         ↓                                                               │
│  AMPLICON-SPECIFIC PROCESSING                                           │
│  ├── 16S V4: DADA2 → GreenGenes2                                       │
│  ├── 16S V1-V3: DADA2 → SILVA + custom Lactobacillus DB                │
│  ├── cpn60: UMI consensus → cpnDB + FRESH-DB                           │
│  ├── rpoB: UMI consensus → Custom DB (build from isolates)             │
│  └── Functional: Quantify → Normalize to spike-in                      │
│         ↓                                                               │
│  INTEGRATION                                                            │
│  ├── Taxonomic concordance scoring                                     │
│  ├── Spike-in normalization (absolute abundance)                       │
│  ├── Functional gene quantification                                    │
│  └── Composite scores (Inflammation, Protection, Risk)                 │
│         ↓                                                               │
│  OUTPUT                                                                 │
│  ├── Per-sample: Taxonomy + Absolute abundance + Functional scores     │
│  ├── Per-cohort: Integration with metadata, HIV outcomes               │
│  └── QC reports: Concordance, spike-in recovery, controls              │
│                                                                         │
└─────────────────────────────────────────────────────────────────────────┘
</code></pre>
<hr />
<h2>Development Phases</h2>
<pre><code>Phase 1: Primer Development (Months 1-4)
├── Obtain/synthesize cpn60 primers (+ UMI version)
├── Design rpoB primers (DPO format, + UMI version)
├── Design functional gene primers (nanH, vly, speA, ldcC, ldhD, ily)
├── In silico validation against databases
└── Order synthesis

Phase 2: Wet Lab Validation (Months 4-8)
├── Test on mock communities
├── Test on 50-100 archived FRESH samples with known 16S
├── Optimize multiplexing pools
├── Validate spike-in quantification
├── Compare to existing 16S V4 data
└── Establish SOPs

Phase 3: Pipeline Development (Months 4-10, parallel)
├── UMI processing module
├── Multi-marker integration
├── Concordance scoring
├── Functional quantification
├── FRESH-DB construction (as isolates are sequenced)
└── Visualization/reporting

Phase 4: Scale-up (Months 8-18)
├── Process all 3600 samples
├── Integrate with grant Aim 1.2 (host data)
├── Feed candidates to Aim 2 (model systems)
└── Publish methods paper

Phase 5: Refinement (Ongoing)
├── Update FRESH-DB with new isolates
├── Iterate functional scoring based on outcomes
├── Develop field-deployable qPCR version
</code></pre>
<hr />
<h2>Questions to Finalize</h2>
<ol>
<li><strong>Sequencing platform preference?</strong> </li>
<li>Illumina MiSeq/NovaSeq for short-read multiplexed amplicons?</li>
<li>
<p>Interest in Nanopore/PacBio for full-length cpn60/rpoB? (higher cost, simpler bioinformatics)</p>
</li>
<li>
<p><strong>Functional gene priorities?</strong> </p>
</li>
<li>My Tier 1 (nanH, vly, speA, ldcC, ldhD) = 5 genes</li>
<li>Add ily and ldhL? = 7 genes</li>
<li>
<p>This affects multiplexing complexity</p>
</li>
<li>
<p><strong>UMI on all amplicons or just cpn60/rpoB?</strong></p>
</li>
<li>Full UMI adds cost and complexity</li>
<li>
<p>Could be selective (strain-resolution amplicons only)</p>
</li>
<li>
<p><strong>Timeline for isolate WGS?</strong></p>
</li>
<li>If early, informs primer design</li>
<li>
<p>If later, primers designed from public databases, validated against your strains</p>
</li>
<li>
<p><strong>Interest in methods publication?</strong></p>
</li>
<li>"A multi-amplicon platform for high-resolution FGT microbiome profiling"</li>
<li>Could be companion to your main findings papers</li>
</ol></div></div></div>
        

<div class="pagination">
<a href="index.html" class="index-link">Index</a>
<a href="page-002.html">&larr; Prev</a>
<a href="page-001.html">1</a>
<a href="page-002.html">2</a>
<span class="current">3</span>
<a href="page-004.html">4</a>
<a href="page-004.html">Next &rarr;</a>
</div>

    </div>
    <script>
document.querySelectorAll('time[data-timestamp]').forEach(function(el) {
    const timestamp = el.getAttribute('data-timestamp');
    const date = new Date(timestamp);
    const now = new Date();
    const isToday = date.toDateString() === now.toDateString();
    const timeStr = date.toLocaleTimeString(undefined, { hour: '2-digit', minute: '2-digit' });
    if (isToday) { el.textContent = timeStr; }
    else { el.textContent = date.toLocaleDateString(undefined, { month: 'short', day: 'numeric' }) + ' ' + timeStr; }
});
document.querySelectorAll('pre.json').forEach(function(el) {
    let text = el.textContent;
    text = text.replace(/"([^"]+)":/g, '<span style="color: #ce93d8">"$1"</span>:');
    text = text.replace(/: "([^"]*)"/g, ': <span style="color: #81d4fa">"$1"</span>');
    text = text.replace(/: (\d+)/g, ': <span style="color: #ffcc80">$1</span>');
    text = text.replace(/: (true|false|null)/g, ': <span style="color: #f48fb1">$1</span>');
    el.innerHTML = text;
});
document.querySelectorAll('.truncatable').forEach(function(wrapper) {
    const content = wrapper.querySelector('.truncatable-content');
    const btn = wrapper.querySelector('.expand-btn');
    if (content.scrollHeight > 250) {
        wrapper.classList.add('truncated');
        btn.addEventListener('click', function() {
            if (wrapper.classList.contains('truncated')) { wrapper.classList.remove('truncated'); wrapper.classList.add('expanded'); btn.textContent = 'Show less'; }
            else { wrapper.classList.remove('expanded'); wrapper.classList.add('truncated'); btn.textContent = 'Show more'; }
        });
    }
});
</script>
</body>
</html>